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Synopsis 
Colorectal cancer (CRC)  is the one of the commonest causes of cancer and cancer 
related death worldwide. Its aetiology is linked to a number of reversible and 
irreversible genetic and environmental factors, including age, sex, genetics, 
smoking and diet. There has been a drive in recent years for non-invasive 
biomarkers for many malignant and non-malignant diseases across multiple 
medical specialties. One of the areas of interest is the detection of volatile organic 
compounds (VOCs) in various bodily substances by means such as mass 
spectrometry and electronic noses. CRC patients have been shown to be 
distinguishable from healthy controls using urinary VOC detection in several 
studies, including two published by the research group at UHCW and the 
University of Warwick. There has also been much interest in recent years into the 
role that the intestinal microbiome plays in health and disease in humans.  
The aim of this thesis was to characterise the urinary VOC and stool microbiome 
profiles of CRC patients, their spouses and first degree relatives. The aim being to 
determine whether the urinary VOC profiles could be distinguished using this 
technology and to try and better understand the underlying mechanism which 
lead to CRC carcinogenesis. The first degree relatives and spouses were selected 
as “common gene pool” and “shared environment” control groups respectively.  
This work was done using an LC-FAIMS-MS hybrid machine to detect urinary VOCs 
and 16s RNA sequencing using an Illumina Miseq platform. Comparisons were also 
made between pre-treatment and post-treatment CRC samples to try and 
determine if there was any change in either VOC or microbiome profiles after CRC 
treatment.  
The urinary VOC profiles of CRC subjects could be distinguished from both sets of 
healthy controls using a 5-fold cross validation and sparse logistics regression and 
Random Forrest statistical classifiers, achieving sensitivities of 63-69%, 
specificities of 64-69% and AUC 0.71-0.72. No statistically significant differences 
could be found in the urinary VOC profiles of pre-operative and post operative 
samples.  
Microbiome analysis revealed over 1300 operational taxonomic units (OTUs), with 
a similarity of >93% between the CRC samples and the control groups, with 
significantly different bacterial abundances identified in only 82 OTUs (6.2%), 
mainly Clostridiales bacteria.  Pre-treatment and post-treatment sample analysis 
revealed differences of 17 (3%) and 22 (4%) OTUs at 3 and 6 months respectively, 
again principally clostridiales.  
This thesis provides further data on the microbiome composition in CRC. It also 
provides further proof of the utility of urinary VOCs, for the first time here using 
LC-FAIMS-MS technology, a variant of the previously utilised FAIMS technology, as 
a non-invasive biomarker for CRC.    
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1.0 Introduction  
Cancer is a leading cause of death worldwide irrespective of the socioeconomic 
status of individual countries. The number of cancer cases is expected to grow 
rapidly in line with population increases, and the greater prevalence of lifestyle 
risk factors, such as tobacco use, physical inactivity and obesity, particularly in low 
and middle income countries.  Colorectal cancer (CRC) is one of the most common 
types of cancer, and cause of cancer-related death worldwide, with 1 in 20 people 
developing CRC in their life time.  
Currently diagnosis of CRC, in the United Kingdom, is made via 3 main routes; 
Emergency presentation with a complication of the primary tumour, such as bowel 
obstruction, via the two week wait pathway, where patients with symptoms 
suggestive of CRC are referred urgently to hospital for investigation, and via the 
Bowel Cancer Screening Programme, where asymptomatic individuals undergo a 
screening test based on Faecal occult blood testing. As will be discussed later in 
this thesis, the accuracy of the FOB test is poor, and the test itself has a relatively 
poor uptake due to the nature of the sample involved. There has been a recent 
quest for a more reliable and acceptable method of screening for CRC. This has 
included analysis of the profile of volatile organic compounds (VOCs) in various 
bodily secretions of CRC patients using numerous different technologies. VOCs are 
normal by products of an individuals metabolism, which are believed to be 
perturbed in disease states such as CRC. The analysis of CRC derived VOCs is part 
of a much wider field of study in the area of VOCs in health and disease, including 
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malignant and non-malignant conditions, across many body systems, including 
respiratory, gastrointestinal, metabolic and renal.  
This thesis will be a continuation of research I have previously carried out on the 
urinary VOC profiles of CRC patients. This study discussed later in this thesis found 
that CRC patients were distinguishable from healthy controls with a sensitivity of 
83% and specificity of 60%. This thesis, though independent of this previous work, 
follows on from it. The primary aim is to analyse the urinary VOC patterns, and the 
faecal microbiomes, of patients with CRC, their first degree relatives and an 
individual who lives in the same environment as them. Urinary VOC screening 
could represent a more acceptable screening medium to patients than the current 
faecal based tools in the screening for CRC.  
The aim of this analysis is to determine whether urinary VOC profiles of CRC 
patients are unique, compared to environmental (co-habitor), and genetic 
controls (first degree relative). The previous studies had used healthy controls 
completely distinct from the CRC subjects.  
The urinary profiles of VOCs before, and after, tumour resection will also be 
studied to determine whether any changes in the VOC profile occurs after removal 
of the primary lesion. 
The composition of the microbiome within all 4 groups, the initial CRC patient 
specimens, the post-treatment CRC patient specimens, the co-habitors and the 
relatives, will also be studied using 16s RiboNucleic Acid (RNA) analysis of stool 
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samples. This is with the aim of elucidating any differences in the intestinal 
microbiome between the groups. Additionally it should provide further 
understanding of the changes which occur in the microbiome after CRC surgery.   
The combination of these experiments will hopefully allow greater understanding 
of the potential role of urinary VOCs as a non-invasive biomarker in the screening 
for CRC and the variation of the faecal microbiome across the main study groups.   
As this thesis will cover the aetiology of CRC, the VOC profiling of malignancy, 
including CRC, and the microbiome of patients with CRC, each of these areas will 
be discussed individually in the following chapter.   
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CHAPTER 2 
Colorectal Cancer, Volatile Organic Compounds and the 
Microbiome 
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2.1. Colorectal Cancer  
2.1.1. Epidemiology 
2.1.1.1. Incidence 
Globally, CRC is the third and second commonest cancer in males and females 
respectively, with incidence and mortality appearing to be on the increase. In 
2008, an estimated 1.2 million people were diagnosed with CRC (1). By 2012 this 
number had increased to 1.4 million (2). Worldwide, the age standardised rate for 
CRC incidence is 17.3 per 100, 000 and cumulative CRC risk from birth to age 74 
years is 0.9%. CRC incidence is higher in men, with an age standardised male to 
female ratio of 1.4: 1 (1). Within the United Kingdom (UK), CRC is the fourth most 
common cancer overall, and the third most common in both men and women, 
with 41,100 cases diagnosed in 2013 (3).  
Despite its global presence, there is marked variation in CRC incidence rates 
worldwide. Developed or higher income countries account for almost two-thirds 
of CRC cases, but the incidence rates in these countries are, for the most part 
stable or declining. The incidence rates in developing countries and those with 
historically low rates, such as those in Latin America, Asia and Eastern Europe are, 
however, rising (1, 2).  These increases are believed to be due to the effects of 
adopting a more westernised diet, reduced physical activity and increased tobacco 
use (4).   
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The decreasing incidence rates in higher income countries have been attributed 
to screening programmes for CRC, which result in the removal of pre-cancerous 
lesions and polyps, and also a reduction in risk factors, particularly smoking.  
Despite these overall falling incidence rates, higher income countries have been 
experiencing an increase in the incidence rates for those aged less than 50 years, 
for whom screening is not currently recommended. The underlying reasons for 
this rise have not been established (4).   
Within the UK, bowel cancer incidence rates are increasing, with a 14% increase 
since the 1970s. This is likely to be due, in part, to the implementation of the bowel 
cancer screening programme and an increase in lesion detection (5).  
2.1.1.2. Mortality 
Globally, mortality figures from CRC continue to increase in line with the rising 
incidence.  In 2008, there were 668,000 CRC related deaths, and in 2012 there 
were 693,900 (1, 2). Overall, it is the fourth leading cause of cancer deaths, 
accounting for 8% of all cancer deaths worldwide. In the UK, it is the second most 
common cause of cancer death after lung cancer, with 15,900 people dying in 2014 
(6).  
In more developed countries, such as the US and many European countries, 
despite a higher incidence rate, mortality rates are decreasing. Again, this is 
attributed to screening programmes detecting the disease at earlier, more 
treatable stages, and also to the vast improvement made in treatments (7). 
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Conversely, countries with rising incidence and mortality rates e.g. Brazil, Chile, 
Romania and Russia, have increasingly westernised diets and life style risk factors, 
but have relatively less resources for screening and treatment, resulting in poorer 
mortality statistics (4). 
The UKs mortality from CRC has been falling since the 1970s, with 16,200 dying in 
2012. Over the last decade, the mortality has reduced by 14%. The UK currently 
ranks the 10th lowest for males and 14th lowest for females in terms of CRC 
mortality (6).  
The mortality rate of CRC is approximately half of the incidence rate, giving it a 
relatively good prognosis. The 5 year prevalence of CRC worldwide is 
approximately 3.26 million (1) whilst in the UK it is 91,777.   The UK 5 year survival 
is 59%, and 57% at 10 years (8).  
2.1.2. Aetiology 
Epidemiological studies have identified numerous factors which increase the risk 
of CRC, but also many which decrease CRC risk. Those such as personal or family 
history of CRC, along with history of inflammatory bowel disease cannot be 
modified, but lifestyle risk factors such as smoking, alcohol use, diet and physical 
inactivity, can be.  
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2.1.2.1. Age 
Age is a major non-modifiable risk factor for both CRC and CRC mortality.  In the 
UK, 43% of bowel cancer was diagnosed in those aged >75 years, whilst 95% were 
diagnosed in those aged 50 and over. The bowel cancer screening programme 
(BCSP) was introduced in England in 2006, and has subsequently been rolled out 
across the whole of the UK. This led to a 14% increase in CRC incidence for those 
aged 60-69 years between 2004-2006, and 2008-2010 (6).  
2.1.2.2. Sex 
Worldwide, and in the UK, men are at greater risk of CRC than women, but the 
reasons for this are not well understood. They have been postulated to be related 
to hormonal, genetic and molecular interactions, as well as environmental risk 
factors (9).   
2.1.2.3. Genetic predisposition 
Approximately 5% of CRC can be directly attributed to genetic predisposition. The 
main inherited genetic syndromes predisposing to CRC are Familial Adenomatous 
Polyposis (FAP) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC), also 
known as Lynch Syndrome. 
FAP accounts for approximately 1% of CRC. It shows an autosomal dominant 
inheritance pattern and is due to a germline mutation in the adenomatous 
polyposis coli (APC) gene, located on chromosome 5q21. FAP is characterised by 
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the development of hundreds to thousands of gastrointestinal polyps, which 
undergo near inevitable progression to CRC by the age of 40-45 years (10). The 
treatment of these patients involves genetic screening of families, endoscopic 
surveillance and colectomy.  
HNPCC meanwhile accounts for approximately 1-4% of CRC, which also shows an 
autosomal dominant pattern of inheritance and is due to mutations in DNA 
mismatch repair genes including MSH2, MLH1, MSH6 and PMS2. These mutations 
lead to microsatellite instability and subsequent carcinogenesis. Additionally, 
HNPCC confers a higher risk of other gastrointestinal (GI) cancers, such as gastric, 
but also endometrial cancer. The lifetime risk for developing CRC with HNPCC is 
approximately 80% (11).  
Other syndromes associated with increased CRC risk are Peutz-Jegher's syndrome 
and mutY homolog (MUTYH) associated polyposis. Peutz-Jegher's syndrome is a 
rare autosomal dominant condition caused by mutations in the STK11 gene. 
Patients develop characteristic hyperpigmentation of the fingers, toes and lips and 
are at increased risk of developing hamartomatous polyps of the GI tract. MUTYH-
associated polyposis is an autosomal recessive condition caused by mutation in 
the base excision repair gene MUTYH, resulting in multiple colorectal adenomas 
which can progress to CRC (7). 
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2.1.2.4. Family History 
Non-genetic susceptibility CRC, or sporadic CRC, does still appear to have a genetic 
component to it. Family history is an important risk factor for the development of 
CRC, even without the presence of genetic predisposition. A first degree relative, 
such as a child, parent or sibling, having suffered from CRC leads to a doubling of 
the risk of developing CRC by the age of 70 (equating to a 1 in 30 risk). This risk is 
further increased if multiple relatives are affected, or diagnosis occurs at younger 
than 60 years of age. This increase has been suggested to be due to an interaction 
of genetic and environmental causes (12).   
It has been found that adopted children are less likely to develop CRC if their 
biological parents did not have CRC, compared to if they did. Also children with 
adoptive parents who suffer from CRC are not at increased risk of developing CRC 
(13). This would suggest that the genetic factors, rather than environmental 
factors, underpin the increased family history risk of CRC.  
Genome wide association studies (GWAS) have been conducted to examine for 
markers of CRC risk. These studies initially showed only a few low penetrance 
markers, and failed to identify specific genes. However, further, more powerful 
studies have identified multiple low penetrance susceptibility loci which would 
account for a higher proportion of CRC. This would support the theory that 
sporadic familial CRC results from the cumulative effects of multiple low 
penetrance genes. These familial clusters of sporadic CRC may represent 
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approximately 20% of all CRC, with the remaining 75% of CRC representing true 
sporadic CRC caused by the accumulation of multiple somatic mutations (14-17).    
2.1.2.5. Personal Medical History 
A past medical history including any of; adenomatous polyps, previous CRC, 
inflammatory bowel disease (IBD), gallstones, type 2 Diabetes Mellitus and the 
metabolic syndrome places people at an increased risk of developing CRC.   
• A pooled analysis of adenomas and polyps has shown that 1% of people 
with adenomas measuring greater than 20millimetres, or adenomas of any 
size with high grade dysplasia will develop CRC within 4 years of adenoma 
removal (18). Even the presence of low risk adenomatous polyps increases 
your risk of developing CRC by 80% compared with people who have no 
polyps (19).   
• IBD (Ulcerative Colitis or Crohn's Disease) conveys an increased risk of 
developing CRC. This risk is not now thought to be as high as previously 
believed, but is still 70% higher than the general population (standardised 
incidence ratio 1.7). Greater risk is found in those with more extensive 
disease, longer disease duration and younger age at diagnosis. The 
cumulative risk of CRC were found to be 1%, 2% and 5% after 10, 20 and 
>20 years of disease duration respectively (20).  
• The presence of gallstones confers a 33% increased risk of developing 
rectal cancers and more than doubles the risk of developing a colonic 
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adenoma compared to those who do not have gallstones. Interestingly, 
cholecystectomy does not affect the risk of developing adenoma or CRC 
(21, 22).  
• Several studies have found an increased CRC risk in patients with type II 
diabetes mellitus, compared to non-diabetics. This risk appears to be 22-
30% greater (23-27). CRC risk is also higher by 33-41% in patients with the 
metabolic syndrome (characterised by a combination of diabetes, 
hypertension and central adiposity) (28). 
2.1.2.6. Obesity 
Obesity is a recognised risk factor for developing many forms of cancer, including 
CRC. Obesity, measured by body mass index (BMI) >30, conveys a 33% increased 
risk compared to those with normal BMI. This association is stronger for colon 
cancer than for rectal cancer, and for men compared to women. Waist 
circumference is also a risk factor for CRC, with larger waist circumference leading 
to a 46% increased risk in CRC (29).   
2.1.2.7. Physical activity 
Physical activity has been shown to be strongly protective against the 
development of CRC, with a 17-24% reduction in risk in the most physically active 
people compared to the least physically active people (30, 31).   
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2.1.2.8. Diet 
Many dietary components have been implicated in both increased and decreased 
risk of developing CRC.  
2.1.2.8.i. Fruits and vegetables 
Non-starchy vegetables and fruit show an inconclusive relationship with CRC in 
terms of risk. Some studies have shown a reduction in risk with increased 
consumption (32-34), whereas other studies have shown only a weak, or absent, 
protective effect (35, 36).                                             
2.1.2.8.ii. Red Meat and Processed Meat 
Red meat and processed meat consumption have been linked with an estimated 
21% of UK CRC, with an increase in risk of 17-30% per 100-120g/day of red meat 
intake and 9-50% per 25-50g/day of processed meat intake (37-40). Haem iron, 
which is found in red meat, is associated with an increased risk of 12% per 
1mg/day intake (41).  Although, in another cohort study, CRC risk was not found 
to be linked to whole dietary iron intake (42). 
2.1.2.8.iii. Fibre 
Dietary fibre is believed to be protective against CRC. 12% of CRC in the UK is linked 
to consuming less than 23g/day of fibre (43). There is believed to be a 10% 
reduction in risk per 10g/day of total dietary fibre and cereal fibre, but 
interestingly there seems to be no association with fruit and vegetable fibre. 
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Whole grains appear to reduced CRC risk by 20% for every 90g consumed per day 
(44).     
2.1.2.8.iv. Calcium and dairy 
Milk and calcium are protective against the development of CRC. Milk reduces the 
risk of CRC by 9-15% per 200-250g consumed per day (45). Calcium meanwhile, 
reduces the risk by 8% per 300mg consumed per day, and the risk was found to be 
22% lower in the highest calcium intake group, compared to the lowest (46). 
Calcium supplementation of the diet shows a mixed picture of evidence, with 
some support for 9% lower risk per 300mg consumed per day, whilst other studies 
have shown no risk reduction (47, 48).       
2.1.2.8.v. Micronutrients 
There has been much study into the role of micronutrients into the risk of CRC. 
Retinol blood levels have been linked with a 37% reduction in CRC for the highest 
versus the lowest serum levels (49, 50). Vitamin D has been linked with a 15-26% 
reduction in CRC risk per 10-20ng/ml rise in serum levels (49-52), although, there 
is also some evidence that it has no effect on CRC risk (42). Beta-carotene (31%), 
Vitamin E (35%), Vitamin C (40%) and Zinc (20%) have all been linked with 
reduction in CRC risk for those with the highest intake versus those with the lowest 
intake (53, 54).                                                              
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2.1.2.9. Smoking 
Cigarette smoking is one of the most common preventable risk factors for the 
development of many types of cancer, including CRC. It is estimated that 8% of 
CRC cases are linked to tobacco smoking, with CRC risk greater by 17-21%, 
compared to non-smokers. The association is stronger for colon cancer than rectal 
cancer, and for males compared to females. The risk is higher in heavier smokers, 
with an increase of 7-11% for every 10 cigarettes smoked per day (55, 56).  
2.1.2.10. Alcohol 
In addition to cigarette smoking, alcohol consumption is another of the 
commonest preventable risk factors for the development of CRC. An estimated 
11% of CRC cases in the UK are linked to alcohol consumption, with an increase in 
risk of 21% for those consuming 1.5-6 units per day; and 52% for those consuming 
6 units or more per day. Overall this equates to an increase of 7% per unit of 
alcohol consumed per day (57).  
2.1.2.11. Medication 
Several medications have been found to have a chemoprotective effect against 
developing CRC. The strongest evidence is for Aspirin and Cyclo-Oxgenase-2 (COX-
2) inhibitors, such as celecoxib and rofecoxib (58), although the latter two are no 
longer in widespread clinical use. Daily aspirin use for 5 years or more conveys a 
32-49% risk reduction in developing CRC, compared to those who do not use 
aspirin (59). It also reduces the risk of developing adenomatous polyps by 17% 
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(60). Unfortunately, the risks of regular aspirin use, such as GI haemorrhage, mean 
that at the moment aspirin is not recommended for primary prophylaxis of CRC 
(61). 
Hormone Replacement therapy (HRT) and oral contraceptives have both been 
shown to have a protective effect against CRC. HRT carries a 16% lower risk for 
people who have used it, compared to those who have never used it. There is 
some evidence that current users have better protection than previous HRT users 
(62-65). Oral contraceptives, meanwhile, convey a 14-19% reduced risk for those 
who have used them, compared to those that have never used them (60, 66).  
There is contradictory evidence for the role of folate. Some studies have found a 
protective effect against CRC (67), some found no effect (68, 69) and one study 
found that folate may increase adenoma risk (68).                                                                      
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2.1.3. Diagnosis 
Clinical features of CRC depend on the location of the tumour. Approximately 50% 
of tumours arise in the rectum and sigmoid colon, approximately 30% in the 
caecum and ascending colon, and the remaining 20% arise between the hepatic 
flexure and the sigmoid-descending colon junction (70, 71). Left sided and rectal 
lesions tend to present earlier, due to the narrower lumen of the left sided colon 
and the more formed nature of the stools within it. The presenting symptoms are 
usually altered bowel habit, lower abdominal pain, rectal bleeding, and tenesmus 
(feeling of incomplete evacuation), or sometimes with more advanced obstructive 
symptoms, including perforation. Right sided lesions present more insidiously, as 
the caecum and ascending colon have a larger lumen with more liquid stools 
passing through. This means that obstructive symptoms are rarer and later. These 
patients usually present with symptomatic anaemia, weight loss and, potentially, 
an abdominal mass (72).  
Investigation of a patient with suspected colorectal cancer is based around the 
patient's history, physical examination findings (including rectal examination), 
laboratory blood test findings and endoscopic examination of the colon with a 
colonoscopy, including biopsy specimens from any lesions identified as suspicious 
for CRC. Patients may also undergo a Computerised Tomography (CT) scan of the 
abdomen as an initial investigation, or, alternatively, a staging CT scan of their 
whole body as part of their assessment once a CRC lesion has been detected. 
Other potential staging investigations include, a Magnetic Resonance Imaging 
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(MRI) scan of the liver, to assess for potential metastases, a MRI scan of the rectum 
for rectal cancers, to allow better delineation of the anatomy pre surgery, or a 
trans rectal ultrasound scan (USS), again, to better assess a rectal cancer before 
deciding on the surgical treatment of the CRC.  For those patients who are not 
suitable to undergo a colonoscopy, then a "virtual colonoscopy", or CT 
colonography, can be performed to assess for possible colonic tumours (72). 
The histological confirmation of CRC is a vital part of the Multi-Disciplinary Team 
(MDT) approach to the management of patients with the disease. More than 90% 
of CRC are adenocarcinomas, which originate from the epithelial cells of the 
colorectal mucosa. This tumour type is characterised by its glandular appearance. 
It is held that in well differentiated adenocarcinoma >95% of the tumour is gland 
forming, moderately differentiated adenocarcinoma shows 50-95% gland 
formation, and poorly differentiated adenocarcinoma is mostly solid, with <50% 
gland formation. The commonest subtype is moderately differentiated, 
comprising approximately 70% of CRC adenocarcinoma. Within the bracket of 
adenocarcinoma, there are some rare histological subtypes, including mucinous, 
signet ring cell, and medullary type. Other rarer forms of CRC include, 
neuroendocrine tumours, squamous cell, adenosquamous, spindle cell and 
undifferentiated carcinomas (73).   
The staging of CRC tumours is by far the most important prognostic predictor of 
clinical outcome for these patients. CRC is staged via the TNM system which was 
first introduced in 1946 (74), and defines the pattern of CRC disease in terms of 
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depth of tumour invasion (T), the extent of nodal metastases (N), and the presence 
of any distant metastases (M) (see table 2.3.1 for full TNM staging). This system is 
utilised, along with the Duke's staging system, which provides a simplified form of 
staging (see table 2.3.1 for full Duke’s staging). Duke's staging was first described 
in 1929, and, after several revisions, is now well-defined. It describes the tumour 
pattern in terms of 4 stages, ranging from minimal colonic wall invasion, to more 
extensive wall invasion, the invasion of surrounding lymph nodes and finally, to 
include  distant metastases (75). The more advanced the disease is, unsurprisingly, 
the poorer the expected prognosis. Data from 2002 – 2006 in the UK showed that 
Duke's stage A carries a 5 year survival of >90%, Duke's B >80%, Duke's C >60% 
and Duke's D 5-10% (8).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
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TMN staging 
Primary Tumour (T) 
TX Primary Tumour cannot be evaluated 
T0 No evidence of primary tumour 
Tis Carcinoma in situ. Tumour confined to mucosa  
T1 Tumour invades the submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades sub-serosa or beyond 
T4 Tumour invades adjacent organs or perforates the 
visceral peritoneum 
Regional Lymph Nodes (N) 
NX Regional Lymph nodes cannot be evaluated 
N0 No regional lymph node involvement 
N1 Metastasis to 1 to 3 regional lymph nodes 
N2 Metastasis to 4 or more regional lymph nodes 
Distant Metastasis (M) 
MX Distant metastasis cannot be evaluated 
M0 No distant metastasis 
M1 Distant metastasis is present 
 
Table 2.1. Full TNM staging criteria (74).  
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Table 2.2. Dukes staging and equivalent TNM stage (8).  
 
 
 
 
 
 
Dukes Stage  TNM equivalent 
A Tumour limited to submucosa 
 
T1-2,N0,M0 
B Tumour involves muscularis 
propria 
 
T3,N0,M0 
C1 Tumour spread to 1-4 local 
lymph nodes 
 
T1-2,N1,M0 
C2 Tumour spread to more than 4 
regional lymph nodes 
 
T3-4,N1-2,M0 
D Distant metastasis 
 
T1-4,N1-2,M1 
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2.1.4. Treatment  
Once CRC has been adequately staged, the treatment is determined by the disease 
extent. Treatment options include surgical resection of the affected section of the 
bowel. The type of resection is determined by factors including tumour location, 
the functional status of the patient, their preference, and the skill of the surgeon. 
Wherever possible a direct anastomosis is attempted to ensure continuity of the 
bowel. In cases where this is not technically possible, a stoma, either temporary 
or permanent, will be sited. However, in patients with low positioned rectal 
tumours, the patient may have to undergo an abdominoperineal resection and 
have a permanent colostomy. Previously metastatic disease was considered a 
contraindication to surgery, however, increasingly; amenable solitary liver or lung 
metastases are resected either synchronously, or at a later date (72).  
Following surgical resection, the cancer will be fully staged by histological 
examination of the excised tumour. This will allow determination of the depth of 
tumour invasion, the presence of surrounding lymph node involvement, and any 
vascular invasion. Patients with Duke’s C and D, and some with Duke's B, will 
undergo adjuvant chemotherapy to reduce the risk of CRC recurrence. 
Chemotherapy regimens include combinations of Fluorouracil, oxaliplatin and 
capecitabine. They are given as combination therapy or as a monotherapy, and 
the choice depends on the patients' functional status, the CRC phenotype, and the 
oncologist’s choice and experience. Some patients with particularly bulky disease 
may undergo neo-adjuvant chemotherapy, that is, pre-operative chemotherapy, 
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in an attempt to reduce the size of the tumour, thus possibly allowing easier and 
potentially curative surgical resection. 
In addition, some patients with rectal cancer will undergo neo-adjuvant, or 
adjuvant, radiotherapy, either to reduce the size of tumour pre-operatively, or 
reduce the risk of tumour recurrence post-treatment. This may be used in isolation 
or in conjunction with chemotherapy.  
Approximately two thirds of patients present with potentially curable disease, and 
of these 30-50% will develop recurrent disease (76, 77). Disease recurrence is 
typically at the site of resection, or the liver or lungs, with 80% of recurrences 
occurring within 3 years, and most within 5 years (78, 79).  
After surgical resection, patients will be monitored for several years to assess for 
disease recurrence. There is little evidence to suggest that intensive follow-up 
increases survival, but neither is there evidence to the contrary (80). There is also 
variation between centres in terms of the form of follow-up, but most patients will 
undergo a CT scan to assess for potential liver metastases, and a colonoscopy to 
assess for metachronous lesions (80).  The current British Society of 
Gastroenterology guidelines state that colonoscopy follow-up should be 
performed 5 years after surgery, and then every 5 years subsequently until benefit 
is outweighed by co-morbidities (80).  However, many centres instead follow the 
National Comprehensive Cancer Network guidelines, which include a colonoscopy 
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1 year post-surgery, an annual CT scan for 3 years and 6-monthly Carcino 
Embryonic Antigen (CEA) monitoring for 5 years (81).  
2.1.5. Bowel Cancer Screening Programme: 
2.1.5.1 Background 
CRC is a condition which is well-suited to screening. It is common, with a high 
mortality rate, and the symptoms are frequently non-specific and perceived as 
common, leading to many patients ignoring them. This leads to the disease often 
presenting at a later and hence more likely incurable, stage. As discussed earlier, 
prognosis in CRC is strongly linked to stage at diagnosis. Earlier detection of CRC 
may lead to reduced mortality, with clinically incurable disease being potentially 
curable if identified earlier. Screening for CRC could also prevent many future 
cases of the disease by virtue of the detection, and removal, of potentially pre-
malignant adenomatous polyps. The natural history of colonic adenomas is not 
fully understood, but it is believed that the transformation from adenoma to 
carcinoma takes approximately 10 years. If these lesions are detected early and 
removed, then the incidence of CRC could be reduced (82).  
It has been demonstrated that screening for CRC using guaiac based faecal occult 
blood tests (gFOBT) can reduce mortality by 16% in people offered screening, and 
25% in those who accept screening. Economic analysis of screening CRC has shown 
cost effectiveness, with a cost per quality adjusted life year gained of <£3000 for 
gFOBT screening (83).  
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Screening programmes have been introduced successfully in many countries, 
including the United Kingdom, which began its programme in July 2006 in England. 
It was based on biannual gFOBT screening of 60-69 year olds and was subsequently 
rolled-out countrywide and then to the rest of the United Kingdom, with complete 
roll-out by January 2010 (83).  The upper age limit was then extended to 74 years 
in 2012, although, those aged over 74 can still request a screening kit to be sent 
to them. If the kit returns a positive result then the individual is invited to undergo 
a colonoscopy. There are three main outcomes: 1) if the colonoscopy is normal, 
then they are discharged from that round of screening and will be invited to take 
part in the next round 2 years later. 2) If any polyps are detected then the patient 
will leave the screening programme and enter into the polyp surveillance 
programme, which is based on the current BSG guidelines for polyp surveillance. 
3) If cancer is detected, the patient will follow the MDT route of management for 
their CRC (83).  
2.1.5.2. Effectiveness 
Reports into the effectiveness of the Bowel cancer Screening Programme (BCSP) 
found that uptake of the programme varied according to geographic location, and 
socioeconomic status. However, across England, uptake of gFOB testing was 52%, 
which is comparable with pilot studies carried out in the 1980s and in 2000 (83).  
Women were more likely to return the kit (54.4%), compared to men (49.6%). 
Abnormal results were found in 2% of all cases, with 2.5% of men returning a 
positive result – as might be expected, given the higher disease burden in males. 
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Of those with an abnormal gFOBT; 10.1% were subsequently diagnosed with CRC 
(11.6% men, 7.8% women), a further 12% of men and 6.2% of women were found 
to have polyps defined as high risk, and 19.3% of men and 14.6% of women were 
found to have intermediate risk polyps (83). 
The location of CRC detected in the screening programme showed that 28.7% 
were reported as rectal cancers, and, overall, 77.3% were recorded as left-sided, 
with only 14.3% recorded as right-sided. This was a slightly surprising finding as it 
was previously found that the only 66% of CRC was left-sided in non-screening CRC 
population. 71.3% of detected CRC was found to be the earlier Dukes Stages of A 
or B, which is again comparable to the 2000 English pilot study (72%) (83).   
2.1.5.3. Future 
Following the successful extension of the BCSP to 60-74 year olds, a further 
screening programme, Bowel Scope Screening (BSS), underwent pilot studies 
beginning in early 2013. This involved a one-off flexible sigmoidoscopy for those 
aged 55-60 years. At the age of 60, they would then enter the BCSP. Analysis of 
the 6 pilot centres results showed an uptake of 43.1%, and surprisingly, compared 
to the BCSP, uptake was higher in men than in women (45% vs 42%). National roll-
out of the programme began following these pilots and, as of March 2015, two-
thirds of BCSP centres now offer BSS. One of the pilot studies reported they found 
adenomas in 9.8% of screened patients, and CRC in <1% (84).  
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Another potential development in the BCSP is the replacement of gFOBT with 
faecal Immunohistochemical Tests (FIT). This is based around the apparent 
superiority of FIT testing to gFOBT in terms of diagnostic accuracy, but also with 
regards to uptake rate (85-87). gFOBT is based on a peroxidase reaction which 
makes it susceptible to false positive results, especially with diets rich in meat, 
vegetable and fruit products which contain peroxidase (88). This potentially 
explains the low positive predictive value of ~10%. FIT testing, meanwhile, is based 
on antibody testing against human haemoglobin, which allows for quantitative 
results of the levels of haemoglobin (7). The Scottish BCSP has introduced a two-
tier system of gFOBT and FIT (89).   A subsequent trial of FIT as the first line 
screening test revealed a higher uptake rate of 58.5% compared to gFOBT, but a 
similar positive predictive value, though given the increased uptake this may 
represent more cases diagnosed (86). Other studies have shown a 13-15% higher 
participation rate as a result of FIT testing (90, 91).  It seems likely that in the 
coming years FIT testing will replace gFOBT as the screening test for the BCSP.  
Other, more novel technologies which are being developed include, Faecal DNA 
testing, faecal protein testing and pyruvate kinase isoenzyme type M2 (M2-PK).  
Faecal DNA testing involves looking for specific genetic changes, such as mutations 
in the WNT and MAPK pathway genes (e.g. Kras and APC), which are known to be 
present in neoplastic cells and are shed into the colonic lumen. These tests are in 
the development phase, and are mostly being used on patients who have been 
demonstrated to have CRC, and would need assessing in the screening population. 
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However, they appear promising, with a sensitivity of >85% for CRC and >50% for 
large adenomas (90). A multi-target faecal DNA test was recently compared to FIT 
in an average risk screening population, and found to have a sensitivity of 92.3% 
for CRC, and 42.4% for adenomas with high grade dysplasia. The sensitivity was 
approximately 20% higher than the comparator; FIT. The specificity was lower for 
the faecal stool analysis, 86.6%, compared to 94.9% for FIT (92).  
Several faecal proteins, such as lactoferrin, lysozyme and albumin have been 
assessed as potential faecal biomarkers of organic pathology, although, only faecal 
calprotectin (FC) has shown any promise, due to the poor diagnostic accuracy of 
the other tests (88, 93). Faecal calprotectin is an inflammatory protein released 
from white blood cells in response to inflammation or malignancy. It has a mean 
sensitivity of 83% and specificity of 84% for organic bowel pathology, but, as it is 
unable to distinguish between malignancy and inflammation, it is unsuitable for 
CRC screening (88).  
Pyruvate kinase isoenzyme type M2 has shown promise as a potential stool 
biomarker for GI cancers, including CRC. The rationale behind its use is that 
different isoenzymes of pyruvate kinase are expressed depending on the 
metabolic functions of tissues. During rapid cellular division, as seen in CRC, 
specific isoenzymes are replaced with M2-PK in its dimeric form. The main 
advantages are that only one stool test is required, and points of care tests are 
available commercially. A pooled analysis of 12 studies, revealed a sensitivity of 
~80% for CRC, and 44% for adenomas >1cm. However, this only included 704 
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patients, and therefore, larger scale studies are required before M2-PK could be 
used as a screening tool for CRC (88, 94).  
Blood serum markers for CRC are also undergoing investigation at present. DNA 
originating from cancer cells has been found circulating in plasma, which could 
allow serological screening for CRC. DNA methylation occurs early in 
carcinogenesis and thus, biomarkers of these epigenetic events may permit earlier 
diagnosis. Some genes are more heavily methylated e.g. Septin-9 (SEPT9), and this 
target is currently under assessment in the screening population (90). A 
commercially available test, including molecular assays for aberrant methylation 
of BMP3, NDRG4, KRAS and an immunochemical FOB test, is available. This test 
gives better sensitivity than FOB, but at the expense of specificity (88).  The current 
cost of these DNA sequencing technologies, at present, prevents their use as a 
viable screening test at present.  
There is an ongoing quest for non-invasive biomarkers of disease, particularly 
cancer. This search has led to the exploration of volatile organic compounds as a 
potential biomarker.   
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2.2. Volatile Organic Compounds 
The quest for a non-invasive method of screening for, or detecting, early stage 
cancers has been applied to genomics, proteomics and metabolomics. One of the 
most promising metabolomic approaches is the detection and analysis of volatile 
organic compounds (VOCs). The detection of patterns of VOCs by both invasive 
and non-invasive methods, and their utility as disease specific gas phase 
biomarkers, has been a rapidly developing area within several medical domains 
over recent years (95).  
VOCs are a widely diverse group of carbon based chemicals and are classified 
according to their boiling points and retention times. They represent the product 
of metabolic processes within the body and are simple chemicals such as alcohols, 
aldehydes, alkanes etc. They are present in exhaled breath as well as blood, urine, 
faeces and sweat. Alterations in the patterns of VOCs have been suggested to 
result from pathological processes in the body generating new VOCs, which are 
not produced during normal physiological processes, thus allowing their use as 
biomarkers of disease (95).  
VOCs have been shown to produce disease specific patterns which allow the 
distinction of cancer from non-cancer, but also, other non-cancerous diseases 
from controls, across a wide range of medical specialties, including respiratory; 
gastroenterology and metabolic medicine (96). The study of this technology has 
developed as a result of the desire for non-invasive, rapid, point-of-care tests 
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which will allow patients to be tested for various disease states, and responses to 
treatment.  
2.2.1. Background and Animal studies 
Initial interest in non-invasive VOC detection as screening tests for disease arose 
from the observation of canine olfactory detection of cancer in humans. This was 
first reported in 1989, with a dog reported to have persistently sniffed a spot on 
its owners leg which, on medical examination and biopsy, was proven to be 
melanoma (97). A study in 2004, using 2 separate dogs on 7 patients, found the 
dogs were able to detect biopsy proven melanoma in 6 of them (98). Another 
study in 2004, demonstrated that canines were able to detect malignancy in the 
urine of patients with bladder cancer (99). Further early studies, looking at lung, 
breast, prostate and ovarian cancer, have all suggested a role for canine detection 
of human malignancy (100-102). These studies showed varying success rates, 
sensitivities and specificities. Gordon et al demonstrated only 22% sensitivity for 
detecting breast cancer in urine specimens, and only a 17% success rate for 
prostate cancer. The authors suggest that this may be due to the urine being dried 
first, resulting in evaporation of VOCs, as fresh samples demonstrated a 50% 
sensitivity (101). Other studies into breast and lung cancer detection via exhaled 
breath, showed sensitivities of 88% and 99% respectively, and specificities of 98% 
and 99% respectively (100).   A review of the early studies highlighted several 
problems in terms of lack of controls, and the use of canines, which need to be 
specifically trained to perform the task (103).  Subsequently, a study in 2011, into 
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canine detection of CRC using both breath and stool samples showed high 
sensitivity and specificity for both sample types (sensitivity 91%, specificity 99% 
for breath and sensitivity 97%, specificity 99% for stool). Interestingly, the canine 
detection remained high even for earlier stages of CRC. This suggests that the 
changes in the VOC profile occur early in the carcinogenesis pathway. The authors 
also found that canine scent detection was not confounded by smoking status, the 
presence of benign polyps or IBD (104).   
A further study demonstrated that four trained dogs were able to distinguish 
bladder cancer from controls through urine, with a pooled sensitivity of 64%, and 
specificity ranging from 56% to 92%. Again, this study demonstrated no 
confounding by smoking, gender or age. Although they did find that sensitivity and 
specificity were affected by other, non-cancerous, urological co-morbidities (105).  
Better success appears to have been found with prostate cancer. One study 
reported that using urine specimens, the dog, which had received 24 months of 
training, was able to distinguish prostate cancer specimens from controls with a 
sensitivity and specificity of 91% (106).  This was followed by a larger study looking 
at urine from 362 patients with prostate cancer and 540 healthy controls, which 
found that 2 dogs achieved respective sensitivities of 100% and 98.6%, and 
specificities of 98.7% and 97.6% (107).  
In recent years, subsequent studies into the animal detection of various cancers 
by bodily substance olfaction have included; studies assessing lung cancer 
detection from breath samples (sensitivity 71-82%; specificity 82-93%) (108, 109) 
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and one study assessing lung cancer detection from breath and urine samples 
(110).  
The problems with animal olfactory detection of cancer include; training time for 
the animal, the variability of training and also 'olfactory fatigue'. This phenomenon 
describes where the olfactory receptors become saturated with a particular odour 
and, hence, will lose sensitivity with continuous exposure (111, 112). This, in part, 
has accelerated the quest to find a technology which will allow for rapid, 
reproducible testing of bodily samples for VOC patterns that show a high 
diagnostic accuracy.   
Interestingly, as previously mentioned, canine cancer detection has repeatedly 
been shown to be unaffected by confounders such as smoking status, food odours 
and drug metabolites. This suggests that while the robotic VOC detection methods 
may be more reproducible, they lack the "canine element" of being able to tune 
out potential confounding smells (113).  The argued benefits of canine detection 
over mechanical detection are that dogs give a clear binary response (yes/no) to 
the presence of cancer, and the sample can be analysed at the bedside, which 
reduces the risk of sample degradation due to storage (114). Most mechanical 
forms of VOC detection, with some exceptions, detect individual VOCs, whereas 
canines are most likely sensing the overall "smell print" of multiple VOCs in the 
bodily sample.  
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2.2.2. Current and future technologies and VOC sample type 
There are several available analytical tools which can be used to detect VOCs in 
various bodily substances. The current gold standard is widely held to be GC-MS.  
A systematic review from 2015 looked at the use of exhaled breath in detection of 
all types of cancer. Of these studies, 42 relied on GC-MS as their analytical 
machine, whilst 24 utilised E-nose technology. A summary of the various 
technologies used for VOC detection can be found in Table 2.3.  
GC-MS technology allows identification of individual VOCs within the specimen 
chosen for sampling. Significant differences in the type of VOCs found between 
cancer patients and healthy controls have been identified. Individual VOCs 
identified vary according to cancer type, however, some have been found to be 
elevated in cancer compared to non-cancer patients. These include 2-methyl-
3phenyl-2propenal; p-cymene, anisole, 4-methyl-phenol and 1,2-dihydro-1, 1,6-
trimethyl-napthalene, whereas dimethyl sulphide was found to be present at 
lower concentrations in cancer patients as compared to non-cancer (115).  
Though GC-MS allows identification of individual VOCs, it is a large, expensive 
piece of equipment, with significant operational costs and specific laboratory 
requirements. Furthermore, there have been to date no unique VOCs identified 
which are consistently present through out cancer patients, rather a panel of VOCs 
are used to identify the cancer patients. These factors mean it is unlikely to 
translate from research to clinical application easily.  
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Technology Benefits Limitations 
GC-MS • Identify individual 
VOCs 
• Most studied/well 
characterised 
• Currently held Gold 
standard 
• Expensive 
• Requires Laboratory 
infrastructure 
• Unlikely to be used in 
clinical settings 
• Individual VOCs unlikely 
to be successful as 
biomarkers 
 
E-Nose • Can be used at point 
of care 
• Recognises overall 
pattern of VOCs 
• Does not identify 
individual chemicals 
• Affected by high levels 
of water vapour 
• No absolute calibration 
• Sensors can drift 
• Not quantitative data 
FAIMS • Can be used at point 
of care 
• Recognises overall 
patterns of VOCs 
• Rapid sample analysis 
• Does not identify 
individual chemicals 
• Affected by high levels 
of water vapour 
• No absolute calibration 
• Sensors can drift 
• Not quantitative data 
Other MS 
based, inc SIFT-
MS, TOF-MS, 
PTFR-MS 
• Identify individual 
VOCs 
 
• Expensive 
• Requires Laboratory 
infrastructure 
• Unlikely to be used in 
clinical settings 
• Individual VOCs unlikely 
to be successful as 
biomarkers 
• Limited data/studies 
 
 
Table 2.3. Summary of the benefits and limitations of the various technologies 
which are currently being used for detection of cancers by VOC analysis   
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Miniaturised GC equipment has been under development since the 1970s but, so 
far has met with limited commercial success, due to combined difficulties in 
creating stable coatings and poor compatibility with existing GC equipment (96). 
E-nose is a broad ranging term which does not describe individual sensor 
technology but rather the method of detection. In contrast to GC-MS, these 
sensors do not detect individual chemicals but rather the overall pattern, or “smell 
print”, of the sums of the individual VOCS present, much like a human or canine 
nose would.  The E-noses, typically comprise a sensor array of between 8 and 32 
different chemical sensors, which are broadly tuned to different chemical groups 
including alcohols, ketones and low pressure gases. When the sensor array is 
exposed to the air above the biological sample, the “headspace”, each sensor 
produces a unique response to the chemicals present. It is possible to extract a 
feature from this response and use it to train a pattern recognition engine within 
the machine, and, if presented with a similar VOC pattern in the future, the E-nose 
will be able to recognise the sample as a specific disease (96).  
The types of sensors used for E-noses are wide ranging and include; carbon black 
composite polymers, semi-conducting metal oxide chemo resistors, polymer 
coated quartz crystal microbalances, optical dyes and electrochemical sensors. 
Drawbacks to the E-nose technology include; loss of sensitivity in the presence of 
high levels of water vapour or single components; the sensors can drift; there is 
no absolute calibration method and, as previously discussed, the data obtained is 
not quantitative (116). 
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In addition to the above technologies, there are now many new technologies 
which can be included under the E-nose umbrella. These include IMS, GC 
technology utilising gas sensors as the detector, and optical gas spectrometers. 
The added benefits of these newer technologies is a more rapid sample processing 
time of just a few minutes, giving much faster results and potentially allowing for 
point of care bedside testing of samples (96). Field Asymmetric Ion Mobility 
Spectrometry (FAIMS), a type of IMS, in particular, appears to give higher 
sensitivities than the other technologies. It identifies VOCs by tracking the mobility 
of single ions as they pass through an electric field. Thus, allowing identification of 
minute changes in the VOC composition, although again, without the ability to 
detect individual VOCs (96). 
Other technologies include Selected Ion Flow Tube Mass Spectrometry (SIFT-MS), 
which combines chemical ionisation with mass spectrometry. It allows rapid 
quantification of trace VOCs, even when there is a large amount of atmospheric 
gases present. Unfortunately, the time for sample analysis is limited to the 
exhalation time and, so, precise and sensitive quantifications of low concentration 
compounds could be limited (117). This technology, being based on mass 
spectrometry, requires laboratory infrastructure and is unlikely to be able to be 
utilised in clinical settings. Yet, there may be a role for it in the detection of 
diseases via breath samples, given its ability to detect VOCs in the presence of 
atmospheric gases.   Proton Transfer Reaction Mass Spectrometry (PTR-MS) has 
also been applied as a potential analytical tool, but it is less accurate than GC-MS, 
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in that it is unable to distinguish between two compounds of the same molecular 
weight, although, it is the most sensitive equipment for detecting aromatic 
hydrocarbons (95).  
Potential future technologies include the advent of portable, hand held, E-nose 
type equipment. Some are already near to commercialisation for non-malignant 
conditions including; tuberculosis, Clostridium difficile and bacterial overgrowth. 
The future use of such technology for cancer detection could include the 
integration of the sensors, with the electronic interface and analytical centre, onto 
a single chip which could be placed inside a portable device, allowing point-of-care 
testing. This could revolutionise the clinical screening of conditions such as CRC 
(96).  
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2.2.3. Mechanical VOC detection 
2.2.3.1. Initial progress 
Despite most of the initial interest in the non-invasive detection of cancer having 
originated from observations of canine detection of cancer, the first studies into 
the role of VOCs in human cancer detection actually predate the 1989 case report 
by Williams. As early as 1985, exhaled breath analysis using Gas Chromatography 
and Mass Spectrometry (GC-MS) was shown to be able to distinguish patients with 
biopsy proven lung cancer from healthy controls with a classification accuracy of 
93%. Using the GC-MS technology they were able to find several chemical peaks 
which seemed to be unique to the lung cancer patients, although not universally 
so, meaning that a panel approach had to be used to reach the achieved 
classification accuracy (118). This was followed in 1988, with an analysis of the 
components of exhaled gas using GC-MS, which showed that specific chemicals, 
namely o-toluidine and aniline, were present in the breath of lung cancer patients, 
but not the control samples (119).  Again, anilidine, was not found in all of the 
patient’s breath samples. Subsequently; several potential VOCs, principally alkane 
and benzene derivatives, were identified as being unique biomarkers for lung 
cancer (120). The next study to assess the utility of exhaled VOCs as a biomarker 
for lung cancer was by Phillips and colleagues in 1999. Breath samples of patients 
with abnormal chest radiographs due to undergo bronchoscopy were collected 
and analysed using GC-MS. They found that a panel of 22 exhaled VOCs, 
predominantly alkanes, alkane derivatives and benzene derivatives, discriminated 
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between those who had benign disease and those patients diagnosed with lung 
cancer, with 100% sensitivity and 81.3% specificity (121).  
Following this research, there was a marked increase the in the number of studies 
conducted into the non-invasive detection of many different cancers.    
2.2.3.2. Lung Cancer 
Following the initial efforts of Gordon and Phillips described above, the first 
decade of the 21st century saw a rapid expansion in the number of studies aimed 
at analysing the VOC patterns in bodily substances of patients with lung cancer. 
Krilaviciute et al conducted a systematic review in 2015, analysing the use of 
exhaled breath in all cancer detection, not just lung cancer. They found that over 
73 studies researched exhaled breath VOC detection and, of these, two thirds 
were focused on lung cancer (122). 
Further to their work in 1999, Phillips et al, in 2003, analysed the breath samples 
of 108 subjects (67 lung cancer, 41 healthy controls) using GC-MS to detect for the 
presence of a panel of 9 VOCs. They found a sensitivity of 89.6% and specificity of 
82.9% (123). Subsequently, they conducted a larger study of 193 lung cancer 
patients and 211 healthy controls, again using GC-MS to detect a panel of 16 VOCs. 
They achieved a sensitivity of 84.6% and specificity of 80% (124). This data was 
later reanalysed using a weighted digital analysis model, giving a slightly higher 
specificity of 81% (125).  There have been several studies which have looked at the 
ability of GC-MS technology to distinguish or detect lung cancer from exhaled 
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breath VOCs, including both single and multiple VOCs. The sensitivities and 
specificities from these studies ranged from 51% - 100%, and 69% to 100%, 
respectively. To date, no one single VOC has been shown to be consistently 
effective at distinguishing lung cancer from controls. This suggests that it is the 
overall pattern of VOCs, which allows distinction of cancer from controls, rather 
than one single biomarker.   
More recently, fourier transform-ion cyclotron resonance mass spectrometry (FT-
ICR-MS) has been used to analyse exhaled breath samples from lung cancer 
patients (126). This has been shown to distinguish patients with lung cancer from 
ex-smokers, current smokers and patients with benign lung nodules, with 
classification accuracy of 97%, 95% and 89% respectively (127).  
Attempts have been made to identify individual VOCs from the headspace above 
lung cancer cell cultures using GC-MS. These have shown an altered VOC 
expression profile between different lung cancer cell types, although again, no 
consistent tumour marker has been identified, and there appears to be variable 
correlation with exhaled VOCs (128-132). A problem identified from using cell line 
cultures is that, as the cells are not in their native environment, their metabolism 
will be different and produce a different VOC profile (133).  It has also been 
suggested that cell culture methods do not provide as relatively hypoxic an 
environment as that found in vivo during carcinogenesis of lung cancer, and that 
cell culture mediums should attempt to mimic this environment (134).  
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Technology other than GC-MS has also been utilised. In 2005, Machado et al used 
a Cyranose 320 Electronic nose (E-nose) to compare exhaled VOCs from 14 lung 
cancer patients to 20 healthy controls, and create a training set for the machine. 
Validation analysis of a further 14 lung cancers, with 62 controls, showed that the 
E-nose could discriminate cancers from controls with a sensitivity of 71.4%, and 
specificity of 91.9% (135).  
Dragonieri then demonstrated that the same E-nose model could distinguish lung 
cancer patients from those with Chronic Obstructive Pulmonary Disease (COPD) 
and healthy controls with an accuracy of 85% and 90%, respectively, from exhaled 
breath (136). McWilliams et al demonstrated that the Cyranose could distinguish 
exhaled breath from lung cancer patients from high risk controls (smokers and 
COPD patients) with an accuracy of >80% (137).  
Other types of E-nose technology include colorimetric sensor arrays, which were 
used by Mazzone et al, in 2007, to study exhaled lung cancer VOCs. A colorimetric 
sensor array is embedded with chemically sensitive compounds which change 
colour in response to chemical stimuli. They determined that the array could 
distinguish lung cancer patients from other pulmonary conditions, including 
pulmonary fibrosis, COPD, sarcoidosis and also healthy subjects, with a sensitivity 
of 72.3% and specificity of 72.4% (138). In 2012, they augmented their protocol by 
using clinical data such as smoking status, age and sex to improve the accuracy of 
their model with an area under the curve (AUC) of 0.811. It also demonstrated 
some promise in distinguishing squamous cell cancers from adenocarcinomas 
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(AUC 0.864), early from late stage disease (AUC 0.784) and survival <12 months vs 
survival >12 months (AUC 0.770) (139). The same group further refined their 
technique and were able to achieve accuracies of 79% to 86% for distinguishing 
cancer patients, and subgroups, from controls (140).   
Peng et al used GC-MS to identify potential VOCs from breath samples from 
multiple cancer types and then trained a gold particle based nano-sensor array (a 
variant of an electronic nose). They were able to distinguish lung cancer patients, 
from those with CRC, prostate cancer, and healthy controls (141).   Barash et al 
also used a gold nano-particle array to distinguish between the breath of non-
small cell lung cancer patients and controls with 100% accuracy (142).    
In 2003, Di Natale et al used a Quartz sensor based E-nose and demonstrated 
90.3% accuracy for discriminating between the breath of lung cancer patients, 
healthy volunteers and post-surgery lung cancer patients (143). The same group 
carried out a further study in 2009, and showed that the exhaled breath of 
confirmed lung cancer patients could be distinguished from healthy non-smokers 
with a sensitivity of 85% and specificity of 100%. It could also distinguish lung 
cancer from other lung diseases with a sensitivity of 93% and specificity of 79% 
(144). Santanico et al also used a Quartz sensor based E-nose to compare 20 
confirmed lung cancers with 10 healthy controls. They analysed exhaled breath 
with bronchoscopically obtained alveolar air and found that the bronchoscopically 
obtained sample gave better results than the exhaled samples, with a sensitivity 
of 97.5% and specificity of 75%. They also found a 75% classification accuracy 
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between squamous cell cancer and adenocarcinoma patients (145). Recently, 
further attempts to use Quartz sensor based E-nose technology has looked at 
distinguishing lung cancer patients from healthy controls in the presence of 
potential metabolic confounders such as diabetes, obesity and dyslipidaemia. This 
found an overall sensitivity and specificity of 81% and 91%, respectively. 
Comparing the presence of metabolic confounders, against their absence, gave a 
sensitivity and specificity of 85% and 88% vs 76% and 94%. They also found that 
when analysed by stage of lung cancer, the best sensitivity was for stage I (92%) 
vs stage II/III/IV (54%) (146). 
In 2009, Westhoff et al, used a Nickel-63 based Ion Mobility Spectrometry (IMS) 
device to analyse exhaled breath of lung cancer patients. IMS technology 
separates VOCs by virtue of their mobility in response to being passed through an 
electrically charged field. Westhoff et al were able to distinguish between 32 lung 
cancer patients and 54 healthy control subjects, including smokers and non-
smokers, with an accuracy of 100% (147). Subsequently IMS technology has been 
used to demonstrate that the VOC profiles of patients with lung cancer vary 
between different histological subtypes of tumour, and between the diseased and 
disease-free lung (148).  
Peled et al used a custom made sensor array combining carbon nanotube 
technology with gold nano-particles to analyse exhaled breath VOCs. This allowed 
differentitation between cancerous and non-cancerous pulmonary nodules with 
an accuracy of 88% (AUC 0.986). It was also able to distinguish early from late 
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disease, and adenocarcinoma from squamous cell carcinoma with accuracies of 
88% and AUCs of 0.961 and 0.974 respectively (149).  
There have been suggestions that VOCs could be used in the follow-up of patients 
undergoing treatment, including curative resection for lung cancer, similar to the 
use of tumour markers for monitoring response to treatment and for potential 
disease recurrence. Poli et al analysed exhaled breath at one month, and at three 
years post lung cancer resection. They demonstrated that at one month, the only 
VOC to change in level was isoprene. At three years, some VOC levels, for example, 
pentane, had increased and some, such as isoprene, had decreased. It was found 
that most VOCs in the post-surgical samples were still present at higher levels than 
controls. This suggests there may be a potential role for the use of VOCs in post 
cancer treatment monitoring, but that further work is required to determine 
exactly how the VOC profiles change in response to treatments over time (150).    
More recently, E-nose technology (Quartz sensor based) was compared to GC-MS 
in the detection of lung cancer via analysis of breath samples from both the 
affected and unaffected lung. It was found that the E-nose gave a classification 
accuracy of over 90%, regardless of the lung from which the sample was taken, 
whilst the GC-MS only gave a 76% correct classification when both lung samples 
were compared. Interestingly, they found that the VOC profile was preserved 
between bronchoscopically sampled air from the lung and exhaled breath (151).   
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Other E-nose technology, BIONOTE, has been used to distinguish lung cancer 
patients from healthy controls with a sensitivity and specificity of 86% and 95%, 
respectively (152).  
Other than the main histological types of lung cancer, VOC detection has also been 
used to study malignant mesothelioma. In 2012, Dragonieri's et al demonstrated 
that E-nose could distinguish patients with malignant pulmonary mesothelioma 
from patients with asbestosis with a sensitivity of 92.3% and specificity of 85.7%, 
from exhaled breath (153). Chapman et al have also demonstrated 85% accuracy 
in detecting mesothelioma from patients exhaled breath using E-nose technology 
(154).   
Whilst most studies involving lung cancer VOCs have been based around patients’ 
exhaled VOCs, some have looked at other sources. VOCs derived from pleural fluid 
aspirates have also been studied to distinguish malignant effusions from benign 
effusions using GC-MS technology, with some promise in terms of unique VOC 
profiles (155). Urinary VOCs have been studied using GC-MS analysis and 9 
potential VOCs were shown to have individual sensitivities and specificities ranging 
85-95% and 70-100% respectively, with AUCs of 0.79 - 0.96 (156). 
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2.2.3.3. Gastrointestinal Cancer 
After lung cancer, the GI tract has been the main system studied for the non-
invasive detection of cancer via VOC detection, with the bulk of the studies 
focusing on CRC. 
The majority of the research into CRC detection through VOC analysis has looked 
at patients exhaled breath and urine samples, mainly using GC-MS technology for 
analysis, with E-nose being the next most commonly used method (157).  
Peng et al, appear to be the first group to demonstrate that CRC could be detected 
by VOC analysis, in 2010. Using a custom-made gold nanoparticle E-nose sensor 
array and GC-MS to analyse exhaled breath samples, they were able to prove that 
they could distinguish patients with CRC, lung cancer, breast cancer and prostate 
cancer from each other, and from healthy controls (141).  The E-nose technology 
demonstrated that 26 CRC patients were completely distinguishable from 22 
healthy controls. Although, the sensitivity dropped when GC-MS analysis of 6 
identified VOCs were used. This would suggest that it is the overall pattern of 
chemical components, rather than individual chemical compounds, which 
contribute towards the distinction of the two groups.   
Subsequent breath analysis studies have shown further promise for distinguishing 
CRC patients from healthy controls. Altomare et al, in 2013, analysed 37 CRC 
patients and 41 healthy controls using GC-MS. By applying a profile of 15 VOCs, 
they were able to distinguish CRC patients from controls with 86% sensitivity and 
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83% specificity, with an AUROC of 0.85. They performed a validation study on 25 
blinded subjects which showed an accuracy of 76% (158). Wang et al 
demonstrated that 9 VOCs were significantly higher, and 1 VOC significantly lower, 
in the exhaled breath of 20 CRC patients, as compared to healthy controls (159). 
Amal et al analysed the exhaled breath of 65 CRC patients, 22 patients with 
adenomas and 122 healthy controls, first using GC-MS to identify potential VOCs, 
and then utilising E-nose technology. From this, they achieved a sensitivity of 85%, 
specificity of 94% and an accuracy of 91% (160).  
The use of urinary VOCs to distinguish CRC subjects from healthy controls has also 
been studied in this context. This was first done in 2009 by Ma et al, who compared 
urinary VOCs of 24 CRC patients with 80 healthy volunteers using Time of Flight 
mass spectrometry (TOF-MS). They were able to distinguish the controls from the 
CRC patients. They found statistically significant higher levels of 2 low molecular 
weight compounds in the CRC patients compared to the healthy controls, and also 
found that, post-treatment, the levels of the 2 chemicals were significantly 
reduced (161). Silva et al analysed the urinary VOC profile of 12 CRC, 7 lymphoma 
and 14 leukaemia patients compared to 21 healthy controls. Their conclusion was 
that a panel of 16 VOCs could distinguish cancer patients from healthy controls; 
however, this study did not specifically compare CRC with the other cancers (115).  
Two subsequent studies into urine were conducted by Arasaradnam et al. The first 
of these studies utilised FAIMS technology to analyse the urinary VOCs of 83 CRC 
patients and 50 healthy controls. It achieved 83% sensitivity and 60% specificity in 
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distinguishing the 2 groups (162). I was second author for this study and this thesis 
is primarily a continuation of this work and the questions that were raised from it.  
Subsequently, a bespoke E-nose, the WOLF system, was developed by the 
University of Warwick engineering department. This system comprised a 
combination of different sensor types. This was used to analyse the urine of 39 
CRC patients, 35 irritable bowel syndrome patients and 18 healthy controls; 
achieving a sensitivity of 78% and specificity of 79% (161). Neither study identified 
any unique VOCs when GC-MS analysis was used. This again suggests that it is the 
overall "smell print" which is important, rather than individual chemical 
components. The main results of these studies are shown in figures 2.1 and 2.2. 
The authors considered that since urine samples were far more acceptable to 
patients than collecting stool samples, that urine use in screening programmes 
would be likely to improve compliance (163).  
VOCs from stool samples were first studied in CRC patients in 2014 by De Meij et 
al. They used a Cyranose320 E-nose to assess 40 CRC patients, 60 patients with 
advanced adenomas and 57 healthy controls. They demonstrated sensitivity of 
85% and a specificity of 87%, for distinguishing CRC patients from controls. Having 
also conducted FIT testing on the same samples, they found a sensitivity of 63% 
and a specificity of 100% (164). Similarly, Batty et al studied the faecal VOCs in 31 
CRC/high grade adenoma patients compared to 31 controls, using SIFT-MS, and 
they demonstrated a sensitivity of 72% and specificity of 78% (165).  
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To date, there has been one study evaluating the VOC profile of blood from 
patients with CRC. Wang et al demonstrated that 3 VOCs were significantly less 
expressed, and 1 was expressed at significantly higher levels in 31 CRC patients as 
compared to 31 healthy subjects (166).  
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Figure 2.1. Results of Arasaradnam et al, demonstrating distinction of CRC from 
healthy controls via urinary VOC detection using a FAIMS instrument with 83% 
sensitivity and 60% specificity (160).  
 
 
 
Figure 2.2. Results of Westenbrink et al, demonstrating distinction of CRC from 
healthy controls and IBS via urinary VOC detection using a custom made E-nose 
instrument with 78% sensitivity and 79% specificity (161).   
78 
 
The profiling of VOCs to detect upper GI cancers, such as oesophageal, gastric, 
pancreatic and hepatobiliary cancers has also been studied. Xu et al 
demonstrated, in 2013, that the exhaled breath of patients with gastric cancer 
could be distinguished from benign gastric conditions, such as gastritis and ulcers, 
with a sensitivity of 89% and specificity of 90%, using GC-MS analysis (167). One 
group has studied the VOC patterns in the exhaled breath, urine and gastric 
contents of patients with oesophago-gastric cancer using SIFT-MS. Using these 
VOCs they were able to distinguish the cancer patients with an accuracy of 0.91 in 
exhaled breath (168), 0.90 in urine (169) and 0.90 in gastric contents (170).  
Further to this, they carried out a larger validation study using the exhaled breath 
of 81 upper GI cancer patients and 129 controls, and found an AUC of 0.97 for 
oesophageal cancers and 0.98 for gastric cancers (171).  Amal et al followed up 
their work on CRC by analysing the exhaled breath of 484 patients, including 99 
with gastric cancer, initially using GC-MS to identify potential VOCs, and then 
utilising cross reactive nano-array E-nose type technology. Using the GC-MS they 
identified 8 VOCs and with the nano-array, they achieved sensitivity of 73%, 
specificity of 98% and accuracy of 92% (172). 
Two separate studies have used tissue cultures to try to identify potential VOCs in 
gastric cancer. Buszewski et al compared VOCs from gastric cancer with those of 
healthy gastric tissue taken from the stomach of the same cancer patients, and 
found that the cancer cultures produced different VOCs (173). Zhang et al used 
GC-MS to identify potential VOCs for gastric cancer and then built a Carbon Nano-
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tube E-nose array which was able to distinguish gastric cancer cells in culture, from 
healthy gastric mucosa in culture (174). A more recent study has shown that 
gastric cancer VOCs appear stable over the course of several days, but can be 
influenced by changes in the gut microbiome (175).  
Attempts to characterise the VOCs of patients with pancreatic and biliary 
pathology have been made in two studies. Navaneethan et al used SIFT-MS to 
analyse the VOC profiles in the bile of 24 patients with pancreatic cancer, 
compared to 72 patients with benign biliary strictures; achieving sensitivity and 
specificity of 83 and 82% respectively (176). The same group then studied the VOC 
profiles in urine to try and obtain the same outcome; achieving a sensitivity of 80% 
and a specificity of 100% (177).  
There have been two studies into the VOC profiles of Hepatocellular carcinoma 
(HCC) patients. This was first done by Qin et al in 2010, using GC-MS to analyse the 
VOCs in the exhaled breath of patients with HCC, compared to healthy controls 
and patients with cirrhosis. They determined that a panel of 3 VOCs could 
distinguish HCC from healthy controls, with a sensitivity of 83.3% and specificity of 
91.7% (178). Amal et al then studied the VOC profiles from tissue cultures of HCC 
cells using GC-MS, and found they could completely distinguish HCC from healthy 
controls (179).  
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2.2.3.4. Breast Cancer 
Following lung cancer and CRC, breast cancer is the malignancy that has received 
the most interest and study into non-invasive VOC profiling.  Most of the studies 
to date have revolved around GC-MS analysis of exhaled breath samples, and have 
been conducted by Phillips et al, who also extensively studied lung cancer VOCs. 
Their first study, in 2003, assessed a cohort of women with abnormal 
mammograms, with 51 out of 198 being subsequently diagnosed with breast 
cancer. GC-MS analysis of exhaled breath samples gave a sensitivity of 88.2% and 
specificity of 73.8%. They found that breath analysis had a better negative 
predictive value than screening mammogram (99.93% vs 99.89%), but a weaker 
positive predictive value (1.29% vs 4.63%) (180). The group then refined their 
technique and used a panel of five VOCs, resulting in an improvement in sensitivity 
to 93.8% and specificity to 84.6% (181). Attempts  to further refine their analysis 
in 2010  yielded a slightly poorer sensitivity of 78.5%, but an improved specificity 
of 88.3% (182). In 2014, the same group studied a point of care breath test, using 
GC-MS analysis. The breath test had a 6 minute turnaround time. They were able 
to achieve a sensitivity of 75.8%, specificity of 74% and accuracy of 78% for 
distinguishing between biopsy proven cancer and biopsy proven non-cancer. 
Additionally, they found that it could detect breast cancer, where the screening 
mammogram was normal with a sensitivity of 81.8%, specificity of 70% and an 
accuracy of 79% (183).  
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Other studies into breast cancer detection via exhaled VOC detection have been 
on a smaller scale. Shuster et al studied a cohort of 36 women, with 13 confirmed 
breast cancer patients. They used GC-MS analysis of exhaled breath and achieved 
a sensitivity of 94% and specificity of 80% for detecting benign breast disease 
(184). Patterson et al studied a cohort of 20 breast cancer patients and 20 healthy 
controls and, using GC-MS analysis of exhaled breath, were able to achieve a 
sensitivity of 72% and specificity of 64%, with an accuracy of 77% (185).  Mangler 
et al studied a small cohort of 10 breast cancer patients and 10 healthy controls. 
They found that 4 VOCs were significantly reduced in the breast cancer patients 
compared to the healthy controls, and that 1 VOC was significantly increased 
(186).   
More recently, a larger study of 276 participants, by Barash et al, attempted to 
discriminate between patients with malignant breast lumps, ductal carcinoma in 
situ (DCIS), benign conditions and healthy volunteers, using GC-MS and nano-array 
analysis of exhaled breath samples. GC-MS identified 23 potential VOCs, and 
subsequent nano-array analysis gave an accuracy of 83% for distinguishing benign 
from malignant conditions. Distinction between the various subtypes was 
achieved with sensitivities ranging from 81-88%, specificities from 76-96% and 
accuracies of 82-87% (187).  
There has been one study, to date, which analysed the urinary VOC profile of 26 
patients with breast cancer and 21 healthy controls using GC-MS. There were 6 
VOCs identified which had statistically significant levels between the breast cancer 
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patients and healthy controls. Analysis resulted in an accuracy of 70.3% for 
discriminating between the two groups (188).  
2.2.3.5. Other cancers 
Other cancers that have been studied include head and neck, thyroid, ovarian, 
urological and skin cancers.  
Following on from the initial work of Gordon, in 2008, into the canine detection of 
prostate cancer, and the study of Peng et al comparing lung, breast and prostate 
cancer in 2010, there have been three studies looking at the detection of urinary 
VOCs to distinguish prostate cancer patients from healthy controls. 
Asimakoupolus et al analysed the urinary VOCs of 41 patients undergoing prostate 
biopsy, using an E-nose. 14 patients went on to have biopsy-proven prostate 
cancer, and the E-nose was able to distinguish cancer from non-cancer with a 
sensitivity of 71.4% and specificity of 92.6% (189). Later in 2014, Roine et al 
compared the urinary VOCs of 50 patients with confirmed prostate cancer, to 
those with benign prostatic hyperplasia, again using an E-nose. They were able to 
distinguish between the two groups with a sensitivity of 78% and specificity of 
67%, AUC 0.77 (190). Khalid et al analysed the urinary VOCs of 59 prostate cancer 
patients compared to 43 cancer-free controls with GC-MS; using a model based 
around a panel of 4 VOCs, and taking into account prostate specific antigen (PSA) 
levels. They also used several statistical models, and achieved sensitivities ranging 
from 72-83%, and specificities ranging from 24-58% (191).  
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The first study to assess the use of VOCs in the detection of ovarian cancer was in 
2010, when Horvath et al analysed the VOCs arising from 15 tissue samples of 
ovarian cancer using an E-nose. They achieved a pooled sensitivity of 84.8% and 
specificity of 86.8% (116). In 2015, Amal et al, studied the breath samples of 182 
subjects, including 48 with known ovarian cancer, other benign ovarian pathology, 
and healthy controls using GC-MS and a nano-array. They were able to distinguish 
the cancer patients from the controls with a sensitivity, specificity and accuracy of 
71%.  The technique was more sensitive for distinguishing cancer patients from 
healthy controls, achieving a sensitivity of 79%, specificity of 100% and accuracy 
of 89% (192).  
Head and neck cancers have also undergone evaluation for VOC signatures. This 
was first done in 2008, by Schmutzhard et al, comparing the exhaled breath 
samples of 22 patients with head and neck squamous cell cancer (HNSCC) to 
healthy controls, high risk patients and post-therapy patients, using GC-MS. They 
concluded that there were statistically significant differences between the groups 
for some VOCs, but did not calculate sensitivities or specificities (193). Leunis et al 
then followed this up, in 2014, by using an E-nose to compare the exhaled breath 
of 36 HNSCC patients to 22 patients with benign conditions. They achieved a 
sensitivity of 90% and specificity of 80% (194). Subsequently, Gruber et al studied 
87 participants, including 22 with HNSCC, and 21 with benign conditions, using GC-
MS and a nano-array approach. They achieved a sensitivity of 77%, specificity of 
90% and overall accuracy of 83% for distinguishing the HNSCC from the healthy 
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controls (195).  HNSCC has more recently been distinguished from lung cancer via 
exhaled breath analysis using an E-nose, with an accuracy of 85% (196).  
VOCs from skin biopsies, analysed by GC-MS, have also been demonstrated to 
have a distinct profile compared to healthy skin biopsies from the same patients 
in two studies (197, 198).  
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2.2.4. VOC generation and detection in bodily secretions 
A potential issue with the use of VOCs as a screening tool for the detection of 
VOCs, is that the precise mechanism of VOC generation has yet to be elucidated. 
Several theories have been postulated for the mechanism by which VOCs are 
generated.  
It has been proposed that VOCs produced by tumour cells are the product of Major 
Histocompatibility Complexes (Human Leucocyte Antigen – HLA, in humans) genes 
within cancerous cells. This theory is supported by the finding that human body 
odour is genetically determined by HLA. HLA proteins are soluble, and detectable 
isoforms are present in bodily fluids such as blood, urine and sweat. It has also 
been demonstrated that there is a strong link between changes in HLA expression 
and carcinogenesis. Cancer cells are able to evade the host immune system by 
alterations in the expressions of HLA molecules, in a similar mechanism to that 
seen by the evasion of maternal immunity in the developing foetus. This suggests 
that carcinogenesis could result in an alteration of HLA expression in the tumour 
cells, resulting in a different odour profile of the patient, allowing its detection by 
VOC analysis (199). 
Other theories suggest that VOCs are generated by cancerous cells in response to 
the overall abnormal cellular metabolism, and alterations in non HLA gene/ 
protein expression. This is thought to be as a result of carcinogenesis and the 
activity of reactive oxygen species, which can cause protein oxidation and lipid 
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peroxidation, thus affecting the VOC profile (200, 201). There is also some 
evidence that cytochrome p450 enzymes may play a role in the generation of 
aberrant VOCs, as their activity is elevated in cancerous processes, possibly to 
neutralise excessive levels of reactive oxygen species and their derivatives (200).   
The role of oxidative stress has been questioned by Darwiche et al, who found that 
bronchoscopically obtained VOC profiles were different between the affected and 
non-affected lung, in lung cancer patients. They suggested that the VOC 
generation was more likely due to metabolic tumour processes +/- microbiological 
activity (148). This finding was supported by Wang C et al, when they extracted 
breath samples from both the cancer-containing lung and the disease-free lung 
(201), and by several studies looking at VOC generation in the headspace above 
lung cancer tissue cells. Chen et al demonstrated, using solid phase 
microextraction-gas chromatography (SPME-GC), that squamous cell carcinoma, 
adenocarcinoma, bronchoalveolar carcinoma, non-small cell carcinoma and 
bronchial epithelial cells all had distinct VOC profiles (202). Other studies have 
confirmed that lung cancer cells release higher levels of certain metabolites 
compared to healthy controls, and also that lung cancer tissue appears to have 
lower levels of certain metabolites. Thus, suggesting they are either not produced, 
or are in fact consumed by the cancerous cells in their metabolic processes (203, 
204).   
Other factors which can influence the VOC profile include external elements such 
as environmental pollution, medications and diet (Peng 2010).  In fact, it has been 
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demonstrated recently that proton pump inhibitors can result in a much altered, 
and less diverse intestinal flora profile, which would affect any fermentation 
occurring in the GI tract and, potentially, alter the VOC profile (205). Indeed, a 
study by Amal et al showed that the VOC profile of gastric cancer patients was 
stable over repeated sampling, except where interventions which alter the 
intestinal microbiome have occurred. This resulted in affected VOC profiles, and, 
as such, anything which affects the microbiome could result in an altered VOC 
profile (175). This highlights the potential role that the microbiome could have on 
the overall VOC signature for an individual. Certainly, the current most plausible 
theory behind VOC generation is that it represents the complex interaction 
between bodily metabolic processes (including altered disease metabolism), 
microbiome metabolic processes and dietary factors (96).   
VOCs present in exhaled breath can be either exogenous or endogenous. 
Exogenous VOCs are chemicals which are inhaled from the external environment 
and then exhaled unchanged. Endogenous VOCs are compounds which are 
produced within the body as a result of metabolic processes. They can also be 
compounds produced by the metabolic process of symbiotic bacteria in the human 
body (206).  Hakim et al reviewed all identified exhaled VOCs for lung cancer in 
2012, and found that 112 VOCs had been identified from the breath of lung cancer 
patients and 88 VOCs had been identified from lung derived cancer cell lines. On 
further analysis, they found that 36 VOCs were identified in two or more studies. 
These were divided into 7 chemical families: hydrocarbons (e.g. alkanes and 
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alkenes); primary and secondary alcohols; aldehydyes; ketones; esters; nitriles and 
aromatic compounds (200).  
Breath analysis is the most common means of VOC detection in the literature, and 
principally, for lung cancer diagnosis. The mechanism by which VOCs are found in 
breath is believed to be via the release of abnormal VOCs from the tumour into 
the blood stream, and then subsequent gas exchange in the alveoli of the lung, 
resulting in their presence in exhaled breath (200). Breath analysis, compared to 
blood and urine samples, is less invasive and can be collected easily at any point, 
allowing for simple repeat sampling. Less stringent storage conditions are 
required, the samples often do not require any form of processing prior to 
analysis, and VOCs have been found to be present in higher concentrations than 
in blood samples (95, 200).  There are some issues with exhaled breath, these 
include that approximately only half of the exhaled VOCs are endogenous, and the 
other half are exogenous. This can present a problem in terms of determining 
whether a VOC is a biomarker or not. Food consumption, smoking and oral and 
pharyngeal bacterial colonies can also affect the VOC composition (95).  The 
logistics of breath sampling can also be a challenge. The first part of exhalation is 
"dead space", that is ~150ml of air which has come from the upper airways, rather 
than air from the deeper lung airways and alveoli, which would have been involved 
in gas exchange. The dead space air has little, or no, value in VOC analysis. The 
best fraction of breath to analyse is that latter part of exhaled breath, or alveolar 
breath. This will also reduce contamination by exogenous VOCs. It has been 
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demonstrated that different fractions of breath have affected the ability of a 
Cyranose E-nose to detect lung cancer (207).  There are adaptable device mouth-
pieces available which allow the preferential extraction of alveolar breath, without 
the need to make the patient hyperventilate, but this adds a layer of complexity 
to the sampling (208). A major problem with all of the studies conducted so far is 
that there is no consensus on what breath sampling method constitutes a gold 
standard. Many different breath samples and sampling systems have been 
utilised, and this often prevents direct comparison between the results of the 
various studies (209).  
The presence of VOCs in various bodily substances is the result of their transport 
in the blood stream throughout the body. This allows their delivery to the renal 
glomerulofiltration unit, and thus, their presence in urine, and global delivery to 
the bodily sweat glands (210).  
Sweat VOCs are mainly derived from the secretions of sweat glands, but can also 
be derived from sebum; the secretions of the sebaceous glands. Although some of 
the VOCs are the direct result of internal metabolic or hormonal changes, most 
appear to be produced as a result of skin symbiotic bacterial action on secreted 
compounds. Any alteration in either the nature of the secreted chemicals or the 
skin cells themselves, or the bacteria living on the skin, will result in an alteration 
of the VOC profile (206).  
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The analysis of blood and urine samples for biomarker VOCs is also not without 
issue, as the VOCs may not necessarily be endogenous. Exogenous VOCs could be 
inhaled and bound or dissolved in blood or bodily compartments, then later 
excreted in urine.  They can also be affected by smoking status, medications, diet 
and other environmental factors.  Urine has the advantage over blood that the 
analytes are concentrated in the kidneys before being excreted, which should 
allow for easier detection of low concentration chemicals. A summary of the 
various bodily secretions to contain VOCs and benefits and limitations of each can 
be found in Table 2.4. Despite these potential confounding factors, there is 
growing evidence, as described above, that clinically relevant biomarkers can be 
found in urine, blood, stool and breath of cancer patients (95).  
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Bodily secretion Benefits Limitations 
Breath • Easy to collect 
• Less invasive 
• No processing prior to 
analysis 
• Acceptable to patients 
• Most studied secretion 
• No concensus on optimal 
collection method 
• Contamination by mouth 
bacteria/flora 
• Smoking confounding 
• VOCs for non-respiratory 
conditions may be at 
lower concentrations 
Urine • Easy to collect 
• Less invasive 
• Acceptable to patients 
• VOCs at high 
concentrations due to 
renal filtration 
• Potential contamination 
from genitourinary 
bacteria 
• No consensus on optimal 
storage  
• Requires removal of 
particulates  
• VOCs may be lost if 
container not immediately 
sealed 
Faeces • May have had direct 
contact with colonic 
pathology 
• Less acceptable to 
patients 
• Collection more difficult 
• Potential microbiome 
fermentation effects on 
VOCs from colonic 
pathology 
• VOCs may be lost if 
container not immediately 
sealed 
Blood • Acceptable to patients 
 
• Invasive 
• Limited studies 
 
Sweat • Easy sample collection • Affected by deoderants, 
soaps and cosmetics 
• Limited studies 
 
 
Table 2.4. Summary of the benefits and limitations of the various bodily 
secretions currently being studied for the detection of cancers by VOC analysis  
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2.2.5. Clinical applications - screening, diagnosis, monitoring 
As previously discussed, most studies to date have centred on the detection of 
VOCs in the exhaled breath of patients with lung cancer. The long term goal of this 
research is to use VOC detection as a non-invasive screening tool, thus allowing 
more targeted use of CT scans, bronchoscopy and endoscopy.  
There have been some promising results for individual biomarkers eg. 
Hexadecanal, but good levels of discrimination often required the combination of 
multiple VOCs to form a panel, or “smell print”. They also noted reports of the 
same biomarker being implicated in multiple cancer subtypes e.g. methanal in 
breast, prostate and bladder cancer. This would suggest that it is of limited value 
in targetted cancer screening programmes, for example prostate or colorectal 
cancer, because of the lack of specificity. Additionally, the authors found a huge 
degree of variability in the methods of breath collection, sample storage and data 
handling.  They recommended larger studies, in true screening settings, using 
standardised breath collection techniques, with independent validation studies 
(122). 
With regards to the GI tract, breath samples have been shown to be able to detect 
CRC in patients using GC-MS technology with a sensitivity and specificity of 85%, 
and may show potential for application as a non-invasive test in the future (158). 
In addition, early urinary VOC analyses from CRC patients have shown a sensitivity 
of 83% and specificity of 60% (162). A major fault of most breath sampling studies 
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so far, as identified by Smith et al in their 2015 discussion paper, is that the 
majority have collected mouth-exhaled breath, rather than nose-exhaled breath. 
This leads to contamination by oral cavity generated compounds as a result of 
bacterial and enzymatic activity (117). At present there is no agreed upon protocol 
for the ideal collection method for breath samples. Stool samples are likely to have 
a lower uptake rate, as seen in the current BCSP. Therefore, the utilisation of urine 
as a potential screening medium for CRC detection may present a more acceptable 
form of specimen to patients than faeces. The use of urine has other advantages 
beyond patient acceptance. Due to the renal filtration process, VOCs are present 
in urine at nearly the same concentrations as in the plasma (115).  This suggests 
that there will be minimal signal lost due to the renal filtration process, although, 
as yet, no studies have compared the differences in VOC composition or pattern 
between plasma samples and urine samples for the same patients.  
A study into the post-surgical changes of VOCs in lung cancer patients revealed 
that there were some minor changes at one month – reduced isoprene levels, and 
some further changes by three years. Most of the VOCs sampled were still present 
at higher concentrations than in the healthy control group (150). Altomare et al 
also conducted a post-surgical resection study of exhaled VOCs from CRC patients. 
They analysed the exhaled VOCs of 32 disease free CRC patients, 2 years post-
surgery, and compared their VOC profiles to samples collected pre-operatively. 
They found a panel of 11 VOCs could be analysed with GC-MS and distinguish pre-
operative from post-treatment samples with a sensitivity of 100%, specificity of 
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97%, accuracy of 98.8% and AUC 1. When comparing the post-surgery VOCs with 
healthy controls they also found a distinct pattern with a sensitivity of 100%, 
specificity of 90%, accuracy of 94% and AUC of 0.96 (211). This had previously also 
been shown by Ma et al, in 2009, as discussed earlier (161).  These studies suggest 
that, whilst the VOC profile does alter post tumour removal, it does not completely 
revert to what might be expected in the general population. This may indicate 
that, although cancer metabolism contributes to the generation of VOCs, it may 
not be the sole factor responsible for the VOC profiles seen in cancer patients.  The 
residual different VOC profiles could be due to changes produced in the 
microbiome of the subject’s lung, either leading to, or as a result of carcinogenesis.  
A more recent study has shown that 4 cancer specific VOCs reverted to the levels 
of healthy control subjects in lung cancer patients who had successfully undergone 
resection (212). These studies do appear to support the hypothesis that VOC 
profiling could have a role, not just in the screening or diagnosis of patients for 
malignancy, but also as an aid in follow-up to assess for disease recurrence, in the 
same way as other tumour markers, such as CEA, are currently used.  
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2.3. Microbiome in CRC 
As already discussed, risk factors which can predispose to CRC include obesity; 
dietary factors, including red or processed meat, dairy products, fibre, vitamin D 
and micronutrients; medications; alcohol and smoking. A western style diet, in 
particular, that is high in red meat and animal fats, and low in fibre, is associated 
with an increased risk of CRC development. 
There has been rapidly expanding interest over recent years into the role that gut 
bacteria, or the microbiota, play in the health and disease of humans. There 
appears to be growing evidence that the development of CRC could be linked to 
alterations in the gut microbiome. The first study suggesting a link between gut 
microbiome and CRC was reported in 1975 when germ-free rats were observed to 
develop fewer chemically induced CRCs than wild-type rats (213). This finding has 
been subsequently replicated, including in CRC predisposed mice (214).  
The human body contains well over 100 trillion (1x1014) microbial cells, with the 
GI tract having, by far, the highest density within the body, at approximately 10 
trillion micro-organisms, including bacteria, viruses and fungi, constituting the 
microbiota (215-217). The composition of the microbiota in different parts of the 
GI tract appears relatively stable, although the absolute numbers of micro-
organisms vary enormously between the mouth and rectum (214).  
The gut microbiota in an individual is developed during the first few years of life, 
and is a result of colonisation from the commensal flora from the mother's skin, 
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vagina and faeces initially, and then, due to complex interactions between micro-
organisms introduced via the environment, and the hosts physiological processes 
(214). Once the microbiome has stabilised after the first few years of life, the 
composition remains relatively stable over time, with some fluctuation in response 
to pathological and environmental factors (214, 218). This stability is thought to 
represent the long term influence of dietary patterns on the microbiome (219). It 
is increasingly believed that the development and maturation of a healthy immune 
system is vitally dependent on the formation of a balanced and diverse gut 
microbiome in early life. This is based on the observations of immune system 
abnormalities found in germ-free animals reared in bacteria-free conditions (214).    
Evidence for the stability of the gut microbiome being due to dietary factors can 
be found from studies which show that switching from a diet high in fibre and plant 
polysaccharides, and low in animal fat and processed sugar, to a reciprocal diet, 
leads to an altered microbiome composition within one day of the dietary change 
(218, 220, 221). The alteration in microbiome composition included an increase in 
bile-tolerant bacteria e.g. Bilophilia and bacteroides, and a decline in bacteria 
which metabolise plant polysaccharides e.g. Roseburia. These changes would be 
expected in the face of this dietary alteration and represent a degree of natural 
selection (220). However, these changes are not sustained, as, on resuming the 
previous diet, the microbiome reverts to the pre-change composition (219). This 
would indicate that if CRC development was linked to abnormal microbiota that 
prevention is not achievable with short term dietary interventions aimed at 
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remodelling the gut microbiome. Whilst this association of diet and microbiome 
composition is increasingly well understood, what is less well understood is the 
effect on metabolite production by the gut bacteria in response to microbiome 
alterations (222, 223).   
Despite the potential for huge variation in gut microbiome composition between 
individuals, studies have shown that some recurring bacterial species are regularly 
recovered from different individuals. The human gut microbiome is dominated in 
particular by 3 phyla: Firmicutes (30-50%), Bacteroidetes (20-40%) and 
Actinobacteria (1-10%). There is great variability within the GI tract. Bacteroidetes 
and Actinobacteria species comprise approximately 90% of colonic bacteria, but 
only 50% of small intestinal bacteria, where the predominant species are 
Firimicutes (214).  
In health, the gut microbiome helps to form a natural barrier against pathogenic 
infections. This is aided by thick mucus layers which prevent excessive exposure 
of the enterocytes to micro-organisms and dietary antigens. Studies in germ-free 
mice, who share a very similar microbiome composition to humans; have shown 
that these animals have longer intestinal villi, crypt atrophy, reduced epithelial cell 
turnover and less angiogenesis (224).  
The microbiome also plays a major role in maintaining normal gut homeostasis 
through, not only its protective function, but also its metabolic functioning. 
Studies in germ-free mice show that animals reared in bacteria-free conditions are 
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more prone to infections, have reduced digestive enzyme function, vascularity, 
their muscle wall thickness is reduced, along with a reduction in their serum 
immunoglobulins and cytokine production. They also have fewer intraepithelial 
lymphocytes and Peyer's patches throughout the gut (225). Restoring the gut 
microbiome in germ-free mice has led to improved mucosal immune systems, and 
increased expression of genes relating to nutrient uptake, metabolic process, 
angiogenesis and development of the intestinal nervous system (226). The gut 
microbiome has also been shown to influence immunity by facilitating 
development of humoral components of the mucosal immune system, and by 
affecting T-cell levels and T-helper cell cytokine release (214).   
Finally, the gut microbiome has a role in the prevention of intestinal colonisation 
by pathogenic organisms. Whilst the underlying mechanisms for this function are 
unclear, it most likely represents a combination of competition for adhesion 
molecules and nutrients, the production of antimicrobial compounds, and 
stabilisation of the gut mucosal barrier (227, 228).  
The fact that a low fibre, high animal fat diet results in an altered microbiome 
raises the possibility that the higher CRC risk seen in those eating a western diet, 
could be due to dietary effects on the microbiome, rather than the consumption 
(or not) of these food types e.g red meat/fibre, themselves.  
Studies have been conducted into the microbiome composition of CRC patients 
and have demonstrated that the microbiome is perturbed and, indeed, that the 
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diversity is greatly reduced in CRC. This has been referred to as dysbiosis (214, 
218). Specific bacteria identified as being over-represented in patients with CRC 
include; Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, 
Enterococcus faecalis, clostridium septicum, Fusobacterium nucleatum, 
Providencia and Escherichia coli strains (214, 221, 229). Conversely, butyrate-
producing bacteria, such as Roseburia and Fecalibacterium are greatly reduced in 
CRC patients compared with controls (221, 230).  
Whilst these different microbiome profiles have been observed, these findings do 
not establish whether these changes in microbiome composition are the cause of 
CRC, or a consequence of its development.  A further problem with the studies 
described above, is the methodological variation between them. Some have 
utilised colonic tissue, whereas others have utilised faecal matter. A study aimed 
at addressing these shortfalls studied faecal and mucosal samples from both the 
tumour, and also sites proximal and distal to the tumour. The results showed that 
the microbiome of CRC subjects was different from the healthy controls, but that 
the alterations were not restricted to the cancerous tissue. Differences were 
detected throughout the whole colon. They also found a different profile for right 
and left sided tumours and that faecal microbiota was only partially reflective of 
the mucosal microbiota profile. Interestingly, they still observed great variation 
within the CRC subjects, and that they could be stratified into four groups based 
on the relative abundance of various bacterial species, raising the possibility of 
disease "enterotypes" (231). This is supported by previous studies which have 
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suggested the use of a microbiome profile, rather than a single bacterium, as a 
screening tool for CRC (232-234). 
The mechanisms by which gut microbiome could precipitate or protect against 
CRC are multiple:  
• Dietary and digestive components undergo metabolic processing by the 
microbiome with resulting products potentially acting as putative 
oncometabolites, including reactive oxygen species and tumour 
suppressive metabolites. Examples of this process include the processing 
of red meat and bile acids from animal fat to hydrogen sulphide and 
secondary bile acids, respectively. Elevated secondary bile acids have been 
found in CRC patients relative to healthy controls (229). Protective 
metabolites include equol, urolithins and short chain fatty acids (SCFAs) 
such as butyrate, which are derived from the microbiome activity on plant-
based polyphenols and dietary fibre (235).  
• Microbiota can affect inflammatory processes within the gut via the 
production of toxins and virulence factors. Toxins from certain bacterial 
species, namely F.nucleatum, H.pylori and B. fragilis, have all been linked 
with CRC (214). Chronic gut inflammation is a potential factor in 
development of CRC, as seen in patients with long standing IBD (218). As 
discussed earlier, aspirin and NSAIDs have been demonstrated to reduce 
the risk of developing CRC (58, 59) and this would suggest that anti-
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inflammatory effects have a protective mechanism against CRC 
development. 
• The microbiome can also affect gut permeability, and influences the 
exposure of luminal bacteria and bacterial antigens, such as 
lipopolysaccharides and flagellin, to the hosts immune cells and 
enterocytes, potentially leading to further inflammation (218).  
Several theories of how the above changes can lead to the development of CRC 
have been proposed. The "alpha bug theory" proposed by Sears et al, in 2011, 
suggests that there are certain predominant bacterial species, which due to their 
metabolic processes or effects on the gut epithelium, lead to carcinogenesis. They 
may also have a role in terms of "crowding out" potentially carcino-protective 
bacteria (229, 236).  
Another proposed theory is that of the "driver-passenger" model. This suggests 
that certain bacteria, the drivers, may produce the initial damage to the intestinal 
epithelium which can lead to CRC development. The progression of this initial 
damage to CRC, is promoted by the so called "passengers", which are 
opportunistic pathogens  able to proliferate in the altered microenvironment 
caused by carcinogenesis (237).  
A final suggested model is the "intestinal microbiota adaptions" model, which 
suggests that CRC and dysbiosis may have a symbiotic relationship. The CRC 
environment is characterised by host-derived immune and inflammatory 
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processes that would affect microbial regulation. This could, potentially, alter 
microbiome composition and favour the proliferation of pro-carcinogenic 
bacteria, thus amplifying the effect of dysbiosis, and further promoting CRC 
progression (238-240).  
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CHAPTER 3 
Materials and Methods  
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3.1. Ethical Approval 
Scientific and ethical approval was granted by the University Hospitals Coventry 
and Warwickshire (UHCW) Research and Development Office, as well as Solihull 
Ethics committee, ref: 13/WM/0136. Written informed consent was obtained 
from all who participated in the study.  
3.2. Subject recruitment and sample collection 
3.2.1. Patient recruitment 
Patients were recruited between September 2015 and December 2016 from the 
Lower GI MDT list at UHCW. Patients with confirmed CRC, who had been informed 
of the diagnosis and management plan, were approached. Information sheets and 
a cover letter were posted out to them, and a telephone call made several days 
after this to follow up. Patients who were willing to take part in the study were 
sent a specimen collection pack, inclusive of urine and stool collection bottles, a 
consent form and participant questionnaire. The patients produced the samples 
at home on the same morning as they were due in for their operation, or first 
session of chemotherapy. Patients who were not receiving active treatment 
returned the samples to the pathology department at UHCW either in person, or, 
via a same morning courier service utilised by General Practitioners (GPs) in the 
area.  A subgroup of patients with historical CRC who had previously undergone 
surgical resection within 1-3 years of the study start date, had previously given 
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urine samples for the FAMISHED study at UHCW. These patients were re-
approached to take part in this study. They were recruited in the same way.  
Inclusion criteria were adult patients with confirmed CRC, that was not due to a 
hereditary condition, and relatives and spouses/co-habitors who had consented. 
Exclusion criteria were patients who had concurrent malignancy, gastrointestinal 
conditions such as bile acid diarrhoea, coeliac disease and inflammatory bowel 
disease, or urological/renal conditions requiring secondary hospital care.    
3.2.2. Relative and co-habitor recruitment 
The initial cover letter sent to out to patients, informed them that we would only 
approach relatives and spouses/co-habitors who had given their consent to be 
contacted. Once this consent was passed on by the CRC patients, information 
sheets and cover letters were posted to the relatives and spouses/co-habitors. 
They were then contacted by telephone several days later to follow up. Those 
willing to participate were sent a specimen collection pack in the post, as for the 
patients. These were returned either by the GP courier service already mentioned, 
returned directly to the hospital on visiting their spouse/relative, or, for those 
more distant by post in appropriately marked and sealed packages.  
3.2.3. Urine collection, storage and transfer  
Urine samples were collected from patients directly, or via GP courier, and stored 
at -80oC within two hours of receipt of samples. They were transferred to 
Owlstone, Cambridge in a box of dry ice and stored at –20oC. They were then 
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defrosted in a laboratory fridge at 3oC overnight, prior to analysis. Urine samples 
to be analysed at the University of Warwick were collected and stored in the same 
way, transferred to the University in dry ice and stored in a –20oC freezer, and then 
defrosted in a laboratory fridge at 3oC overnight, prior to analysis. 
3.2.4. Faeces collection, storage and transfer  
Faeces samples were collected from patients directly, or via GP courier, and stored 
at -80oC within two hours of collection. They were transferred to the University of 
Warwick in dry ice and stored in a –80oC freezer, and then defrosted for 45 
minutes in room air, prior to analysis. 
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3.3. Sample analysis 
3.3.1.1 LC-ultraFAIMS-MS 
Initially the intention was to utilise the Lonestar FAIMS machine at the University 
of Warwick Engineering department. However, this device was experiencing 
recurrent faults, and break downs. This resulted in a four month delay between 
January and April 2016, waiting for the machine to be repaired. There was a 
subsequent delay due to commercial work on the machine which the engineering 
department had taken on. There were then configuration issues with a custom 
built autosampler in June – July 2016. As a result of this, the decision was made 
with my supervisors to approach Owlstone, the company which made the Lonestar 
FAIMS machine, directly. An agreement was reached to allow me to analyse the 
urine samples myself using some of Owlstone’s equipment in Cambridge.  
The equipment used was a hybrid machine, an LC-FAIMS-MS, which was based on 
the previously utilized FAIMS technology but had an Agilent 1200 series Liquid 
Chromatography (LC) column in series with the FAIMS, which allowed greater 
separation of VOCs prior to their passing through the FAIMS. There was also an 
autosampler (chilled to 4oC) and an Agilent 6230 Time of Flight Mass Spectrometer 
incorporated into the set-up.  
This methodology refers to the urine sample analysis conducted in Chapters 5 and 
6.  
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The samples were stored at –20oC and defrosted in batches of 25 randomly 
selected samples in a laboratory fridge at 3oC overnight, prior to analysis. 
Sample preparation was done as per Owlstone standard operating procedures: 
1. LC column conditioned using a 20ml pooled batch, consisting of 2ml 
samples from 10 randomly selected urine samples (CRCs and relatives/co-
habitors). This also served for quality control runs 
2. 500µL of pooled urine was mixed in an LC autosampler vial with 500µL of 
5% acetonitrile:95% LCMS  grade water + 0.1% formic acid added to 
produce a 1:1 dilution 
3. 10µL of pooled diluted urine applied to LC column (Agilent Poroshell 120 
EC-C18 3.0 x 50mm, 2.7um with a guard column).  
4. The flow rate on the column was 0.85ml/minute and the column 
temperature was maintained at 30oC 
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5. The chromatographic gradient used was as below: 
Time (mins) % Mobile Phase A % Mobile Phase B 
0 95 5 
0.01 95 5 
1.0 95 5 
7.0 60 40 
7.5 10 90 
8.5 10 90 
9.0 95 5 
11.0 95 5 
Mobile Phase A: LC-MS grade water with 0.1% formic acid 
Mobile Phase B: Acetonitrile with 0.1% formic acid 
6. The urinary VOCs are separated based on their affinity for the LC column 
and were passed through an Electrospray to aerosolise the VOCs, which 
then passed through the FAIMS chip and on into the MS.  
7. A blank consisting of 95:05 water:acetontrile with 1% formic acid was 
analysed in between each urine sample 
8. 10 cycles of pooled urine were run in this fashion to condition the column 
9. 1ml aliquots of thawed urine were placed in Eppendorf micro-centrifuge 
tubes and centrifuged at 10,000rcf for 10 minutes 
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10. 500µL of supernatant was mixed in an LC autosampler vial with 500µL of 
5% acetonitrile:95% LC-MS  grade water + 0.1% formic acid to produce a 
1:1 dilution 
11. 10µL of 1:1 sample dilution were applied to the LC column via the 
autosampler and analysed as above 
12. A blank consisting of 95:05 water:acetontrile with 1% formic acid was 
analysed in between each urine sample 
13. After every 5 urine samples a QC sample from the pooled urine was run 
as described 
14. Before each run was started the next day, the Electrospray shield was 
cleaned to prevent urinary sediment build up 
FAIMS parameters were as follows: 
• Initial Compensation Field: –900 
• Final Compensation Field: 4000 
• Number of Compensation Field steps: 10 
• Number of repeats: 590 
• Initial Dispersion Field: 250000 
• Final Dispersion Field: 250000 
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MS settings were as follows: 
• m/z start: 80 
• m/z end: 1700 
• Scan rate: 12.0 
• Gas temperature: 150oC 
• Gas flow: 10 l/min 
• Nebuliser: 20psig 
• Sheath Gas temperature: 250oC 
• Sheath Gas Flow: 12l/min 
• VCap: 3500V 
• Nozzle voltage: 2000V 
• Fragmentor: 200V 
• Skimmer 1: 65V 
• Octopole RF peak: 750V 
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3.3.1.2 Statistical analysis 
3.3.1.2.a Data processing 
The LC-FAIMS-MS apparatus provided a four dimensional output of ion counts – 
one dimension for each of LC and MS, and two for FAIMS, however, as the 
dispersion field for the FAIMS was kept constant this resulted in a three 
dimensional output. Each LC-MS spectrum was run over 10 compensation field 
(CF) FAIMS settings. The two settings which provided the best yield in terms of 
extractable features were then selected for analysis.  
As a result of the modified instrument set up used, the acquired LC-FAIMS-MS files 
were pseudo MS/MS files, with each collision energy setting corresponding to one 
of the 10 FAIMS CFs. All the available software for chromatographic feature 
extraction are designed to perform feature extraction on the total ion current (TIC) 
chromatogram. In this case, LC-FAIMS-MS, the TIC chromatogram varies 
significantly from standard LC-MS data. As a result, of this it was not possible to 
perform feature extraction directly on the raw LC-FAIMS-MS data files. To solve 
this, the acquired data was split into individual chromatograms corresponding to 
acquired FAIMS CF settings, (designated 05_100-57 and 06_101-06) and saved as 
individual files.  
A custom python script written by Owlstone was used to split and extract the CFs 
as separate files, and simultaneously save them in the required format (.mzML). 
The saved .mzML files were subjected to feature extraction using XCMS package 
in R (https://bioconductor.org/packages/release/bioc/html/xcms.html). This is an 
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open source tool which can be used for feature extraction from chromatographic 
data. Feature extraction was then performed on each individual file, and the 
output .csv file created contained the list of features for the analysed sample. 
These output files were subsequently amalgamated into files based on the day on 
which the samples were analysed.  This process is summarised in figure 3.1.  
An example of the output .mzML file can be found in figure 3.2, whilst an example 
output .csv file containing the extracted output feature data can be seen in figure 
3.3. 
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Figure 3.1. Workflow summary of data processing and extraction process.   
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Figure 3.2. Example .mzML output file displayed on a log colour map using 
Zmine.  
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mzmed mzmin Mzmax rtmed rtmin rtmax npeaks maxint CRCN-001pre CRCN-023pre  
80.0615 79.997 80.0948 9.6419952 9.3582483 9.858802 166 9770 26876.90675 499850.2631  
80.0487 80.038 80.0692 0.0657063 0.0307366 0.124988 65 335 395.2577235 460.4560128  
80.0589 80.033 80.0845 10.571786 10.277567 10.9782 77 2141 1321.677 24091.83467  
80.0589 80.033 80.0948 9.1469969 9.1034764 9.206579 8 7494 66166.68187 51919.01005  
80.1281 80.099 80.1973 9.6396184 9.3181235 9.877527 136 279 9086.728646 9377.65262  
80.2358 80.217 80.2537 9.6958347 9.5981027 9.744488 4 115 489.3336 853.02888  
81.0302 81.019 81.0406 2.8058001 2.7881938 2.840769 25 233 94.81971163 868.3385571  
81.0302 81.019 81.0406 1.0641199 1.0183309 1.124352 9 718 310.2324673 221.3541752  
81.0406 81.040 81.0457 9.407566 9.2034002 9.421078 5 664 9415.946081 164.2185484  
81.0509 81.030 81.087 9.6773322 9.5209395 9.870154 55 852 14569.77685 3345.788571  
81.0715 81.056 81.0973 4.0271378 4.0157358 4.157116 32 1083 229.8967707 235.7741977  
81.0457 81.040 81.056 0.3898414 0.3600242 0.407732 11 328 470.353397 652.0176  
81.0612 81.050 81.0921 9.3792202 8.8379852 9.465016 43 847 20676.451 2700.774574  
Figure 3.3. Example section of output .csv file containing the extracted feature data. Each file contained 5000+ data points per 
sample.
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3.3.1.2.b. Statistical methods 
As this technology is novel, there is very limited statistical literature available on 
an optimal analysis technique.  The assistance of a bioinformatician from the 
University of Warwick was utilised to develop a potential pipeline for analysis. The 
bioinformatician has previously worked on other VOC projects from our research 
group. It was felt he was best placed to develop a usable and robust analysis 
method.  
Prior to analysis, data from the LC-FAIMS-MS was processed via a bespoke 
software pipeline, which was developed specifically for this project.  Individual 
data files were read in and linked to their clinical grouping.  The data for each 
sample consisted of a set of features, or peaks, which were extracted from the raw 
data as described in section 3.3.1.2.a. These peaks were aligned and grouped 
together on a standardised grid, based of mass-to-charge-ratio and retention-time 
values. This forced alignment allowed direct comparison across samples, and also 
improved the signal-to-noise of the data, due to the presence of large numbers of 
isolated, likely spurious, peaks in the raw data files. 
Once aligned, these peaks formed a set of standard features for each sample, 
which was then suitable for analysis.  Any features which were found to have zero 
variance across samples were removed automatically, as they would be 
uninformative.  Any sample for which there were no data (i.e. data outputs all 
zeros), was also similarly removed, as this would represent an analysis failure by 
the LC-FAIMS-MS machine.  Any feature containing data for <10% of the samples 
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was also removed, as it would be too sparse to be useful.  The pre-processing of 
the data was completed by normalising the remaining features so that they had 
zero mean and unit variance.  
For each separate analysis of subgroups of the data, the relevant subset of samples 
was extracted, and the different groups defined.  5-fold cross-validation was then 
used to assess classification accuracy across these groups, using three different 
multi-class classifiers: sparse logistic regression, Support Vector Machine, Random 
Forest.  This analysis generated outputs of one-vs-all Receiver Operator Curves 
(ROC) i.e. comparing a single group vs all other groups, for example CRC vs 
relatives and spouses, relatives vs CRC and spouses, spouses vs CRC and relatives. 
Other results generated included the Area-Under-Curve (AUC) statistic, 
sensitivity/specificity values, which were selected automatically to be maximally 
similar given the ROC curve, and a p-value, comparing the result to that expected 
for random chance (AUC=0.5), using a Wilcoxon rank-sum test. 
All analyses were carried out using the R programming language (v3.3.1). 
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3.3.2. FAIMS 
During the planning of the main thesis experiment, a potential issue was identified 
with the storage of urine samples prior to being placed in the freezer. Given the 
fact that some samples were being collected from relatives who live distant to the 
CRC patients, this necessitated the use of the postal service for return of samples. 
This means that potentially, although first class postage was used, samples 
produced for example on a Monday morning and posted that same day, may not 
reach the freezer at UHCW until Wednesday, although, they were transferred in 
sealed universal bottles. This means that the urine would be at room/atmospheric 
temperature for 48 hours and, potentially, up to 72 hours. It has been 
demonstrated that the VOC profile of blood samples can be affected by different 
storage conditions (241), but no studies have been conducted on urine samples.  
A further experiment was conducted whereby urine samples were collected from 
27 healthy volunteers, and informed consent was taken. Aliquots of urine were 
frozen immediately, and then further aliquots were left in sealed universal bottles 
at room temperature for increasing time periods of 12 hours, 24 hours, 36 hours, 
48 hours and 72 hours, before freezing at -80oC. The urine was then transferred to 
the Engineering department at the University of Warwick, in dry ice, for analysis. 
The aim of this experiment being to determine the effect of prolonged storage at 
atmospheric temperature of urine samples.  
A commercial FAIMS instrument was utilised, specifically the Lonestar device 
(Owlstone, UK). This device is separate from that described in section 3.3.1 and is 
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the machine which was originally planned to be used for all urinary sample analysis 
in this thesis. 
FAIMS achieves separation of complex chemical mixtures as a result of the 
different molecular mobilities of the chemicals as they are subjected to high and 
low electric fields as the chemical mixture passes through the analysis chamber. 
This allows separation of gas molecules at atmospheric pressure and room 
temperature. This, in turn, allows identification of the chemical composition of 
VOCs, and detection of volatile molecules present at very low concentrations. An 
overview of the FAIMS process can be found in Figure 3.4.   
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Figure 3.4. Diagram of the FAIMS process (adated from Owlstone Standard Operating Procedures). The sample is heated and moved 
through the ionization phase by gas flow. The ionized molecules are then subjected to high and low voltage electric fields. This results in 
separation of the molecules based on their mobility in response to the fields. 
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The FAIMS analysis was conducted by myself at the University of Warwick 
Engineering department as per the Engineering Departments standard operating 
procedures.  
This methodology refers to the urine samples analysed in Chapter 4.  
5mls of each individual urine sample were aliquoted into a 22ml borosilicate glass 
vial (Fisher Scientific, UK) with a rubber bunged cap, and placed in a custom built 
chilled auto-sampler tray at 4⁰C, before sampling via an ATLAS sample system 
(Owlstone UK) attached to the Lonestar FAIMS machine. The ATLAS system heats 
the sample to 40±0.1⁰C and it is then sampled. The dispersion field was stepped 
through 51 equal settings ranging from 0% to 90% of the magnitude of the 
electrical field. For each dispersion field setting, the compensation voltage was 
stepped between +6V and –6V in 512 steps. 
Each sample aliquot had fourteen analyses performed sequentially with a blank 
run performed between each analysis. Sample analysis was run over 90 - 120 
seconds, with equivalent times for blank runs. Each sample run has a flow rate 
over the sample of 2 l/min of clean, dry air. After each sample, clean dry air is run 
through the sensor ten times sequentially as a blank, to "zero" the sensor. Batches 
of 20 samples were loaded onto the chilled autosampler for analysis.   
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3.3.2.1. Statistical Analysis 
Each subjects urine aliquot underwent fourteen sequential samplings for analysis 
on the FAIMS. Each sample produced output data described hereafter as a matrix. 
This matrix represents a plot of signal intensity for the respective dispersion fields 
and compensation voltages. As there are both positive and negative ions being 
detected, this results in 14 positive and 14 negative FAIMS matrices for each time 
point for each subject. The separation of these ions through the high and low 
electric fields is a result of their mass to charge ratio and results in the 
characteristics FAIMS "plumes", which are graphical representations of the 
matrices. Figure 3.5a and 3.5b give examples of positive and negative FAIMS 
plumes, which correspond to an individual matrix.  
The output data has a very large number of datapoints, 52,224, accounted for by 
51 dispersion field settings, each with 512 compensation voltages and both 
positive and negative matrices. When looking for disease states these datasets 
need to be concatenated into a 1D array, and then a Daubechies D4 wavelet 
transformation used to extract important features. This allows reclassification, 
whilst preventing minimal important signal loss. Once this has been completed 
any co-efficients which fall below a given threshold would be excluded, as these 
are predominantly background noise.  
However, in this case, the concatenation and transformation were not performed. 
This is because the samples were not going to be reclassified and, therefore, all 
data was included in the analysis, including low intensity signals.  
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Figure 3.5a. Example of a positive FAIMS plume, which is a graphical representation of 
the positive ions from the FAIMS matrix for a given sample 
Figure 3.5b. Example of negative FAIMS plume, which is a graphical representation of 
the negative ions from the FAIMS matrix for a given sample 
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3.3.2.2. Variation of mean of matrices from baseline: 
To analyse the variation of the urinary VOCs from each healthy subject, at each 
time point, the arithmetic mean of all 14 positive and 14 negative matrices from 
time point zero, were compared to the arithmetic mean of all matrices from that 
patient, at each subsequent time point.    
Notation used:  
Matrix: Mp,t,n,c,s 
p: Patient number 
t: time (0,12,24,36,48 or 72 hours) 
n: spectrum number at each time point (1-14) 
c: compensation voltage index 
s: Separation field index 
P: total number of patients: 20 
T: number of time points: 6 
N: number of spectra for each sample: 14 
V: variation 
C: total ion count 
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The mathematical formula used was: 
Variation(t) = Σp Vp,t 
Where:       Vp,t = ΣcΣs|ΣnMp,t,n,c,s - ΣnMp,t=0,nc,s| 
   ΣcΣs|ΣnMp,t=o,n,c,s| 
 
Spearman's rank correlation coefficient was used to test for a monotonic 
relationship between time and variation of the mean of the matrices from 
baseline. 
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3.3.2.3. Variation of total ion count from baseline: 
The relative variation in the total ion count in the FAIMS matrices was also 
calculated as a function of time.  
The arithmetic mean of the number of ions detected for each patient at each time 
point was calculated. This data was then compared to the arithmetic mean of the 
ion count for that patient, at time zero.  
The mathematical formula used was: 
Count(t)=Σp Cp,t 
                  P 
Where:         Cp,t = ΣnΣcΣs|Mp,t,n,c,s| 
                   ΣnΣcΣs|Mp,t=o,n,c,s| 
Spearman's rank correlation coefficient was used to test for a monotonic 
relationship between time and variation of the mean total ion count from 
baseline. 
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3.3.3. 16s rRNA sequencing 
Analysis of the stool samples was carried out by myself at the University of 
Warwick Life Sciences department as per the following methods.  
3.3.3.1. Bacterial DNA extraction 
Stool samples were defrosted at room temperature for 45 minutes. DNA 
extraction was performed using QIAamp Fast DNA stool mini kits (QIAGEN).  
200mg of stool weighed and placed in a QIAamp Mini spin column. 1.4ml of ASL 
buffer was added to the spin column to lyse human and bacterial cells present 
within the stool. The columns were then pulsed for 2 x 40 seconds in a Fast-Prep 
24 5G lysis machine (MP Bio). The lysed samples were then incubated at 95°C for 
10minutes, after which they were briefly vortexed to ensure the stool was fully 
homogenised. After this, the samples were then centrifuged at 1,200rpm for 4 
minutes to precipitate the stool residue. The supernatant was then removed and 
placed in a fresh 2ml micro-centrifuge tube. 1ml of InhibitEX buffer was added to 
the tubes to bind potential PCR inhibitors from the lysed cells. Following this, the 
samples were vortexed for 1 minute to ensure complete homogenisation. 1.2ml 
of the InhibitEX:supernatant mixture was transferred to a fresh micro-centrifuge 
tube and the mixture was incubated at 95°C for 30 minutes. The samples were 
then vortexed for 1 minute to ensure complete homogenisation, followed by 
centrifugation at 17,000xg for 1 minute to precipitate out the residue.  
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200µl of supernatant was transferred to a fresh 2ml micro-centrifuge tube 
containing 15µl of Proteinase K.  200µl of buffer AL was then added to the micro-
centrifuge tube, which were vortexed for 15 seconds and subsequently incubated 
at 70°C for 10 minutes. The Proteinase K degrades and digests proteins within the 
solution, and AL is a lysis buffer.  The tubes were then briefly centrifuged at 
17,000xg to remove any drops from the lids of the micro-centrifuge tubes and 
200µl of absolute ethanol (96-100%) was added to form a lysate. After this, the 
samples were vortexed for 15 seconds to mix thoroughly and briefly centrifuged 
again at 17,000xg.  
600µl of lysate was applied to QIAamp spin columns and centrifuged at 17,000xg 
for 1 minute. The collection tube and its filtrate were discarded and the column 
was placed in a new collection tube. 500µl of buffer AW1 was applied to the 
column and centrifuged at 17,000xg for 1 minute. The filtrate was again discarded, 
and the column placed in a new collection tube, after which 500µl of buffer AW2 
was added to the column. This was then centrifuged at 17,000xg for 3 minutes 30 
seconds. The filtrate and collection tube were again discarded, the column placed 
in a fresh tube, and re-centrifuged at 17,000xg for a further 3 minutes 30 seconds.  
AW1 buffer contains a higher proportion of ethanol, which removes excess salt 
and improves pH conditions within the column. AW2 buffer undergoes a longer 
centrifugation to remove impurities and digested proteins. The extracted DNA is 
removed from the column by applying 100µl of ATE buffer, incubating at room 
temperature for 5 minutes, and then centrifuging at 17,000xg for 1 minute.  
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3.3.3.2. DNA quantification 
The concentrations of extracted DNA solutions were checked using Qubit 2.0. 
Stock solutions were made of 1:200 dilutions of Qubit dsDNA reagent (Life 
technologies, USA) in dsDNA buffer. 0.5ml tubes were used for quantification. 
190µl of stock solution was added for standards, and 199µl for samples. 10µl of 
Qubit standards were added to the standard tubes and 1µl of samples was added 
to the sample tubes. The samples were mixed by vortexing, and the DNA 
concentrations checked on the Qubit fluorimeter against the standards. The 
concentrations were recorded.  
3.3.3.3. Polymerase Chain Reaction  
The V3-V4 fragment of the bacterial 16s region from the extracted DNA was 
amplified by polymerase chain reaction (PCR). The primers used are listed below:  
V3-V4 
Forward 
primer 
5' 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGC
WGCAG 3' 
V3-V4 
Reverse 
primer 
5' 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGT
ATCTAATCC 3' 
   
 
131 
 
2.5µl of 5ng/µl extracted DNA was placed into PCR reaction tubes with 10µl of 
pooled forward and reverse primers and 12.5µl of PCR Mastermix (ThermoFisher), 
to make a total volume of 25µl. 
This was then run through the following PCR programme: 
Temperature and Time Number of Cycles Purpose 
95°C for 3 minutes 1 Initial Denaturation 
95°C for 30 seconds 
55°C for 30 seconds 
68°C for 30 seconds 
 
25 
Denaturation 
Annealing 
Extension 
68°C for 5 minutes 1 Final Extension 
12°C hold  1 Hold 
The PCR products were then analysed by electrophoresis on a 1% agarose. 1g of 
agarose was dissolved in 1x Tris-acetate (TAE) buffer, and 10µl SYBR safe (Life 
Technologies) was added to give a final concentration of 1:10,000 to allow DNA 
visualisation. The 1x TAE had been diluted with de-ionised water from a 50x stock 
solution. The stock solution consisted of 242g Tris base, 57.1ml glacial acetic acid 
and 100ml 0.5EDTA (pH8.0) for 1 litre.  
The agarose was then melted in a microwave and the molten agarose poured into 
a plastic cast, with a plastic comb inset to produce the requisite wells. The comb 
was removed once the gel had set.  The gel was placed in a horizontal 
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electrophoresis tank, filled with enough 1x TAE buffer to cover the gel. 5µl of PCR 
product was mixed with 5µl of Fermentas 6x loading dye (#R0611) and 5µl of the 
mix was applied to the gel. Hyperladder 2kb (Bioline, UK) was used as a size ladder 
for all gels. The gels were run at 100millivolts for 30 minutes, and the DNA 
visualised by transferring the gel to a BioRad gel-doc system. The size of the V3-V4 
region is ~460 base pairs (bp) (see figure 3.6). 
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Figure 3.6. Gel electrophoresis of the initial PCR reaction from extraction 
bacterial DNA/RNA with 16S v3/V4 specific primers. First and last columns are 
2kB Hyperladders. The V3-V4 region is ~460bp long, corresponding to the 
uppermost signal in each well – marked with a white box.  
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3.3.3.4. Post-PCR DNA purification  
The remaining PCR products were transferred to fresh 1.5ml micro-centrifuge 
tubes. To each sample 20µl of AMPure magnetic beads were added, mixed by up 
and down pipetting, and then incubated at room temperature for 5 minutes, to 
allow the DNA to bind to the magnetic beads. The tubes were then placed in a 
Dyna-Mag2 magnetic stand (ThermoFisher) and left to stand for 2 minutes, to 
allow the beads to pellet against the magnet. The supernatant was then removed 
and discarded. After this, the beads were then washed twice with 200µl of 
absolute ethanol (96-100%), with the supernatant removed and discarded after 
each wash. The beads were left at room temperature to dry for 10 minutes after 
the second ethanol wash. They were then removed from the stand and mixed with 
52.5µl of Elution Buffer (10 mM Tris-Cl, pH 8.5) (QIAGEN), and pipetted up and 
down 10 times to mix and elute the DNA from the AMPure beads. Following this, 
the beads were incubated at room temperature for 2 minutes, before returning to 
the magnetic stand for a further 2 minutes. After the magnetic beads had been 
pelleted, the supernatant, containing the DNA, was carefully removed and stored 
frozen at –20°C prior to the next PCR step.  
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3.3.3.5. Illumina 16s rRNA gene sequencing library preparation 
A further PCR was performed using the cleaned DNA from the first PCR. The 
forward and reverse primers used in this PCR contained a unique barcode, to allow 
identification of 96 individual samples after sequencing. The table (table 3.1) 
overleaf shows how unique pairs of forward and reverse primers allowed for 
identification of each sample.  
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Primers  N701 N702 N703 N704 N705 N706 N707 N708 N709 N710 N711 N712 
S501 1 9 17 25 33 41 49 57 65 73 81 89 
S502 2 10 18 26 34 42 50 58 66 74 82 90 
S503 3 11 19 27 35 43 51 59 67 75 83 91 
S504 4 12 20 28 36 44 52 60 68 76 84 92 
S505 5 13 21 29 37 45 53 61 69 77 85 93 
S506 6 14 22 30 38 46 54 62 70 78 86 94 
S507 7 15 23 31 39 47 55 63 71 79 87 95 
S508 8 16 24 32 40 48 56 64 72 80 88 96 
 
Table 3.1. Table of unique forward and reverse PCR primers to allow identification of unique samples in the Illumina Miseq
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The PCR was performed using 5µl of purified DNA from the last step, 5µl of forward 
primer, 5µl of reverse primer, 10µl of molecular biology grade water and 25µl of 
PCR extensor mastermix.  
The PCR was run using the programme below: 
Temperature and Time Number of Cycles Purpose 
95°C for 3 minutes 1 Initial Denaturation 
95°C for 30 seconds 
55°C for 30 seconds 
68°C for 30 seconds 
 
8 
Denaturation 
Annealing 
Extension 
68°C for 5 minutes 1 Final Extension 
12°C hold  1 Hold 
 
The PCR products were cleaned using AMPure magnetic beads as described above 
with the following alterations.  
• 56µl of AMPure beads were used 
• 27.5µl of Elution Buffer (10mM Tris pH8.5) was used.  
The concentration of the purified DNA was checked using a Qubit 2.0, as outlined 
in section 3.3.3.2.   
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The samples were then diluted to 4nM concentration in 10mM Tris pH 8.5, and 
5µl of the diluted DNA from each sample was added to a fresh 1.5ml micro-
centrifuge tube, to form a pooled 4nM DNA library.  
3.3.3.6. Illumina 16s rRNA sequencing 
To denature the pooled DNA, 5µl of the pooled library was mixed with 5µl of 0.2N 
NaOH, vortexed, then centrifuged at 280xg for 1 minute, and left to incubate at 
room temperature for 5 minutes. This 10µl was then added to 990µl of chilled HT1 
buffer and placed on ice. The pool was then diluted to a final concentration of 
12pM by mixing 360µl of the pooled library with 236µl of chilled HT1 buffer and 
6µl of 10nM PhiX control library. PhiX is a small, well-characterized genome, and 
it provides a quality control for sequencing and bioinformatic analysis. The final 
denatured DNA pool was subsequently sequenced on an Illumina MiSeq, using a 
MiSeq V3 2 x 300bp paired end protocol.  
3.3.3.7 Processing of the 16S rRNA gene-fragment sequences 
Sequenced files (.fastq) were de-multiplexed using default Illumina software. This 
process included the trimming of barcodes and primer sequences and also the 
removal of low quality reads. Forward and reverse reads were merged, using the 
UPARSE pipeline, to produce contiguous sequences. A quality filtering command 
was used to discard reads where there were three or more mismatches in the 
sequences. Where there were less than 3 mismatches, the base with the highest 
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quality value was inserted into the contiguous sequence. The merging and filtering 
steps were performed using the command:  
usearch –fastq_mergepairs read1.fastq – reverse read2.fastq –fastq_maxdiffs 3 –
fastqout output.fastq.  
The merged and filtered sequences were then de-replicated and sorted by size and 
frequency, with singleton sequences excluded. This was done using the 
commands:  
usearch_64_8 –derep_fulllength filter.fa –fastaout rep.fa –sizeout 
usearch_64_8 –sortbysize rep.fa –fastaout rep_sorted.fa –minsize 2 
Each contiguous sequence was subsequently assigned to an Operational 
Taxonomic Unit (OTU). An OTU is a unique bacterial sequence, which will 
encompass all similar sequences from the sequencing step.    
The OTUs were then clustered and filtered to a default 97% identify level, and 
chimeras were removed. This was using the commands: 
usearch_64_8 –cluster_otus re_sorted.fa –otus otus.fa 
usearch_64_8 –usearch_global filter.fa –db otus_name.fa –strand plus –id 0.97 –
uc readmap.uc 
The OTUs were next assigned to each sample using the command: 
assign_taxonomy.py –i otu_name.fa –m uclust –r /blastdb/gg_13_8_otus/rep_set/ 
97.otus.fasta –t /blastdb/gg_13_8_otus/ taxonomy/97_otu_taxonomy.txt –o 
output_directory 
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After this, the 16s RNA OTU sequences were then assigned taxonomic 
classification using the command: 
biom add-metadata –i otu_table.biom –o all.biom --observation-metadata-fp 
taxa.txt --observation-header OTUID,taxonomy,confidence 
Once this processing was completed in UPARSE, then QIIME (Qualitative Insights 
Into Microbial Ecology) software was used to perform alpha diversity analysis 
using rarefied OTU tables. This was performed using the the command: 
Alpha_rarefaction.py –I out_table.biom –o arare_max100/ -t rep_set.tre –m 
fasting_map.txt –e 100 
QIIME was then used to calculate beta diversity using weighted and unweighted 
unifraction analyses using the command: 
beta_diversity.py -i otu_tables/ -m weighted_unifrac -o beta_div/ -t rep_set.tre 
The depth of rarefaction was determined by the lowest number of sequences 
assigned to a sample within a group that was analysed. 
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3.4. Literature search 
A search of Pubmed was conducted using the search terms "Colorectal cancer" or 
“colorectal carcinoma" or "bowel cancer" and "volatile organic compounds" or 
"volatile organic substances" and "biomarkers". Search results were title and 
abstract screened. Additional references were obtained from citations within 
returned search results.  
 
 
 
 
 
 
 
 
 
 
 
   
 
142 
 
 
 
 
 
 
CHAPTER 4 
Characterisation of VOC degradation over time at room 
temperature for healthy individuals 
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4.1. Introduction 
Prior to the collection of samples for the main experiment of this thesis an issue 
was identified that had important practical implications for sample collection and 
storage. That issue is that very little is known about how VOC profiles are affected 
by varying storage conditions e.g. refrigeration or freezing, and how they are 
affected by prolonged storage at room temperature prior to freezing. 
To date, there has been only a few studies into the effects of storage on VOC 
profiles of bodily samples. The first was conducted on the blood of healthy 
volunteers and compared analysis of fresh blood samples with samples 
refrigerated or frozen (241). It found that VOC profiles became more complex over 
time, and that frozen samples had a VOC profile distinct from samples stored in 
refrigerators and at room temperature. The second studied the effects of various 
storage parameters on the faecal VOC profiles of infants using an E-nose. They 
found that faecal sample size, water content, duration of storage at room 
temperature, faecal sample temperature, number of freeze/thaw cycles, and 
sampling method, all affected the VOC profiles. They concluded that the 
methodology of sample, collection, storage and analysis needs to be standardised, 
to allow for faecal VOC analysis to be utilised in a clinical setting (242). Thus far, 
there have been no studies of the effects of storage on VOC profile in urine.  
Given the diverse way in which samples were being returned for the main 
experiment, (hand delivered, courier returned or by postal service) it became 
apparent that this could have implications for data interpretation and validity. It 
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also highlights the lack of a defined optimum protocol for the collection and 
storage of samples used for VOC analysis.  
The experiment described in this chapter attempted to address some of these 
issues and determine whether the results of the main experiment were indeed 
valid.  
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4.2. Methods 
Sample collection and storage was performed as described in sections 3.2.3. 
Samples were collected from 27 healthy volunteers. They were immediately 
divided into 6 aliquots and sealed into universal storage bottles. Aliquots were 
then stored at room temperature before individual aliquots were frozen after  0, 
12, 24, 36, 48 and 72 hour time periods of room termpature storage. Samples were 
thawed and analysed using the Lonestar FAIMS machine (Owlstone, UK) at the 
University of Warwick, as described in section 3.3.2.  
Once sample analysis was performed, the FAIMS data was searched manually to 
identify sample data from blank control samples. The identified data are described 
as matrices, which are a graphical representation or plume of the individual FAIMS 
data collected from each sample aliquot analysis. Each sample for a single subject 
and time point underwent 14 sequential samplings for FAIMS analysis. The FAIMs 
process generates both positive and negative ions, resulting in 14 positive and 
negative matrices for each subject at each time point.   
The data then underwent statistical analysis as described in sections 3.3.2.1 and 
3.3.2.2. 
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4.3. Results 
27 healthy subjects were recruited to provide urine samples. 1 did not return any  
samples, 2 subjects provided insufficient urine for six aliquots and 4 samples were 
incompletely analysed due to technical errors with the FAIMS machine. A per 
protocol analysis was performed on the cohort of 20 complete sample sets.  
The mean age of subjects was 49.6 years (Standard Deviation (SD) 9.6 years), and 
there were 6 males (23%). The mean BMI was 28 (SD 5.8) and there were 2 
smokers (7.7%). Average alcohol consumption was 5.3 units per week per subject 
(SD 5.1). No subjects had significant genitourinary or gastrointestinal disease. 3 
subjects (11.5%) had asthma, 2 hypothyroidism (7.7%) and 4 hypertension 
(15.4%). No subjects were taking NSAIDs, antibiotics or PPIs at the time of sample 
collection. All urine samples were collected in the morning prior to 9am.  
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4.3.1. Mean VOC Variation from Baseline: 
For each patient, the arithmetic mean of all matrices from each successive time 
point (12, 24, 36, 48, 72), was compared to the mean of the same patients’ 
matrices at time point zero, as described in section 3.3.2.2. This was done for both 
positive and negative FAIMS matrices. The relative variation of VOC signatures in 
the FAIMS matrices increased with time, from time point zero to 72 hours, for both 
positive and negative matrices.  There was a plateau phase in the relative variation 
between time point 12 hours and time point 48 hours. This pattern was observed 
across all subjects for positive and negative matrices. Figure 4.1a shows the 
relative variation in the mean of the positive FAIMS matrices compared to time. 
Figure 4.1b shows the relative variation in the mean of the negative FAIMS 
matrices compared to time.  
Using Spearman's rank correlation coefficient to test for a monotonic relationship 
between mean variation from baseline and time, gave ρ0.94, p = 0.017 for positive 
matrices, and ρ0.83 p = 0.058 for negative matrices. When all subjects had positive 
and negative matrix data pooled for each time point, Spearman's rank correlation 
gave ρ0.52, p < 0.001 for positive matrices and ρ0.54, p < 0.001 for negative 
matrices.  
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Figure 4.1a. Variation of positive FAIMS matrices from the mean of the matrices 
from t=0. Bars show standard error. Correlation of mean variation with time: 
Spearman ρ0.94, p = 0.017. Correlation of all points with time ρ0.52, p < 0.001. 
Plateau phase seen between 12 and 48 hours.  
Figure 4.1b. Variation of negative FAIMS matrices from the mean of the matrices 
from t=0. Bars show standard error. Correlation of mean variation with time: 
Spearman ρ0.83, p = 0.058. Correlation of all points with time ρ0.54, p < 0.001. 
Plateau phase seen between 12 and 48 hours.  
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The variation from baseline was also reflected in the FAIMS spectral structures 
when averaged over all patients. Figures 4.2a and 4.2b show the baseline FAIMS 
plume structure, alongside the plumes for time points 12, 24, 36 and 72 hours, for 
positive and negative matrices respectively. They also show the difference in 
matrices between time point 0 and 72 hours for both the positive and negative 
matrices. In both cases there is a predominantly positive difference in the FAIMS 
spectrum which increases consistently with time, as shown by the FAIMS spectra 
from the other time points. This indicates an increase in the number of VOCs with 
increasing time.  
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Figure 4.2a. Positive matrices, difference from baseline with time. Top left: 
FAIMS spectrum at time zero. Middle left: FAIMS spectrum at 72 hours. Bottom 
left: Difference between spectrum at 72 hours and baseline. This shows a 
predominantly positive difference spectrum indicating an increase in VOCs. Right 
hand panels show the difference at 12, 24 and 36 hours from time 0, showing a 
consistent pattern, developing with time. All matrices averaged over all patients.  
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Figure 4.2b. Negative matrices, difference from baseline with time. Top left: 
FAIMS spectrum at time zero. Middle left: FAIMS spectrum at 72 hours. Bottom 
left: Difference between spectrum at 72 hours and baseline. This shows a 
predominantly positive difference spectrum indicating an increase in VOCs. Right 
hand panels show the difference at 12, 24 and 36 hours from time 0, showing a 
consistent pattern, developing with time. All matrices averaged over all patients.  
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To try and identify the source of this variation in the matrices, the average relative 
pairwise differences for all patients across each of the 14 matrices at each time 
point was plotted for both positive and negative matrices. This is shown in figure 
4.3a for positive matrices and figure 4.3b for negative matrices. Each 14x14 block 
corresponds to every pairwise difference between the 14 matrices at each time 
point i.e. Time point 0, matrix 1 vs time point 0, matrix 1/2/3/4 etc. The structure 
of the block suggests that there is significant variation within the fourteen 
matrices at any given time point. The difference between the first matrix from 
each time point and the subsequent matrices from the same time point grows with 
matrix number. This variation from baseline also grows with increasing time point 
from time point 0, as shown above.  
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Figure 4.3a. Pairwise relative differences for all pairs of positive matrices 
averaged across all patients. Blocks correspond to the labelled times, with 14 x 
14 elements corresponding to the associated matrices.  
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Figure 4.3b. Pairwise relative differences for all pairs of negative matrices 
averaged across all patients. Blocks correspond to the labelled times, with 14 x 
14 elements corresponding to the associated matrices.  
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To investigate this further, the relative variation in FAIMS matrix between the 14 
matrices from each time point was calculated for both positive and negative 
matrices. 
Mathematically this was done by:    
Variation t,n = Σp Vp,t,n 
                          P 
Where:       Vp,t,n = ΣcΣs|Mp,t,n,c,s - ΣnMp,t,n=1,c,s| 
         ΣcΣs|Mp,t,n=1,c,s| 
Figures 4.4a and 4.4b show the relative variation in averaged FAIM matrices for all 
patients for positive and negative matrices, respectively, compared to increasing 
matrix number. These show a monotonic increase in relative variation for both 
positive and negative matrices at all time points, with increasing matrix number 
for that time point. 
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Figure 4.4a. Relative variation from baseline of arithmetic mean of all patients as 
a function of matrix number for each time point for positive matrices. Bars show 
standard deviation.   
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Figure 4.4b. Relative variation from baseline of arithmetic mean of all patients as 
a function of matrix number for each time point for negative matrices. Bars show 
standard deviation.  
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This increase in relative variation, with increasing matrix number for each time 
point, was reflected in the FAIMS spectra, as was seen earlier with the relative 
variation of matrix structure seen with increasing time point. Figure 4.5a and 4.5b 
show the differences between the average matrices for all patients from matrix 1, 
time point 0, compared to matrix 14, time point 0 for both positive and negative 
matrices. Matrices 5, 8 and 11 from time point 0 show the consistent pattern of 
change with increasing matrix number. There is a predominantly negative 
difference in spectra between matrix 1 and 14 at each time point. This indicates 
that there is a loss of VOCs with increasing matrix number at each same time point. 
These findings are also seen in the negative matrices.    
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Figure 4.5a. Differences from baseline with increasing matrix number for positive 
matrices averaged over all subjects at t=0. Top left: Matrix 1, time 0. Middle left: 
matrix 14, time 0. Bottom left: difference between spectrum 1 and spectrum 14. 
The predominantly negative difference spectrum indicates a loss of VOCs. Right 
hand panels show the difference for matrices 5, 8 and 11 from matrix 1, showing 
a consistent pattern developing over time.   
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Figure 4.5b. Differences from baseline with increasing matrix number for 
negative matrices averaged over all subjects at t=0. Top left: Matrix 1, time 0. 
Middle left: matrix 14, time 0. Bottom left: difference between spectrum 1 and 
spectrum 14. The predominantly negative difference spectrum indicates a loss of 
VOCs. Right hand panels show the difference for matrices 5, 8 and 11 from 
matrix 1, showing a consistent pattern developing over time.   
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Relative variation in FAIMS spectra, and consequently VOC profile, not only 
increases with increasing room termpeature exposure time prior to freezing, but 
also with increasing matrix number for each time point. This suggests that VOC 
profiles are altering, not only with increased exposure to room temperature 
before freezing, but also to increasing atmospheric exposure on thawing. A subset 
of positive and negative matrices were analysed to see if there was any effect from 
using earlier, "fresher" matrices for each time point.  
Subsets of: the first matrix; the means of the first three matrices and all fourteen 
matrices from each patient at each time point were analysed. There was no 
qualitative difference in relative variation over the various time points when using 
a subset of matrices. The mean variation with time for the mean of all fourteen 
matrices per subject per time point gave a Spearman's rank correlation coefficient 
of ρ0.94, p = 0.017 for positive matrices, and ρ0.83, p = 0.058 for negative 
matrices. When a subset of the first three matrices was used; ρ0.66, p = 0.175 for 
positive matrices and ρ0.66, p = 0.175 for negative matrices. When only the first 
matrix for each patient at each time point was used; ρ0.43, p = 0.41 for positive 
matrices ρ0.66, p = 0.175 for negative matrices. These data are shown in figure 
4.6a and 4.6b.     
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Figure 4.6a. Correlation of mean variation of positive FAIMS matrices from mean 
of matrices from t=0. Red: Athrimetic mean of all 14 matrices from each patient 
at each time point. Green: Artithmetic mean of first 3 matrices from each patient 
at each time point. Blue: Variation calculated using only matrix 1 from each 
patient at each time point. 
Figure 4.6b.  Correlation of mean variation of negative FAIMS matrices from 
mean of matrices from t=0. Red: Athrimetic mean of all 14 matrices from each 
patient at each time point. Green: Artithmetic mean of first 3 matrices from each 
patient at each time point. Blue: Variation calculated using only matrix 1 from 
each patient at each time point.  
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4.3.2. Relative variation in Total Ion Count  
The relative variation in the total ion counts from the urine samples was also 
calculated as a function of time, as described in section 3.3.2.3. This was done for 
positive and negative FAIMS matrices.  
The total ion count was found to increase with time for both positive and negative 
FAIMS matrices. This is shown in figure 4.7a for positive matrices and 4.7b for 
negative matrices. Using Spearman's rank correlation coefficient to test for a 
monotonic relationship between time and variation in mean total ion count from 
baseline, gave ρ0.94, p = 0.017 for positive matrices, and ρ0.94, p = 0.017 for 
negative matrices. When all patients were combined as a single time series, this 
gave ρ0.25, p = 0.009 for positive matrices, and ρ0.27, p = 0.004 for negative 
matrices.   
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Figure 4.7a. Variation in relative ion count for positive matrices from mean of 
matrices at t=0. Bars show standard error. Correlation of mean ion count with 
time: Spearman ρ0.94, p = 0.017; correlation of all points with time: Spearman 
ρ0.25, p = 0.009. Plateau phase seen between 12 and 48 hours.  
Figure 4.7b. Variation in relative ion count for negative matrices from mean of 
matrices at t=0. Bars show standard error. Correlation of mean ion count with 
time: Spearman ρ0.94, p = 0.017; correlation of all points with time: Spearman 
ρ0.27, p = 0.004. Plateau phase seen between 12 and 48 hours.  
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Given the finding that there is an increase in variation when comparing sequential 
matrices from the same sample at a given time point described in the previous 
section, an analysis was run on the total ion count variation for sequential matrices 
from each time point. This analysis showed that the relative ion count reduced 
monotonically for positive matrices, with increasing matrix number at the same 
time point, and increased transiently for negative matrices before also reducing. 
These results are shown in Figure 4.8a and 4.8b. 
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Figure 4.8a. Relative variation of ion count from baseline of arithmetic mean of 
all patients as a function of matrix number for each time point for positive 
matrices. Bars show standard deviation.   
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Figure 4.8b. Relative variation of ion count from baseline of arithmetic mean of 
all patients as a function of matrix number for each time point for negative 
matrices. Bars show standard deviation.   
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As the relative ion count variation increases with time before the sample is frozen, 
but decreases with matrix number after the sample is thawed, subsets of the 
matrices were analysed for each patient at each time point to determine if using 
earlier matrices gave different results.  
Subsets of: the first matrix; the means of the first three matrices and all fourteen 
matrices from each patient at each time point were analysed. There was no 
qualitative difference in relative variation over the various time points when using 
a subset of matrices. The mean variation with time for the mean of all fourteen 
matrices per subject per time point, gave a Spearman's rank correlation coefficient 
of ρ1.0, p = 0.003 for positive matrices, and ρ1.0, p = 0.003 for negative matrices. 
When a subset of the first three matrices was used; ρ0.94, p = 0.17 for positive 
matrices, and ρ0.83, p = 0.058 for negative matrices. When only the first matrix 
for each patient at each time point was used; ρ0.77, p = 0.103 for positive matrices 
ρ0.77, p = 0.103 for negative matrices. These data are shown in figure 4.9a and 
4.9b.  
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Figure 4.9a. Correlation of mean mean relative ion count variation of positive 
matrices from t=0. Red: Athrimetic mean of all 14 matrices from each patient at 
each time point. Green: Artithmetic mean of first 3 matrices from each patient at 
each time point. Blue: Variation calculated using only matrix 1 from each patient 
at each time point. 
Figure 4.9b.  Correlation of mean relative ion count variation of negative 
matrices from t=0. Red: Athrimetic mean of all 14 matrices from each patient at 
each time point. Green: Artithmetic mean of first 3 matrices from each patient at 
each time point. Blue: Variation calculated using only matrix 1 from each patient 
at each time point. 
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4.4 Discussion 
Analysis of the patterns of VOCs found in the urine of healthy subjects, in response 
to prolonged storage at room temperature prior to freezing, shows that the 
variation within the FAIMS matrices, and hence the VOCs, increases with 
prolonged exposure to room temperature, despite storage in a sealed container. 
This pattern was uniform across all subjects, suggesting that this is an inherent 
property of the VOCs themselves. The presence of a plateau within this increase 
in variation, between 12 and 48 hours, is interesting. This could indicate that, after 
an initial degradation period, only minimal further alteration to the VOC profile 
occurs. This may represent the VOCs reaching a "steady state", and that it is only 
with exposure to room temperature beyond 48 hours that further degradation of 
VOCs occurs. The variation within the spectra was shown to increase with time, 
however, within each time point, the variation also increased in sequential 
matrices, despite an overall loss of the number of ions seen. This suggests that the 
samples were degrading to produce a more diverse pattern, but a reduced overall 
number of ionised VOCs.  
The cause of this degradation is unclear. All samples were aliquoted and sealed 
immediately upon collection. This reduces the likelihood of outside contaminants, 
but does not completely eliminate it. Urine was previously held to be a sterile 
substance, although this has recently been disproved (243). Despite none of our 
subjects had genitourinary disease, the presence of bacterial contamination from 
the urinary tract cannot be excluded, and, cannot be controlled for beyond 
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selecting healthy individuals. Bacterial contamination from the environment is a 
possibility, with potential introduction during the collection of the samples, 
although exposure of the samples to the atmosphere was kept to a minimum, and 
sterile universal bottles used. Any universal bottle which had a loose or absent lid 
when removed from its storage bag was discarded. Bacteria could potentially have 
been introduced during the sample analysis, although, exposure to atmospheric 
air was kept to a minimum, with samples being defrosted with the bottle caps 
secured. All samples were defrosted at room temperature and only re-exposed to 
atmospheric air once they were thawed and ready for analysis. This time was kept 
to a minimum, but, as before, outside contamination cannot be completely 
excluded.  
Given the consistent pattern of sample degradation, it suggests that any source of 
outside bacterial contamination occurred across all samples. Freezing the samples 
to -80°C would not kill all potentially contaminating bacteria, so if contamination 
were present then the bacteria could have lain dormant within the samples and 
metabolic processes restarted as the samples were thawed. Once again, this is 
unlikely given the healthy nature of our subjects but cannot be excluded.  
The increase in variation of VOCs with time was also reflected in an increase in 
total ion count within the samples with time exposed to room temperature prior 
to freezing. This suggests that the chemicals and VOCs within the sample are 
undergoing a degradation process, which results in several smaller molecules 
arising from the original molecules. The mechanism by which this occurs is unclear, 
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it could represent the activity of enzymes present in the urine, or other catalytic 
substances present within the urine, which allow the degradation and alteration 
of chemicals and VOCs, found within the samples, to multiple smaller compounds, 
and hence lead to an increase in VOC variation and total ion count.  
The observation that VOC variation increases and total ion count decreases with 
increasing matrix number for each time point is interesting. This suggests that VOC 
degradation continues upon thawing of the samples, and, with prolonged 
exposure to atmospheric conditions after thawing. This results in a greater relative 
variation of the VOC profile from the first matrix of each time point, to matrix 
fourteen of each time point, but an overall reduction in ion count number. This 
variation was consistent across all subjects and time points. The finding that total 
ion count reduces with increasing matrix number for each time point could suggest 
that the ions are being consumed in the process of producing new VOC 
degradation products, and that the ions themselves may be driving the 
degradation process.  
From a practical point of view, this study has far reaching effects for any further 
work which is to be performed using VOC analysis, as it affects sample collection 
and storage. Given the rapid degradation of VOC profile which occurs between 0 
and 12 hours, and then the plateau which occurs between 12 and 48 hours, there 
are two potential strategies. The first is that only absolutely fresh samples should 
be used, and they must be frozen immediately to prevent degradation. This has 
logistical implications for sample collection in a research environment and may 
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not always be achievable, particularly if the research subjects are uncomfortable 
with providing samples in a hospital or research setting. The second option would 
be to allow subjects to produce their samples at their convenience and return the 
samples, provided this occurs within 12-48 hours of the urine being passed into 
the bottle. This would rely on a high level of patient education and compliance. 
This would also require that any freshly produced urine should be stored at room 
temperature, so that all samples are frozen at the same time, to ensure that they 
are all exposed to atmospheric temperature for an equal amount of time.  
As an example from the main experiment of this thesis, the urine collected from 
the CRC patients, their relatives and spouses, was collected in a very heterogenous 
fashion. Some samples were provided on the day of surgery and were frozen with 
30 minutes of production. Others were done the same morning, and some the 
night before. Some specimens were returned via hospital courier, which would 
add several hours of exposure to atmospheric temperature. At the extreme end 
of the experiment, some samples were returned via the postal service, which, 
although first class postage was used, could result in a 48-72 hour exposure to 
atmospheric temperature. Although the vast majority of samples would have been 
returned and frozen within the 12-48 hour plateau phase of the degradation curve. 
This means that the results of the main experiment, detailed in the next chapter, 
are valid within the context of sample degradation. No samples were exposed to 
atmospheric temperature for greater than 72 hours. 
   
 
174 
 
This wide ranging spectrum of times for storage at atmospheric temperature 
means that some samples will have been further along the degradation curve than 
others. This could result in skewing of results due to overly degraded samples, 
however, the majority of samples were returned within the 12-48 hour plateau 
phase and the numbers of samples from the two extremes of the time spectrum 
were equally distributed this effect should be negated.  
Given the uniform way in which the samples appear to degrade with exposure to 
room temperature, there is the possibility that a "degradation algorithm" could be 
calculated, that would allow predicted of the original VOC profile, if the time a 
sample was exposed to atmospheric air was known. This again would require a 
high level of subject compliance, to accurately write the time and date the sample 
was produced on the collection bottle. It could also require good documentation 
at the tissue bank to accurately record when samples were frozen. This would 
allow the time the sample was exposed to room/atmospheric temperature to be 
calculated and the necessary calculations performed. This calculation is beyond 
the scope of this thesis, but is an interesting consideration for VOC research as it 
moves forward.  
This experiment highlights how little is known of the natural history of VOCs in 
health and disease. This experiment was conducted on healthy subjects, and there 
is currently no available research into the degradation of VOCs in diseased 
subjects. It is not known if the degradation follows a similar pattern, as in healthy 
subjects. Furthermore, this study had a sample size of only 20.  Further, larger 
   
 
175 
 
scale studies, potentially over longer time periods and with more interim time 
points, are needed, to allow a full mapping of the degradation patterns of VOCs in 
urine with prolonged exposure to atmospheric temperature prior to freezing for 
subsequent analysis.  
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CHAPTER 5 
Urinary VOC profiling of colorectal cancer patients, their first 
degree relatives and co-habitors 
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5.1. Introduction 
This experiment was aimed at characterising the urinary VOC profiles of colorectal 
cancer patients, prior to surgery or chemo/radiotherapy, in addition to their first 
degree relatives and spouses/co-habitors.  
The aim of this experiment was, in the first place, to confirm that CRC patients 
produce a unique VOC profile, which is distinct from those who share genetic 
traits, and those who share an environment. Previous studies into VOC profiling of 
CRC patients had used unrelated controls who also did not share an environment 
with the subjects.  
A further aim of the study was to determine whether either of the control groups 
had a VOC profile which more closely resembled that of the CRC group. In other 
words, could we determine if environment or genetics appeared to be a greater 
contributor towards the VOC profile being detected in CRC patients.  
The characterisation of the urinary VOC profiles was initially planned to be 
conducted on a Lonestar FAIMS machine at the University of Warwick, however, 
due to technical issues with the machine and recurrent delays, the decision was 
made to approach the company which manufactured the FAIMS machine, 
Owlstone, directly, to perform the analysis. This was performed on a variant of the 
FAIMS machine, which had a liquid chromatography column and time of flight 
mass spectrometer attached to the main FAIMS machine.  
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 5.2 Methods 
CRC patients were recruited as described in section 3.2.1. Relatives and spouses 
of the CRC patients were recruited as described in section 3.2.2. Only first degree 
relatives were approached to preserve as much of the genetic “signal” as possible. 
This included siblings and children. Children still co-habiting with the CRC patients 
were excluded as they would represent both genetic and environmental controls 
and could lead to confounding. Sample collection and storage was performed as 
described in sections 3.2.3.  The samples were frozen at -80ºC as soon as possible 
after their receipt. The results of Chapter 4 show that the time frame for sample 
collection (0-72 hours) will not cause a significant effect on the results gathered 
here, as while there is alteration of the signal with increasing sample exposure to 
atmospheric temperature, it is not enough to sigficiantly affect the results 
gathered. They were transferred to Owlstone, Cambridge in dry ice and again 
stored frozen at -80ºC. Samples were thawed and analysed using the LC-FAIMS-
MS hybrid (Owlstone, UK), as described in section 3.3.1. Data processing and 
statistical analysis were performed as described in sections 3.3.1.2a and 3.3.1.2.b. 
 
  
   
 
179 
 
5.3. Results 
72 CRC patients were recruited, in addition to 61 first degree relatives and 56 
spouses. Samples were returned by 56 pre-treatment CRC patients, 37 first degree 
relatives and 45 spouses.   
The mean ages of the three cohorts were 65.4 years (SD 11.5), 50 years (SD 14.1) 
and 60.7 years (SD 12.1) respectively. Normal distribution of ages was confirmed 
using Shapiro-Wilk testing. Analysis of Variance (ANOVA) testing and post-hoc 
Tukey’s honest significance difference (HSD) test showed no statistically significant 
differences in ages between CRC patients and their spouses. However, there was 
a significant difference between both CRC and first degree relatives, and spouses 
and first degree relatives, p < 0.01. This is due to presence of both siblings and 
children of the cancer patients in the cohort. This is an unavoidable consequence 
of recruiting children of the cancer patients.  
There were 33 males and 23 females with CRC in the final cohort, this ratio, was 
expectedly, reversed in the spouse cohort, with 15 males and 30 females. The male 
to female ratio in the relative cohort was 17:20. The male: female distribution was 
analysed using the Chi squared test, and found to be significantly different, chi 
squared statistic 10.3, p = 0.016.  Again this is to be expected, given the male 
predominance in CRC.  
The average cigarette consumption per day was 1.5 (SD 4.2) for CRC patients, 2.5 
(SD 5.3) for first degree relatives, and 1.6 (SD 5.7) for spouses. There was no 
statistically significant difference using ANOVA testing, p = 0.26.  
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Average alcohol consumption (units per week) was 8.8 (SD 11.6) for CRC patients, 
7.3 (SD 8.1) for first degree relatives and 6.7 (SD 10.1) for spouses. There was no 
statistically significant difference using ANOVA testing, p = 0.94.   
Mean BMI for the CRC cohort was 27.5 (SD 5.2), 25.5 (SD 3.8) for the first degree 
relatives and 26.7 (SD 4.8) for the spouses. There was no statistically significant 
difference using ANOVA testing, p = 0.45.   
The Duke’s stage of the CRC patients was as follows: A = 8 (14.2%), B = 17 (30.4%), 
C1 =20 (35.7%), C2 =9 (16.1%). The anatomical distribution of the CRC subjects 
was: right sided = 24 (42.8%); left sided = 17 (30.4%) and rectal = 15 (26.8%). The 
referral pathways that the CRC patients were detected through were: Screening 
programme = 18 (32.1%), 2 week wait pathway = 31 (55.4%), and other (including 
routine, emergency and incidental findings) =7 (12.5%).    
The demographics of the recruited subjects can be found in figure 5.4. 
No CRC patients, relatives or spouses had received recent courses of antibiotics. 
The CRC subjects had not undergone colonoscopy, and hence consumed bowel 
preparation medication, within the previous 2 weeks.  
3 CRC patients had a first degree relative (sibling or parent) with a history of CRC, 
these relatives were all diagnosed over the age of 60, meaning that all of our 
patients were sporadic CRC patients.  
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Table 5.1 Demographic data from recruited pre-treatment CRC patients, their first 
degree relatives and co-habitors/spouses.  
  
Group Pre-treatment 
CRC 
Relative Spouse P value 
Samples 56 37 45  
Mean age (SD) 65.4 (11.5) 50.0 (14.1)* 60.7 (12.1) * <0.01 
Sex (M:F) 33:23 17:20 15:30 0.016 
Number of cigarettes 
smoked  per day (SD) 
1.5 (4.2) 2.5 (5.3) 1.6 (5.7) 0.26 
Alcohol units per week (SD) 8.8 (11.6) 7.3 (8.1) 6.7 (10.1) 0.94 
Mean BMI (SD) 27.5 (5.2) 25.5 (3.8) 26.7 (4.8) 0.45 
Dukes stage (%) 
A 
B 
C1 
C2  
 
8 (14.2%) 
17 (30.4%) 
20 (35.7%) 
9 (16.1%) 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
Site (%) 
Right 
Left 
Rectal 
 
24 (42.8%) 
17 (30.4%) 
15 (26.8%) 
 
- 
- 
- 
 
- 
- 
- 
 
Referral Route (%) 
Screening 
2WW 
Other 
 
18 (32.1%) 
31 (55.4%) 
7 (12.5%) 
 
- 
- 
- 
 
- 
- 
- 
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The LC-FAIMS-MS data was analysed as described in section 3.3.1.2. The relevant 
subset of samples was extracted, and the different groups defined.  5-fold cross-
validation was then used to assess classification accuracy across these groups, 
using three different multi-class classifiers: sparse logistic regression, Support 
Vector Machine, Random Forest.  This analysis generated outputs of one-vs-all 
ROC curves i.e. comparing a single group vs all other groups, for example CRC vs 
relatives and spouses, relatives vs CRC and spouses, spouses vs CRC and relatives. 
Other results generated included the Area-Under-Curve (AUC) statistic, 
sensitivity/specificity values, which were selected automatically to be maximally 
similar given the ROC curve, and a p-value comparing the result to that expected 
for random chance (AUC=0.5), using a Wilcoxon rank-sum test. 
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This analysis showed that the LC-FAIMS-MS technology was able to distinguish 
pre-treatment CRC subjects from relatives and spouses as follows: 
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.63  
(0.48 – 0.76) 
0.64  
(0.52 – 0.74) 
0.72  
(0.63 – 0.81) 
9 0.000256* 
Support 
vector 
Machine 
0.59  
(0.44 – 0.72) 
0.58  
(0.47 – 0.77) 
0.64  
(0.55 – 0.74) 
9 0.0617 
Random 
Forrest 
0.69  
(0.54 – 0.81) 
0.69  
(0.57 – 0.79) 
0.71  
(0.62 – 0.8) 
9 0.00058* 
 
The Receiver Operator Curve plots for these 3 analyses can be found in figure 5.1.  
The positive predictive value for the Sparse logistic regression analysis was 54%, 
and negative predictive value 46%. The positive predictive value of the Random 
Forrest analysis was 60%, and negative predictive value 76%.  
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A.  
B.  
C.  
Figure 5.1. Receiver Operator Curve plots for statistical pipelines used to distinguish pre-
treatment CRC patients from the relative and spouse/co-habitor control groups. A. Sparse 
logistic regression B. Support vector machine C. Random Forest algorithm.   
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When the relative and spouse groups were individually cross validated against a 
combination of the other 2 groups e.g. relatives vs CRC and spouses, spouses vs 
CRC and relatives, then the following, non-statistically significant, results were 
achieved: 
Relatives  
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.56  
(0.38 – 0.72) 
0.57  
(0.46 – 0.67) 
0.59  
(0.48 – 0.7) 
9 0.933 
Support 
vector 
Machine 
0.58  
(0.41 – 0.74) 
0.59  
(0.48 – 0.69) 
0.61  
(0.5 – 0.71) 
9 0.569 
Random 
Forrest 
0.56  
(0.38 – 0.72) 
0.55  
(0.45 – 0.66) 
0.62  
(0.51 – 0.73) 
9 0.287 
 
The Receiver Operator Curve plots for these 3 analyses can be found in figure 5.2.  
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B.  
C.  
Figure 5.2. Receiver Operator Curve plots for statistical pipelines used to distinguish 
relatives from the pre-treatment CRC patients and spouse/co-habitor groups. A. Sparse 
logistic regression B. Support vector machine C. Random Forest algorithm.  
A. 
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Spouses 
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected 
p value 
(*<0.05) 
Sparse 
logistic 
regression 
0.54  
(0.37 – 0.69) 
0.54  
(0.43 – 0.65) 
0.63  
(0.52 – 0.74) 
9 0.133 
Support 
vector 
Machine 
0.51  
(0.35 – 0.67) 
0.52  
(0.41 – 0.63) 
0.49  
(0.37 – 0.6) 
9 7.2 
Random 
Forrest 
0.56  
(0.4 – 0.72) 
0.56  
(0.45 – 0.67) 
0.57  
(0.45 – 0.69) 
9 1.81 
 
The Receiver Operator Curve plots for these 3 sets of results can be found in 
figure 5.3.  
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A.  
B.  
C.  
Figure 5.3. Receiver Operator Curve plots for statistical pipelines used to distinguish 
spouses from the pre-treatment CRC patients and relative groups. A. Sparse logistic 
regression B. Support vector machine C. Random Forest algorithm. 
   
 
189 
 
A comparison of the relative and spouse groups was made to determine whether 
the two control groups could be distinguished from each other.  
The results of the cross-validation were non-statistically significant and are as 
follows: 
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.53  
(0.35 – 0.7) 
0.54  
(0.37 – 0.69) 
0.53  
(0.4 – 0.66) 
6 3.79 
Support 
vector 
Machine 
0.5  
(0.33 – 0.67) 
0.51  
(0.35 – 0.67) 
0.48  
(0.34 – 0.61) 
6 4.3 
Random 
Forrest 
0.5  
(0.33 – 0.67) 
0.51  
(0.35 – 0.67) 
0.53  
(0.4 – 0.66) 
6 3.94 
 
The Receiver Operator Curve plots for these 3 analyses can be found in figure 5.4. 
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A.  
B.  
C.  
Figure 5.4. Receiver Operator Curve plots for statistical pipelines used to distinguish 
the spouse/co-habitor group from the relative group. A. Sparse logistic regression B. 
Support vector machine C. Random Forest algorithm. 
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To further analyse the ability to distinguish the VOC profile of the pre-treatment 
CRC subjects, a subset analysis was performed. This time a smaller subset of CRC 
patients was used (n=35), and, to be included the CRC patients must have either a 
relative or a spouse sample included. This reduced the sample size for the CRC 
group, but not the relative or spouse group. 
This analysis showed: 
CRC patients 
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number 
of 
hypothes
es tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.53  
(0.35 – 0.71) 
0.55  
(0.4 – 0.68) 
0.5  
(0.37 – 0.63) 
9 8.77 
Support 
vector 
Machine 
0.56  
(0.38 – 0.74) 
0.57  
(0.42 – 0.7) 
0.52  
(0.39 – 0.65) 
9 7.04 
Random 
Forrest 
0.56  
(0.38 – 0.74) 
0.57  
(0.42 – 0.7) 
0.55  
(0.42 – 0.67) 
9 4.39 
The Receiver Operator Curve plots for these 3 analyses can be found in figure 5.5.  
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A.  
B.  
C.  
Figure 5.5. Receiver Operator Curve plots for statistical pipelines used to distinguish 
the reduced pre-treatment CRC patients from the relative and spouse/co-habitor 
control groups. A. Sparse logistic regression B. Support vector machine C. Random 
Forest algorithm. 
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A further cross validation, using this reduced number of CRC patients, was 
performed, with the relative and spouse groups each cross validated against all 
other groups e.g. relatives vs CRC and spouses, spouses vs CRC and relatives, and 
the following non statistically significant results were achieved: 
Relatives  
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.68  
(0.48 – 0.84) 
0.68  
(0.55 – 0.8) 
0.65  
(0.52 – 0.77) 
9 0.261 
Support 
vector 
Machine 
0.54  
(0.34 – 0.72) 
0.54  
(0.41 – 0.68) 
0.56  
(0.43 – 0.69) 
9 3.55 
Random 
Forrest 
0.54  
(0.34 – 0.72) 
0.54  
(0.41 – 0.68) 
0.51  
(0.38 – 0.64) 
9 8.16 
 
The Receiver Operator Curve plots for these 3 analyses can be found in figure 5.6. 
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A.  
B.  
C.  
Figure 5.6. Receiver Operator Curve plots for statistical pipelines used to distinguish the 
relative group from the reduced pre-treatment CRC and spouse/co-habitor groups. A. 
Sparse logistic regression B. Support vector machine C. Random Forest algorithm. 
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Spouses 
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.6  
(0.39 – 0.79) 
0.6  
(0.47 – 0.72) 
0.6  
(0.44 – 0.75) 
9 1.44 
Support 
vector 
Machine 
0.6  
(0.39 – 0.79) 
0.6  
(0.47 – 0.72) 
0.65  
(0.52 – 0.77) 
9 0.327 
Random 
Forrest 
0.6  
(0.39 – 0.79) 
0.6  
(0.47 – 0.72) 
0.64  
(0.52 – 0.76) 
9 0.39 
 
The Receiver Operator Curve plots for these 3 sets of results can be found in 
figure 5.7.  
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A.  
B.  
C.  
Figure 5.7. Receiver Operator Curve plots for statistical pipelines used to distinguish the 
spouse/co-habitor group from the reduced pre-treatment CRC and relative groups. A. 
Sparse logistic regression B. Support vector machine C. Random Forest algorithm. 
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5.4. Discussion 
The urinary VOC profiles of pre-treatment CRC patients were analysed using LC-
FAIMS-MS technology and compared to the profiles of a first degree relative and 
a spouse/co-habitor. Statistical analysis utilised three different multi-class 
statistical classifiers in a 5-fold cross validation and demonstrated a significant 
difference between the CRC patients and their relatives and spouses for 2 of the 
models; sparse logistics regression and Random Forrest. The AUC for the sparse 
logistics regression model was 0.72, with a sensitivity of 0.63 and specificity of 
0.64. The Bonferroni corrected p value was 0.000256. The Random Forrest 
classifier gave AUC, sensitivity and specificity of 0.71, 0.69 and 0.69 respectively, 
p = 0.00058. These results confirm that there is a distinct pattern of VOCs found in 
the urine of patients with CRC when compared to disease free controls. This 
confirms the findings of previous studies of urinary VOCs in CRC patients (115, 161-
163), although this is the first study to do so using this precise FAIMS apparatus, 
the LC-FAIMS-MS.  
The PPV was 54% for the sparse logistics regression model and 60% for the 
Random Forrest, whilst NPVs were 46% and 76% respectively. Whilst the positive 
predictive values compare very favourably to those demonstrated for FOBT and 
FIT of ~8-10% (85-87, 244) (Kearns, 85-87), the specificities and NPV compare less 
favourably to the 98% from previous studies (Kearns). The relatively poor 
specifities and NPV results represent one of the bigger obstacles that would need 
to be overcome for VOCs to enter clinical use as a screening tool for CRC.  
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There was no statistically significant difference in the urinary VOC profiles of the 
relatives and spouse cohorts when compared to each other. This suggests that the 
composition of the VOC profile in non-diseased individuals is very heterogenous, 
and that neither environment nor genetic factors cause a significant difference to 
the VOC profile, but that the presence of disease does. The reclassification analysis 
demonstrated that when the CRC cohort was combined with either the relative or 
spouse cohort, and then compared to the remaining cohort, the statistically 
significant difference was lost, with AUC, sensitivity and specificity falling to 0.49 - 
0.63, 0.51 - 0.58 and 0.52 - 0.59 respectively across the 3 classifiers used. The p 
values were all non-statistically significant, with Bonferroni correction leading to 
values of 0.13 - 7.2. This result indicates that the addition of either the relative or 
spouse VOC profiles, to the CRC patient profiles, led to a dilution of the unique 
signal found within the CRC cohort. This dilution was to such an extent that the 
clear difference between a pure CRC cohort and the combined control profiles was 
disguised. This would suggest that the LC-FAIMS-MS technology has the ability to 
distinguish “disease” from “non-disease”, but that either it is unable to distinguish 
the two types of controls, or that the two types of controls have indistinguishable 
VOC profiles. The similarity of AUC, sensitivity and specificity of the reclassification 
of the genetic and the environmental controls suggests that the study may have 
been underpowered to detect these changes. Future studies would need to have 
larger numbers in each cohort to determine whether the lack of difference seen 
here was a result of underpowering or whether neither control cohort possess a 
VOC profile which is more similar to the CRC profile than the other  
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A sub-analysis of the cohorts, where samples were only included if there was a 
relative or spouse matched to the CRC patient sample, i.e. lone CRC samples were 
excluded, was also performed. This led to reduction in in CRC samples from 56 to 
35. This analysis returned non-significant results with AUC, sensitivity and 
specificity of 0.5 - 0.55, 0.55 - 0.57 and 0.53 - 0.57 respectively, with p values of 
4.39 - 8.77. The loss of statistical significance seen here is most likely due to the 
reduction in the sample size of CRC cohort, and hence underpowering of the 
analysis.  
The results of the urinary VOC degradation study conducted in chapter 4 do raise 
the possibility that the observed effects here may have been diminished, or indeed 
accentuated by differences in the times that urine samples were stored at room 
temperature. Particularly the relatives cohort, as more samples from this cohort 
were returned via the postal service than for the other 2 groups. Some CRC 
samples were provided on the day of surgery and were frozen with 30 minutes of 
production. Others were done the same morning, and some the night before. 
Some specimens were returned via hospital courier, which would add several 
hours of exposure to atmospheric temperature. At the extreme end of the 
experiment, some samples, usually relative samples, were returned via the postal 
service, which, although first class postage was used, could result in a 48-72 hour 
exposure to atmospheric temperature. There was, however, no statistically 
significant difference between groups in the duration of exposure of the urine 
samples to atmospheric temperature and pressure. Over 90% of samples were 
frozen when they had been at room temperature for >12 hours but less than 48 
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hours, corresponding with the plateau phase of the degradation plots found in 
Chapter 4. This means that whilst confounding as a result of differing lengths of 
time from collection to freezing cannot be excluded, if present, it should have 
negligible effect. This means that the results of the main experiment, detailed in 
the next chapter, are valid within the context of sample degradation. No samples 
were exposed to atmospheric temperature for greater than 72 hours. 
This wide ranging spectrum of times for storage at atmospheric temperature 
means that some samples will have been further along the degradation curve than 
others. This could result in skewing of results due to overly degraded samples, 
however, the majority of samples were returned within the 12-48 hour plateau 
phase and the numbers of samples from the two extremes of the time spectrum 
were equally distributed this effect should be negated.  
The current theory of VOC generation suggests that VOCs represent the results of 
interactions between cellular metabolic processes, consumed food and 
medications and microbiome fermentation (96). The spouses/ co-habitors were all 
consuming the same food types as the CRC subjects and none of the 3 groups were 
consuming special diets (vegan, vegetarian, gluten free). This removes the 
potential for confounding in terms of food contributions to VOC profiles. There is 
the possibility that the relative and spouse groups were underpowered as 
discussed above, however no trends were noted and therefore it is unlikely that if 
present, and differences in VOC profiles between the control groups are unlikely 
to be significant.  
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There is the possibility that a different microbiome composition would produce 
different metabolic/ fermentation products from the same food substrate. This 
will be addressed in Chapter 7. The relatives would have a similar genetic 
constitution to the CRC patients and so a closer metabolic “fingerprint” than the 
spouses/ co-habitors. The fact that the CRC subjects are distinguishable from the 
relatives cohort, indicates that any differences in VOC profile would most likely be 
coming from either different food profile consumption, or a different metabolic 
profile as a result of the CRC, or different microbiome. This latter point will be 
addressed in Chapter 7. As the relatives and spouses had indistinguishable VOC 
profiles this suggests that neither food consumption nor microbiome can have 
significant influence over the VOC profile. Therefore, any differences observed 
must be a result of metabolic profile differences. As the relatives should share a 
closer metabolic profile to the CRC patients and yet are still distinguishable, this 
suggests that any difference in VOC profile should indeed be arising as a result of 
the presence of CRC, which could produces either a different profile of metabolites 
or cancer specific metabolites, detectable via the LC-FAIMS-MS technology.  
This experiment demonstrates that CRC patients appear to have a unique urinary 
VOC profile, when compared to environmental and genetic controls. This adds to 
the growing body of evidence which indicates that urinary VOCs can be used to 
distinguish CRC patients from non-diseased controls, whether they are the 
independent controls used in previous studies, or the environmental or genetic 
controls used here. There was no statistical significance between the relative and 
spouse cohorts urinary VOC profiles, and when they were reclassified in 
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conjunction with the CRC patient samples, there did not appear to be a closer 
association between the either of the two control groups and the CRC subjects. 
This suggests that whilst environmental and genetic factors are believed to play a 
role in the development of sporadic CRC, that neither appears to result in a 
detectable VOC profile.    
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CHAPTER 6 
Urinary VOC profiling of colorectal cancer patients prior to 
treatment and after treatment and by disease site and referral 
method 
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6.1 Introduction 
As an extension of the primary study, the urinary VOC profiles of CRC patients were 
also studied in post-operative samples, which were collected at 3 and 6 month 
intervals after the subjects had undergone their initial surgery. This was to attempt 
to determine whether the VOC profile alters after the primary cancer has been 
removed.  
At present the surveillance of post-treatment CRC patients includes a combination 
of colonoscopy, CT scanning and CEA blood monitoring. The aim of this experiment 
was to determine whether the VOC profiles of CRC patients could potentially be 
used as an alternative surveillance tool for detecting disease recurrence.  
Further analysis was conducted to determine whether site of CRC (right sided, left 
sided, or rectal) affected VOC profile, and whether there was any difference with 
regards to referral method (2 week wait pathway, screening or other, which 
included emergency presentations, incidental findings and routine referrals). 
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6.2 Methods 
CRC patients, who were recruited for the primary experiment, as described in 
section 3.2.1, were approached 3 and 6 months after their initial treatment. If they 
agreed to provide further samples then samples were collected and stored as 
described in sections 3.2.3.  A further cohort of patients had samples collected. 
These were patients who have previously had curative resection of CRC, 24-36 
months previously with no recurrence at the time of recruitment. This second 
cohort would act as a long term comparison group for the pre-treatment CRC 
patient profiles, the aim being to detect any changes that occur after patients have 
been cancer free for a prolonged period of 2 or more years.  
The samples were frozen at -80ºC as soon as possible after their receipt. They were 
transferred to Owlstone, Cambridge in dry ice and, again, stored frozen at -80ºC. 
Samples were thawed and analysed using the LC-FAIMS-MS machine (Owlstone, 
UK), as described in section 3.3.1.  
Data obtained from the LC-FAIMS-MS hybrid was pre-processed and analysed as 
described in sections 3.3.1.2a, and then underwent analysis using the statistical 
methods  described in section 3.3.1.2b.  
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6.3. Results 
As for the experiment outlined in Chapter 5, 56 CRC patients returned pre-
operative samples. Of these, 23 returned samples after 3 months and 9 returned 
samples after 6 months. 30 CRC patients who were 24-36 months post initial 
treatment and currently in disease free surveillance also provided urine samples 
for VOC analysis.  
The mean age of the pre-treatment group was 65.4 years (SD 11.5). For the 3 
month post-treatment samples it was 66.5 (SD 13.0), and 64.7 (SD 12.7) for the 6 
month post-treatment samples, and for the long term CRC follow up patients it 
was 66.5 (SD 11.7). There was no statistically significant difference between the 
ages of the groups using ANOVA analysis, p = 0.57.  
There were 33 males and 23 females with CRC in the pre-treatment cohort; with 
12 males and 11 females in the 3 month post-treatment cohort, 5 males and 4 
females in the 6 month post treatment cohort and, finally, 20 males and 10 
females in the long term CRC follow up cohort. The male: female distribution was 
analysed using the Chi squared test, and found to not be significantly different; chi 
squared statistic 1.2, p = 0.75.   
The average cigarette consumption per day was 1.5 (SD 4.2) for the pre-treatment 
CRC group, 0.5 (SD 2.1) for the 3 month post-treatment cohort, 0 (SD 0) for the 6 
month post-treatment cohort and 0.2 (SD 0.9) for the long term CRC follow up 
cohort. There was no statistically significant difference using ANOVA analysis, p = 
0.16.  
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Average alcohol consumption (units per week) was 8.1 (SD 11.6) for the pre-
treatment CRC group, 6.5 (SD 11.2) for the 3 month post-treatment cohort, 9.9 
(SD 15.6) for the 6 month post-treatment cohort and 6.6 (SD 9.0) for the long term 
CRC follow up group. There was no statistically significant difference using ANOVA 
testing, p = 0.83.   
No CRC subject had received recent courses of antibiotics prior to providing either 
pre-treatment or post-treatment samples. They had not undergone recent 
endoscopic investigation, so had not consumed bowel preparation medications.  
Mean BMI for the CRC cohort was 27.5 (SD 5.2), 26.5 (SD 7.7) for the 3 month post-
treatment cohort, 26.7 (SD 11.6) for the 6 month post-treatment cohort and 27.2 
(SD 4.5) for the long term CRC follow up group. There was no statistically 
significant difference using ANOVA testing, p = 0.93.   
The Duke’s stages of the various groups are shown in table 6.4.1. There was no 
statistically significant difference seen in the grouping using Chi squared analysis; 
chi squared statistic 3.6, p = 0.93.  
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Duke’s Stage Pre-treatment 
CRC 
3/12 CRC 6/12 CRC Long term 
CRC 
A (%) 8 (14.2%) 4 (17.4%) 1 (11.1%) 7 (23.3%) 
B (%) 17 (30.4%) 7 (30.4%) 2 (22.2%) 10 (33.3%) 
C1 (%) 20 (35.7%) 9 (39.1%) 5 (55.5%) 9 (30%) 
C2 (%) 9 (16.1%) 2 (8.7%) 0 (0%) 3 (10%) 
 
Table 6.1. Duke’s stages of the pre-treatment CRC group, the 3/12 and 6/12 
samples of the same group, and the long term CRC follow up group.  
The anatomical distribution of the various groups is shown in table 6.4.2. There 
was no statistically significant difference seen in the grouping using Chi squared 
analysis; chi squared statistic 5.2, p = 0.52.  
Anatomical 
distribution 
Pre-
treatment 
CRC 
3/12 CRC 6/12 CRC Long term 
CRC  
Right sided (%) 24 (42.8%) 13 (56.5%) 4 (44.4%) 14 (46.7%) 
Left sided (%) 17 (30.4%) 7 (30.4%) 4 (44.4%) 6 (20%) 
Rectal (%) 15 (26.8%) 3 (13.4%) 1 (11.1%) 10 (33.3%) 
 
Table 6.2. Anatomical distribution of the pre-treatment CRC group, the 3/12 and 
6/12 samples of the same group, and the long term CRC follow up group. 
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The referral pathways that the CRC patients were detected through were as 
follows: Screening programme = 18 (32.1%), 2 week wait pathway = 31 (55.4%), 
other (including routine, emergency and incidental findings) = 7 (12.5%).  The long 
term CRC follow up patients were referred as follows:  Screening programme = 5 
(16.7%), 2 week wait pathway = 17 (56.7%), other (including routine, emergency 
and incidental findings) = 7 (23.3%).  There was no statistically significant 
difference seen in the grouping using Chi squared analysis; chi squared statistic 
3.2, p = 0.20. 
The LC-FAIMS-MS data was analysed as described in section 5.3.2. The relevant 
subset of samples was extracted, and the different groups defined.  5-fold cross-
validation was then used to assess classification accuracy across these groups, 
using three different multi-class classifiers: sparse logistic regression, Support 
Vector Machine, Random Forrest.  This analysis generated outputs of one-vs-all 
ROC curves i.e. comparing a single group vs all other group(s), for example pre-
treatment CRC vs 3 month post-treatment sample or for multiple comparisons 
pre-treatment CRC vs all post-treatment CRC (3 month and 6 month) and historic; 
all post-treatment CRC vs pre-treatment CRC and long term CRC follow up; long 
term CRC follow up vs pre-treatment and post-treatment CRC. Other results 
generated included the Area-Under-Curve (AUC) statistic, sensitivity/specificity 
values, which were selected automatically to be maximally similar given the ROC 
curve, and a p-value comparing the result to that expected for random chance 
(AUC=0.5), using a Wilcoxon rank-sum test. 
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The comparison of the LC-FAIMS-MS analysis of pre-operative CRC samples with 
the 3 month post-treatment samples. There was no statistical difference at 3 
months compared to the pre-treatment samples.  
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.57  
(0.42 – 0.71) 
0.57  
(0.34 – 0.78) 
0.59  
(0.45 – 0.73) 
6 1.35 
Support 
vector 
Machine 
0.53  
(0.38 – 0.67) 
0.52  
(0.3 – 0.74) 
0.5  
(0.34 – 0.66) 
6 5.76 
Random 
Forrest 
0.63  
(0.48 – 0.76) 
0.62  
(0.38 – 0.82) 
0.65  
(0.51 – 0.78) 
6 0.329 
  
The Receiver Operator Curve plots for these 3 analyses can be found in figures 6.1.  
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A.  
B.  
C.  
Figure 6.1. Receiver Operator Curve plots for statistical pipelines used to distinguish pre-
treatment CRC patients from the 3 month post-treatment group. A. Sparse logistic 
regression B. Support vector machine C. Random Forest algorithm.  
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The comparison of the LC-FAIMS-MS analysis of pre-operative CRC samples with 
the 6 month post-treatment samples. There was no statistical difference 
between the 6 month samples and the pre-treatment cohort.  
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.51  
(0.37 – 0.65) 
0.56  
(0.21 – 0.86) 
0.6  
(0.38 – 0.82) 
6 2.1 
Support 
vector 
Machine 
0.65  
(0.5 – 0.78) 
0.67  
(0.3 – 0.93) 
0.59  
(0.38 – 0.81) 
6 2.33 
Random 
Forrest 
0.61  
(0.46 – 0.74) 
0.56  
(0.21 – 0.86) 
0.62  
(0.42 – 0.82) 
6 1.44 
  
The Receiver Operator Curve plots for these 3 analyses can be found in figures 6.2.  
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A.  
B.  
C.  
Figure 6.2. Receiver Operator Curve plots for statistical pipelines used to distinguish pre-
treatment CRC patients from the 6 month post-treatment group. A. Sparse logistic 
regression B. Support vector machine C. Random Forest algorithm.  
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An analysis was performed to see if pre-treatment CRC samples could be 
distinguished from grouped post-treatment 3 and 6 months samples, and also 
from long term CRC follow up patients. There was no statistical difference 
between the 3 patients cohorts.  
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.57  
(0.42 – 0.71) 
0.56  
(0.42 – 0.69) 
0.58  
(0.47 – 0.69) 
9 1.34 
Support 
vector 
Machine 
0.51  
(0.37 – 0.65) 
0.51  
(0.37 – 0.64) 
0.52  
(0.4 – 0.63) 
9 7.04 
Random 
Forrest 
0.53  
(0.38 – 0.67) 
0.53  
(0.39 – 0.66) 
0.61  
(0.5 – 0.71) 
9 0.492 
  
The Receiver Operator Curve plots for these 3 analyses can be found in figures 6.3.  
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A.  
B.  
C.  
Figure 6.3. Receiver Operator Curve plots for statistical pipelines used to distinguish pre-
treatment CRC patients from combined 3 and 6 month post-treatment groups and long 
term CRC follow up patients. A. Sparse logistic regression B. Support vector machine C. 
Random Forest algorithm.  
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When the post-treatment and long term CRC follow up groups were individually 
cross validated against a combination of the other 2 groups e.g. post-treatment vs 
pre-treatment CRC and long term CRC follow up, long term CRC follow up vs pre-
treatment CRC and post-treatment CRC, the following results were achieved: 
Post-treatment:  
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.53  
(0.34 – 0.72) 
0.54  
(0.42 – 0.65) 
0.57  
(0.45 – 0.69) 
9 2.37 
Support 
vector 
Machine 
0.57  
(0.37 – 0.75) 
0.56  
(0.45 – 0.67) 
0.6  
(0.48 – 0.73) 
9 0.823 
Random 
Forrest 
0.57  
(0.37 – 0.75) 
0.57  
(0.46 – 0.68) 
0.62  
(0.5 – 0.73) 
9 0.554 
  
The Receiver Operator Curve plots for these 3 analyses can be found in figures 6.4.   
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A.  
B.  
C.  
Figure 6.4. Receiver Operator Curve plots for statistical pipelines used to distinguish 
combined 3 and 6 month post-treatment CRC patients from pre-treatment CRC and long 
term CRC follow up patients. A. Sparse logistic regression B. Support vector machine C. 
Random Forest algorithm.  
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Long term CRC follow up:  
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.52  
(0.33 – 0.71) 
0.53  
(0.42 – 0.64) 
0.59  
(0.47 – 0.71) 
9 1.34 
Support 
vector 
Machine 
0.55  
(0.36 – 0.74) 
0.56  
(0.44 – 0.67) 
0.62  
(0.51 – 0.74) 
9 0.442 
Random 
Forrest 
0.66  
(0.46 – 0.82) 
0.64  
(0.53 – 0.75) 
0.65  
(0.55 – 0.76) 
9 0.129 
  
The Receiver Operator Curve plots for these 3 analyses can be found in figures 6.5.  
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A.  
B.  
C.  
Figure 6.5. Receiver Operator Curve plots for statistical pipelines used to distinguish long 
term CRC follow up patients from combined 3 and 6 month post-treatment CRC patients 
and pre-treatment CRC. A. Sparse logistic regression B. Support vector machine C. 
Random Forest algorithm. 
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When the VOC data was analysed according to site of CRC, right, left or rectal, the 
analysis showed that sites could not be distinguished from each other with 
statistical significance: 
Right sided CRC:  
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.67  
(0.43 – 0.85) 
0.67  
(0.47 – 0.83) 
0.72  
(0.58 – 0.86) 
9 0.0683 
Support 
vector 
Machine 
0.57  
(0.34 – 0.78) 
0.57  
(0.37 – 0.75) 
0.63  
(0.47 – 0.79) 
9 1.03 
Random 
Forrest 
0.57  
(0.34 – 0.78) 
0.57  
(0.37 – 0.75) 
0.66  
(0.5 – 0.82) 
9 0.512 
  
The Receiver Operator Curve plots for these 3 analyses can be found in figures 6.6.  
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A.  
B.  
C.  
Figure 6.6. Receiver Operator Curve plots for statistical pipelines used to distinguish right 
sided CRC from left sided and rectal CRC. A. Sparse logistic regression B. Support vector 
machine C. Random Forest algorithm. 
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Left sided CRC:  
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.57  
(0.29 – 0.82) 
0.57  
(0.39 – 0.73) 
0.58  
(0.41 – 0.75) 
9 3.64 
Support 
vector 
Machine 
0.57  
(0.29 – 0.82) 
0.57  
(0.39 – 0.73) 
0.66  
(0.49 – 0.84) 
9 0.702 
Random 
Forrest 
0.57  
(0.29 – 0.82) 
0.57  
(0.39 – 0.73) 
0.66  
(0.5 – 0.82) 
9 0.67 
  
The Receiver Operator Curve plots for these 3 analyses can be found in figures 6.7.  
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A.  
B.  
C.  
Figure 6.7. Receiver Operator Curve plots for statistical pipelines used to distinguish left 
sided CRC from right sided and rectal CRC. A. Sparse logistic regression B. Support vector 
machine C. Random Forest algorithm. 
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Rectal CRC:  
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.62  
(0.35 – 0.85) 
0.63  
(0.45 – 0.79) 
0.57  
(0.41 – 0.74) 
9 3.7 
Support 
vector 
Machine 
0.56  
(0.3 – 0.8) 
0.57  
(0.39 – 0.74) 
0.66  
(0.5 – 0.82) 
9 0.681 
Random 
Forrest 
0.62  
(0.35 – 0.85) 
0.6  
(0.42 – 0.76) 
0.65  
(0.48 – 0.82) 
9 0.846 
  
The Receiver Operator Curve plots for these 3 analyses can be found in figures 6.8.  
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A.  
B.  
C.  
Figure 6.8. Receiver Operator Curve plots for statistical pipelines used to distinguish rectal 
CRC from left and right sided CRC. A. Sparse logistic regression B. Support vector machine 
C. Random Forest algorithm. 
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When the VOC data was analysed according to the method of referral for the CRC 
patients, screening programme or 2 week wait pathway, the analysis showed that 
sites could not be distinguished from each other with statistical significance. 
Patients referred by other pathways including incidental findings, routine referrals 
or emergency presentations were excluded due to small sample number (n=7).  
Statistical 
method  
Sensitivity 
(Confidence 
intervals) 
Specificity 
(Confidence 
intervals) 
Area under 
Curve 
(Confidence 
intervals) 
Number of 
hypotheses 
tested 
Bonferroni 
corrected p 
value 
(*<0.05) 
Sparse 
logistic 
regression 
0.55  
(0.36 – 0.74) 
0.53  
(0.27 – 0.79) 
0.52  
(0.33 – 0.7) 
6 5.23 
Support 
vector 
Machine 
0.52  
(0.33 – 0.71) 
0.53  
(0.27 – 0.79) 
0.53  
(0.33 – 0.73) 
6 4.54 
Random 
Forrest 
0.52  
(0.33 – 0.71) 
0.53  
(0.27 – 0.79) 
0.53  
(0.34 – 0.73) 
6 4.32 
  
The Receiver Operator Curve plots for these 3 analyses can be found in figures 6.9.  
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A.  
B.  
C.  
Figure 6.9. Receiver Operator Curve plots for statistical pipelines used to distinguish CRC 
patients referred through either 2 week wait pathway or through the screening 
programme. A. Sparse logistic regression B. Support vector machine C. Random Forest 
algorithm. 
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6.4 Discussion 
As an extension of the experiment described in chapter 5, the urinary VOC profiles 
of CRC patients pre- and post-treatment were analysed using LC-FAIMS-MS 
technology. Three different multi-class statistical classifiers were utilised in a 5-
fold cross validation, and demonstrated that there was no statistically significant 
difference between the pre-treatment CRC samples and any of the various post-
treatment samples (3 and 6 months), nor when all post-treatment samples were 
combined. There was also no statistically significant difference between the pre-
operative CRC patients samples and samples collected from long term CRC follow 
up subjects, who were 24-36 months post curative treatment and were in disease-
free surveillance.  
These findings suggest that there may be no role for the use of urinary VOCs in the 
surveillance for CRC recurrence, as those who have had the disease, but are now 
“cured”, are indistinguishable from those who have active disease. The underlying 
reasons for this lack of change in VOC profile after CRC removal would need to be 
further explored. It could represent an underpowering of the study, or that any 
differences between the cohorts are very small. As discussed in chapter 5, the 
various contributing factors to VOC profile are believed to be metabolic processes, 
diet and medication, and microbiome profile. The microbiome of pre and post-
treatment CRC patients will be addressed in chapter 8. No patients altered their 
diets between diagnosis of cancer and providing post-treatment samples. No 
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patients were started on any new medication, other than chemotherapy for some 
of the Duke’s B and all of the Duke’s C patients.  
A sub-analysis of the post-treatment samples according to Duke’s stage, and 
whether or not they had chemotherapy, was not undertaken due to small sample 
sizes (see table 6.1), with 14 out of 23 patients who returned samples at 3 months 
receiving chemotherapy and 7 out of 9 patients who returned samples at 6 months 
receiving chemotherapy. However, as the post-treatment samples could not be 
distinguished from pre-treatment, this indicates that again, either the experiment 
is underpowered or that chemotherapy does not appear to have had a significant 
effect on VOC profile. If it is the latter then this could suggest that any changes in 
metabolome of the CRC patients in response to CRC removal, have not led to a 
significant change in the VOC profile. Thus, indicating, that any metabolic changes 
which occur in the presence of CRC, are long term changes and persist even after 
the CRC has been treated. 
It is possible that there is a difference in the urinary VOC profile of pre and post-
treatment CRC samples; however, if present they may be so small to be of 
questionable clinical significance. It could be that the LC-FAIMS-MS machine is not 
sensitive enough, or not configured in the right way to detect these differences. It 
could also be that the statistical methods used are insufficiently fine-tuned to 
allow detection of these differences.  Both the technology and the statistical 
methods are novel and have never been used in this precise form to distinguish 
patients with CRC from urinary VOCs before, and so, with further improvements 
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to the technology and the statistical methods, differentiation of pre and post-
treatment CRC subjects may become possible. 
There is no conclusive evidence  that VOCs can be utilised in other cancers for 
disease recurrence. Two studies into the use of exhaled VOCs in lung cancer have 
shown variable results, with some alteration in VOC profile in post-treatment 
samples, but the VOC profile did not revert completely back to that of healthy 
controls (150, 212).  
There has been promising evidence to date, of the value of the use of VOCs in 
surveillance for CRC recurrence. Altomare et al found that by using GC-MS to 
analyse exhaled breath of CRC patients, 2 years after curative surgery, they were 
able to distinguish pre-operative from post-treatment samples with a sensitivity 
of 100%, specificity of 97%, accuracy of 98.8% and AUC 1 (211).  Ma et al had 
previously demonstrated that there is a significant reduction in the levels of 2 
individual VOCs post operatively in urinary VOCs, using GC-MS analysis, although 
did not recommend their use in surveying for disease recurrence (161).  
There were also no statistically significant differences in the urinary VOC profiles 
of CRC patients with different sites of CRC (right, left and rectal) or by method of 
referral (2 week wait, screening) This indicates that the CRC itself produces a 
consistently unique VOC profile, which is not affected by differing site of cancer or 
method of discovery. To date, there have been no studies into the VOC profiles of 
CRC from different sites or referral pathways. This would suggest that urinary VOC 
analysis could be a viable method for detecting all types of CRC from all referral 
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pathways, as the VOC changes detected are found in all subtypes of 
adenocarcinoma CRC.  
The results of this experiment suggest that whilst urinary VOC analysis has the 
potential to be used to distinguish patients with CRC compared to controls, as 
described in Chapter 5, the value of VOC analysis in monitoring for disease 
recurrence is limited at this stage, as the unique VOC signature found in pre-
treatment CRC patients persists after they have had treatment, and is 
indistinguishable from patients who are in disease free remission 24-36 months 
later. Further work is needed in this area, and larger studies required, with longer 
term follow up to determine whether VOC analysis could be a useful tool in CRC 
surveillance, or, if its future lies in disease detection only.  
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CHAPTER 7 
Stool 16s RNA profiling of colorectal cancer patients, their first 
degree relatives and co-habitors 
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7.1. Introduction 
16s RNA profiling of the microbiome of pre-treatment colorectal cancer patients, 
their first degree relatives and spouses/co-habitors was undertaken as part of the 
experiments of this thesis.  
The aim was to determine whether CRC patients have a unique microbiome 
profile, which is distinct from those who share genetic traits, and those who share 
an environment. Previous studies into microbiome profiling of CRC patients have 
shown a restricted bacterial profile compared to healthy controls, termed 
dysbiosis. However, these experiments will use environmental and genetic 
controls to determine whether the CRC patients profile is indeed distinct and, if 
so, does it more closely resemble that of those individuals who share genetic 
material with the CRC patients, or, those who share an environment.  
This experiment was planned to allow greater interpretation of the VOC data 
described in chapter 5, and to help to provide information as to whether VOC 
profiles could be affected by different microbiome composition.  
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7.2. Methods 
CRC patients were recruited as described in section 3.2.1. Relatives and spouses 
of the CRC patients were recruited as described in section 3.2.2. Only first degree 
relatives were approached to preserve as much of the genetic “signal” as possible. 
This included siblings and children. Children still co-habiting with the CRC patients 
were excluded as they would represent both genetic and environmental controls 
and could lead to confounding. Sample collection and storage was performed as 
described in section 3.2.4.  The samples were frozen at -80ºC as soon as possible 
after their receipt. They were transferred to the University of Warwick in dry ice 
and, again, stored frozen at -80ºC. Samples were thawed and analysed using 16s 
RNA sequencing on an Illumina MiSeq platform as described in section 3.3.3. 
Processing of the sequence data and analysis was performed as described in 
section 3.3.3.7. 
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7.3. Results 
As described in Chapter 5, 72 CRC patients were recruited, in addition to 61 first 
degree relatives and 56 spouses. Stool samples were returned by 44 pre-
treatment CRC patients, 34 first degree relatives and 39 spouses.   
The mean ages of the three cohorts were 65.3 years (SD 11.2), 51.2 years (SD 12.6) 
and 59.9 years (SD 12.4) respectively. Normal distribution of ages was confirmed 
using Shapiro-Wilk testing. Analysis of Variance (ANOVA) testing and post-hoc 
Tukey’s honest significance difference (HSD) test showed no statistically significant 
differences in ages between CRC patients and their spouses. However, there was 
a significant difference between both CRC and first degree relatives, and spouses 
and first degree relatives, p < 0.01. This is due to presence of both siblings and 
children of the cancer patients in the sample mix. This is an unavoidable 
consequence of recruiting children of the cancer patients.  
There were 25 males and 19 females with CRC in the final cohort, this ratio, was 
expectedly, reversed in the spouse cohort, with 13 males and 26 females. The male 
to female ratio in the relative cohort was 14 to 18. The male: female distribution 
was analysed using the Chi squared test, and found to not be significantly 
different, chi squared statistic 4.7, p = 0.1.   
The average cigarette consumption per day was 0.73 (SD 2.6) for CRC patients, 2.9 
(SD 5.6) for first degree relatives, and 2 (SD 6.4) for spouses. There was no 
statistically significant difference using ANOVA testing, p = 0.24.  
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Average alcohol consumption (units per week) was 7.8 (SD 11.6) for CRC patients, 
6.8 (SD 7.0) for first degree relatives and 8.1 (SD 10.9) for spouses. There was no 
statistically significant difference using ANOVA testing, p = 0.94.   
Mean BMI for the CRC cohort was 27.4 (SD 4.3), 25.3 (SD 4.1) for the first degree 
relatives and 26.6 (SD 4.8) for the spouses. There was no statistically significant 
difference using ANOVA testing, p = 0.30.   
The Duke’s stage of the CRC patients was as follows: A = 8 (18.2%), B = 15 (34.1%), 
C1 =13 (29.5%), C2 =5 (11.4%). The anatomical distribution of the CRC subjects 
was: right sided = 18 (40.1%); left sided = 14 (31.2%) and rectal = 12 (27.3%). The 
referral pathways that the CRC patients were detected through were: Screening 
programme = 17 (40.5%), 2 week wait pathway = 21 (50%), and other (including 
routine, emergency and incidental findings) =6 (9.5%).    
The demographics of the recruited subjects can be found in table 7.1. 
No CRC patients, relatives or spouses had received recent courses of antibiotics. 
The CRC subjects had not undergone colonoscopy, and hence consumed bowel 
preparation medication, within the previous 2 weeks.  
3 CRC patients had a first degree relative (sibling or parent) with a history of CRC, 
these relatives were all diagnosed over the age of 60, meaning that all of our 
patients were sporadic CRC patients.  
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Table 7.1 Demographic data from recruited pre-treatment CRC patients, their first 
degree relatives and co-habitors/spouses.   
Group Pre-treatment 
CRC 
Relative Spouse P value 
Samples 44 34 39  
Mean age (SD) 65.3 (SD 11.2)  51.2 (SD 12.6)* 59.9 (SD 12.4) *<0.01 
Sex (M:F) 25:19 15:19 13:26 0.1 
Number of cigarettes 
smoked  per day (SD) 
0.73 (2.6) 2.9 (5.6) 2 (6.4) 0.24 
Alcohol units per week 
(SD) 
7.8 (11.6) 6.8 (7.0) 8.1 (10.9) 0.94 
Mean BMI (SD) 27.4 (4.3) 25.3 (4.1) 26.6 (4.8) 0.30 
Dukes stage (%) 
A 
B 
C1 
C2  
 
9 (18.2%) 
15 (34.1%) 
13 (29.5%) 
5 (11.4%) 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
Site (%) 
Right 
Left 
Rectal 
 
18 (40.1%) 
14 (31.2%) 
12 (27.3%) 
 
- 
- 
- 
 
- 
- 
- 
 
Referral Route (%) 
Screening 
2WW 
Other 
 
17 (40.5%) 
21 (50%) 
6 (9.5%) 
 
- 
- 
- 
 
- 
- 
- 
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The 16s microbiome OTU data was analysed as described in section 3.3.3.7. Once 
the raw sequence data had been merged, quality controlled and filtered to exclude 
low quality reads, with counts of less than 5000 reads, 10 samples out of 179 had 
been excluded.   
This left remaining sample sizes of 41 for pre-treatment CRC, 38 spouses and 33 
relatives.  
There were 1346 OTUs identified across all samples, including post-treatment 
samples. The data on these will be discussed in Chapter 8.  
Relative abundance plots of the pre-treatment CRC samples and healthy controls 
were made. These can be found in figure 7.1.  
An analysis of similarity (ANOSIM) test was run in QIIME using the script 
compare_categories.py. The ANOSIM script is a non-parametric test which 
determines whether two or more groups of samples are significantly different. The 
ANOSIM analysis returned an R value of 0.067 (p=<0.001). As the R value is close 
to 0, this indicates that the groups contain an even distribution of species and as 
such the pre-treatment CRC samples are very similar to the controls (relatives and 
spouses).    
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Figure 7.1. Relative abundance plots of pre-treatment CRC subjects (left) and all 
healthy controls: relatives and spouses (right).  
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The QIIME script group significance.py was used to compare the pre-treatment 
CRC samples with all controls. Within this the Kruskal-Wallis test was performed 
to check for significant differences between the groups. This script runs a non-
parametric ANOVA test on OTU frequencies in sample groups to ascertain whether 
or not there are statistically significant differences between the OTU abundance 
in the different sample groups.  
Of the 1346 OTUs identified there were 82 (6.2%) which were significantly 
different between the CRC subjects and all controls (relatives and spouses).  These 
are shown in Table 7.2. Of characterised OTUs, 82 out 1346 (6.2%) were 
significantly different between the CRCs and controls, 46 were more common 
among CRC samples, with 31 of these (67%) corresponding to clostridales and 36 
were more common among the controls, with 33 (92%) identified as clostridales. 
The most predominant clostridiales identified was ruminoccus sp. with 16/82 
(19.5%) OTUs characterised as such.  
To further analyse the microbiome differences a subset analysis was performed. 
This time a smaller subset of CRC patients was used (n=31), and, to be included 
the CRC patients must have either a relative or a spouse sample included. This 
reduced the sample sizes to 31 for the CRC group, 27 for the relative and 23 for 
spouses. This analysis determined that there were 45 OTUs (3.3%) with statistically 
significant expression levels between the CRC and controls. These are shown in 
Table 7.3. Of the 45 identified OTUs, 12 (27%) had higher expression levels in CRC 
subjects, with 9 identified as clostridiales.  
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Comparison of the larger analysis and the subset analysis revealed a subset of 22 
OTUs which were found to have significantly different levels of expression in both 
analyses. These can be found in Table 7.4 along with their corresponding 
order/species. Of the 22 OTUs, 8 were found to have higher abundance levels in 
CRC subjects (6 Clostridiales) and 14 lower abundance levels than the control 
groups (12 Clostridiales).  
Principal component analysis of the overall diversity of the 2 main groups showed 
no statistically significant differences between the microbiome composition of the 
pre-treatment CRC subjects and the healthy controls. See figure 7.2.  
Comparison of the healthy control groups (relatives vs spouses) using Kruskal-
Wallis testing identified 567 OTUs, with 25 (4.4%), showing statistically significant 
differences in relative abundance between the two control groups (14 with 
increased abundance in relatives and 11 in spouses). Of these different OTUs, 18 
(72%) were clostridiales. These are shown in Table 7.5.   
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OTU Test-
Statistic 
Pre-
treatment 
mean 
Healthy 
controls 
mean 
Taxonomy 
order/family 
species P 
OTU_95 42.15 47.93 0.07 Clostridiales Peptostreptococcus 
anaerobius 
0.000 
OTU_220 24.49 7.38 0.17 Clostridiales Parvimonas sp 0.000 
OTU_760 21.11 2.81 0.03 Fusobacteriales Fusobacterium sp 0.000 
OTU_197 12.17 23.48 0.20 Bacteroidales Porphyromonas sp 0.000 
OTU_674 11.31 0.86 0.15 Gemellales - 0.001 
OTU_213 10.74 0.74 4.27 Clostridiales  0.001 
OTU_519 10.61 1.26 0.00 Clostridiales Dialister sp 0.001 
OTU_35 9.00 88.14 24.35 Clostridiales Ruminococcus 
gnavus 
0.003 
OTU_236 8.77 0.26 1.83 Clostridiales Ruminococcus sp 0.003 
OTU_453 8.76 1.00 0.00 Erysipelotrichales Bulleidia sp 0.003 
OTU_335 8.76 0.26 0.00 Clostridiales Anaerococcus sp 0.003 
OTU_1053 8.71 1.48 0.90 Clostridiales - 0.003 
OTU_11 8.32 17.79 107.41 Clostridiales Dialister sp 0.004 
OTU_569 8.25 0.48 0.07 Clostridiales Pseudoramibacter 
Eubacterium sp 
0.004 
OTU_606 8.14 3.07 26.75 Clostridiales Dialister sp 0.004 
OTU_448 8.06 1.24 0.21 Clostridiales - 0.005 
OTU_316 7.98 0.98 2.76 Clostridiales Dialister sp 0.005 
OTU_407 7.86 1.60 5.41 Clostridiales Lachnospira sp 0.005 
OTU_151 7.84 0.00 2.99 Clostridiales Ruminococcus sp 0.005 
OTU_38 7.26 5.74 12.85 Clostridiales Lachnospira sp 0.007 
OTU_970 7.13 0.00 0.20 Clostridiales - 0.008 
OTU_982 6.97 0.64 0.04 Clostridiales Ruminococcus sp 0.008 
OTU_628 6.95 0.10 0.00 Erysipelotrichales - 0.008 
OTU_429 6.95 1.38 0.00 Fusobacteriales Fusobacterium sp 0.008 
OTU_294 6.84 0.76 1.94 Burkholderiales Sutterella sp 0.009 
OTU_219 6.64 2.36 4.63 Clostridiales - 0.010 
OTU_126 6.56 4.86 12.08 Bacteroidales Bacteroides sp 0.010 
OTU_1027 6.43 0.00 0.14 Clostridiales Ruminococcus sp 0.011 
OTU_430 6.34 0.64 0.25 Clostridiales Ruminococcus sp 0.012 
OTU_939 6.30 1.50 0.61 Clostridiales Ruminococcus sp 0.012 
OTU_256 6.28 1.05 0.87 Clostridiales Anaerotruncus sp 0.012 
OTU_573 5.93 0.05 0.30 Clostridiales - 0.015 
OTU_1317 5.80 0.33 0.01 Bacteroidales Odoribacter sp 0.016 
OTU_215 5.79 2.60 0.23 Erysipelotrichales Eubacterium 
cylindroides 
0.016 
OTU_31 5.77 20.29 0.38 Synergistales - 0.016 
OTU_481 5.77 0.14 0.01 Clostridiales - 0.016 
OTU_921 5.76 4.67 0.10 Lactobacillales Streptococcus sp 0.016 
OTU_560 5.50 0.02 0.27 Clostridiales - 0.019 
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OTU_113 5.41 17.81 3.48 Clostridiales Ruminococcus sp 0.020 
OTU_264 5.29 1.76 1.18 Clostridiales Dorea sp 0.021 
OTU_465 5.25 0.64 0.08 Clostridiales - 0.022 
OTU_433 5.24 0.38 0.87 Clostridiales Oscillospira sp 0.022 
OTU_192 5.21 0.98 2.24 Clostridiales Ruminococcus sp 0.022 
OTU_238 5.19 30.14 35.48 Clostridiales Ruminococcus sp 0.023 
OTU_218 5.17 2.83 5.30 Clostridiales - 0.023 
OTU_525 5.16 1.17 0.00 Bacteroidales - 0.023 
OTU_450 5.16 0.31 0.00 Coriobacteriales - 0.023 
OTU_1225 5.16 0.17 0.00 Clostridiales - 0.023 
OTU_616 5.16 0.10 0.00 Clostridiales Ruminococcus sp 0.023 
OTU_444 5.16 1.19 0.00 Clostridiales Ruminococcus sp 0.023 
OTU_920 5.16 1.05 0.00 Clostridiales Anaerococcus sp 0.023 
OTU_648 5.04 0.00 0.24 Clostridiales Veillonella dispar 0.025 
OTU_416 4.93 0.05 0.24 Clostridiales - 0.026 
OTU_383 4.87 72.24 100.65 Clostridiales Faecalibacterium 
prausnitzii 
0.027 
OTU_139 4.82 0.95 9.68 Clostridiales - 0.028 
OTU_83 4.70 1.55 7.15 Coriobacteriales - 0.030 
OTU_395 4.52 0.05 0.65 Clostridiales Ruminococcus sp 0.033 
OTU_348 4.48 0.05 0.59 Clostridiales Ruminococcus sp 0.034 
OTU_231 4.48 0.98 2.03 Clostridiales Ruminococcus sp 0.034 
OTU_835 4.40 0.60 0.30 Clostridiales Ruminococcus sp 0.036 
OTU_1278 4.37 0.00 0.34 Clostridiales Ruminococcus sp 0.037 
OTU_181 4.33 6.07 2.07 Turicibacterales Turicibacter sp 0.037 
OTU_1026 4.33 0.29 0.58 Clostridiales - 0.037 
OTU_244 4.31 2.88 5.03 Clostridiales - 0.038 
OTU_186 4.27 3.17 0.61 Coriobacteriales - 0.039 
OTU_589 4.25 0.21 0.61 Clostridiales Anaerococcus sp 0.039 
OTU_510 4.22 6.14 9.62 Clostridiales Faecalibacterium 
prausnitzii 
0.040 
OTU_487 4.20 4.38 2.28 Clostridiales - 0.040 
OTU_132 4.17 4.10 1.76 Clostridiales - 0.041 
OTU_404 4.14 3.12 0.01 Bacteroidales Porphyromonas sp 0.042 
OTU_985 4.07 0.10 0.01 Clostridiales - 0.044 
OTU_771 4.05 0.24 0.56 Clostridiales - 0.044 
OTU_895 4.04 0.36 0.03 Clostridiales - 0.045 
OTU_1269 4.02 0.07 0.32 Clostridiales - 0.045 
OTU_301 4.02 11.90 3.55 Clostridiales Dorea sp 0.045 
OTU_308 3.99 1.79 1.58 Clostridiales Ruminococcus 
gnavus 
0.046 
OTU_873 3.94 0.31 0.13 Clostridiales - 0.047 
OTU_908 3.93 0.50 0.21 Clostridiales - 0.047 
OTU_1044 3.91 0.05 0.21 Clostridiales Ruminococcus sp 0.048 
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OTU_81 3.91 4.55 0.04 Clostridiales Succiniclasticum sp 0.048 
OTU_565 3.88 1.95 2.97 Clostridiales Coprococcus sp 0.049 
OTU_418 3.85 0.86 0.20 Clostridiales Epulopiscium sp 0.049 
 
Table 7.2. Table of OTUs which were statistically significant in distribution between 
the pre-treatment CRC samples and all controls (relatives and spouses). OTUs with 
higher abundance in CRC subjects are highlighted grey. Relative abundances and 
p values included
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OTU Test-Statistic Pre-treatment CRC mean Spouse mean Relative mean taxonoic order/family species P 
OTU_95 31.52 42.62 0.05 0.08 Clostridiales Peptostreptococcus anaerobius <0.001 
OTU_220 15.24 7.86 0.05 0.38 Clostridiales Parvimonas sp <0.001 
OTU_760 13.43 3.07 0.09 0.00 Fusobacteriales  Fusobacterium sp 0.001 
OTU_1224 13.10 4.55 2.68 9.42 Bacteroidales Bacteroides sp 0.001 
OTU_213 12.45 0.48 3.73 2.81 Clostridiales  - 0.002 
OTU_35 11.11 118.93 45.14 10.27 Clostridiales  Ruminococcus gnavus 0.004 
OTU_316 10.72 0.45 3.68 2.85 Clostridiales Dialister sp 0.005 
OTU_1053 10.57 1.76 0.59 0.96 Clostridiales  - 0.005 
OTU_448 10.16 1.31 0.00 0.46 Clostridiales  - 0.006 
OTU_126 10.07 5.62 2.50 22.54 Bacteroidales Bacteroides sp 0.007 
OTU_416 9.85 0.00 0.09 0.35 Clostridiales  - 0.007 
OTU_472 9.69 0.24 1.59 0.00 Bacteroidales Prevotella copri 0.008 
OTU_674 9.56 0.76 0.00 0.23 Gemellales - 0.008 
OTU_491 9.30 0.24 0.41 0.00 Clostridiales Clostridium sp 0.010 
OTU_937 9.08 0.31 0.05 0.46 Bacteroidales Butyricimonas sp 0.011 
OTU_11 8.41 10.76 98.64 154.00 Clostridiales Dialister sp 0.015 
OTU_341 8.20 0.41 0.14 1.04 Clostridiales Oscillospira sp 0.017 
OTU_133 8.13 13.97 1.68 0.92 Bacteroidales Bacteroides sp 0.017 
OTU_236 7.88 0.14 2.23 2.08 Clostridiales  - 0.019 
OTU_407 7.84 1.31 5.18 6.08 Clostridiales Lachnospira sp 0.020 
OTU_606 7.84 2.03 23.32 40.65 Clostridiales Dialister sp 0.020 
OTU_771 7.78 0.21 0.45 1.00 Clostridiales Lachnospira sp 0.020 
OTU_5 7.70 74.86 137.23 86.77 Clostridiales Lachnospira sp 0.021 
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Table 7.3. Table of OTUs which were statistically significant in distribution between the subset of pre-treatment CRC samples and relatives and spouses. 
OTUs with higher abundance in CRC subjects are highlighted grey. Relative abundances and p values included.
OTU_219 7.56 1.69 3.00 8.46 Clostridiales  - 0.023 
OTU_498 7.39 1.97 1.95 1.31 Clostridiales Lachnospira sp 0.025 
OTU_383 7.27 63.90 135.41 89.54 Clostridiales Faecalibacterium prausnitzii 0.026 
OTU_1269 7.21 0.03 0.36 0.35 Clostridiales  - 0.027 
OTU_83 7.19 1.17 2.82 13.73 Coriobacteriales - 0.027 
OTU_1066 7.10 0.03 0.27 0.50 Burkholderiales Oxalobacter formigenes 0.029 
OTU_549 6.92 0.14 0.05 0.54 Clostridiales Dehalobacterium sp 0.031 
OTU_100 6.80 79.24 137.14 83.00 Clostridiales Roseburia sp 0.033 
OTU_1308 6.80 8.93 16.36 7.85 Clostridiales  - 0.033 
OTU_264 6.66 1.83 0.64 0.65 Clostridiales Dorea sp 0.036 
OTU_870 6.63 0.72 1.59 0.88 Clostridiales  - 0.036 
OTU_633 6.60 1.86 1.82 1.23 Coriobacteriales - 0.037 
OTU_58 6.53 7.24 11.09 21.46 Bifidobacteriales Bifidobacterium sp 0.038 
OTU_6 6.46 124.72 222.41 176.08 Clostridiales  - 0.040 
OTU_1259 6.45 0.48 0.95 0.54 Clostridiales  - 0.040 
OTU_376 6.43 22.07 12.05 10.04 Clostridiales Dorea sp 0.040 
OTU_663 6.40 0.28 0.05 0.12 Clostridiales Coprococcus sp 0.041 
OTU_1238 6.33 5.41 3.36 1.65 Clostridiales  - 0.042 
OTU_970 6.10 0.00 0.18 0.27 Clostridiales  - 0.047 
OTU_43 6.10 7.90 23.86 7.35 Clostridiales  - 0.047 
OTU_47 6.08 14.59 17.95 7.00 Coriobacteriales - 0.048 
OTU_143 6.03 5.38 0.41 6.58 Coriobacteriales - 0.049 
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Figure 7.2. Principle component analysis of the overall diversity of pre-treatment 
CRC (red) and healthy controls (blue). 
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OTU taxonoic order/family Species 
OTU_11 Clostridiales Dialister sp 
OTU_35 Clostridiales  Ruminococcus gnavus 
OTU_83 Coriobacteriales - 
OTU_95 Clostridiales Peptostreptococcus 
anaerobius 
OTU_126 Bacteroidales Bacteroides sp 
OTU_219 Clostridiales  - 
OTU_220 Clostridiales Parvimonas sp 
OTU_236 Clostridiales  - 
OTU_264 Clostridiales Dorea sp 
OTU_213 Clostridiales  - 
OTU_316 Clostridiales Dialister sp 
OTU_383 Clostridiales Faecalibacterium 
prausnitzii 
OTU_407 Clostridiales Lachnospira sp 
OTU_416 Clostridiales  - 
OTU_448 Clostridiales  - 
OTU_606 Clostridiales Dialister sp 
OTU_674 Gemellales - 
OTU_760 Fusobacteriales  Fusobacterium sp 
OTU_771 Clostridiales Lachnospira sp 
OTU_970 Clostridiales  - 
OTU_1053 Clostridiales  - 
OTU_1269 Clostridiales  - 
 
Table 7.4. OTUs showing statistically significant aletered abundance in both whole 
group and subset analysis of pre-treatment CRC subjects and controls. Those with 
higher abundance in CRC are highlighted in grey.   
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OTU Test-
Statistic 
Relative 
mean 
Spouse 
mean 
taxonomic 
order/family 
species P 
OTU_1224 7.66 8.67 3.82 Bacteroidales Bacteroides sp 0.006 
OTU_90 6.99 5.61 4.89 Clostridiales - 0.008 
OTU_250 6.97 1.73 0.32 Clostridiales - 0.008 
OTU_126 6.91 20.79 4.53 Bacteroidales Bacteroides sp 0.009 
OTU_133 6.83 0.76 2.61 Bacteroidales Bacteroides sp 0.009 
OTU_491 6.63 0.00 0.37 Clostridiales Clostridium sp 0.010 
OTU_75 6.59 5.39 0.68 Clostridiales - 0.010 
OTU_1086 6.25 0.03 0.34 Clostridiales Ruminococcus 
sp 
0.012 
OTU_448 6.25 0.42 0.03 Clostridiales - 0.012 
OTU_143 6.11 5.61 0.34 Clostridiales - 0.013 
OTU_28 5.92 48.67 21.11 Clostridiales - 0.015 
OTU_911 5.85 0.33 0.71 Clostridiales - 0.016 
OTU_520 5.61 0.00 0.16 Actinomycetales Rothia 
dentocariosa 
0.018 
OTU_472 5.31 0.03 1.00 Bacteroidales Prevotella copri 0.021 
OTU_808 5.18 0.03 0.37 Clostridiales - 0.023 
OTU_341 5.17 0.88 0.26 Clostridiales Oscillospira sp 0.023 
OTU_457 5.05 0.82 0.32 Clostridiales - 0.025 
OTU_359 4.97 0.64 0.03 Clostridiales - 0.026 
OTU_100 4.67 91.42 131.68 Clostridiales Roseburia sp 0.031 
OTU_96 4.53 4.70 0.61 Lactobacillales Enterococcus 
sp 
0.033 
OTU_6 4.28 156.18 202.74 Clostridiales - 0.038 
OTU_318 4.23 0.39 0.29 Clostridiales - 0.040 
OTU_1060 4.17 0.55 1.50 Clostridiales - 0.041 
OTU_43 4.05 11.15 26.21 Clostridiales - 0.044 
OTU_58 3.95 17.58 12.05 Bifidobacteriales Bifidobacterium 
sp 
0.047 
 
Table 7.5. Table of OTUs which were statistically significant in distribution between 
the relative and spouse control groups. OTUs with higher abundance in relatives 
are highlighted grey. Relative abundances and p values included.  
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7.4. Discussion 
The microbial 16s profiling of pre-treatment CRC subjects, and healthy controls, 
comprising relatives and spouses was performed using Illumina 16s sequencing 
and bioinformatics analysis. This revealed that there was no significant difference 
for >93% of the bacterial OTUs identified between the cancer subjects and 
controls.  
Of the identified 1346 OTUs, only 82 (6.2%) were significantly different between 
the CRC patients and controls, with 46 (56%)  more common among the CRC 
subjects. Of these, 31 (67%) were identified as clostridales. There were 36 OTUs 
which were more common among the controls, with 33 (92%) identified as 
clostridales. The most predominant clostridiales identified was ruminoccus sp. 
with 16/82 (19.5%) OTUs characterised as such.  
Other orders with higher representation among the CRC subjects include the 
fusobacteroides and coriobacteroides. This supports the finding of previous 
studies which have found an increase in the relative abundance of these species 
in CRC microbiomes (214, 221, 229, 245).  
Subset analysis of only CRC samples which had a relative or spouse pair revealed 
45 OTUs with statistically significant differences. Again, these were predominantly 
clostridiales. When comparing the 2 analyses there were 22 OTUs which were 
present in both analyses. Of these 22, 8 (36%) showed enhanced abundance 
among the CRC subjects, with the rest showing reduced abundance relative to the 
control groups. These OTUs were again identified as predominantly Clostridiales, 
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Coriobacteriales, Bacteroidales and Fusobacteriales, as previously reported (214, 
221, 229, 245). 
Interestingly a large proportion of the OTUs with an increased expression among 
the healthy controls were also clostridales. This suggests that any contribution of 
an altered microbiome towards CRC carcinogenesis or progression is more likely 
to be related to a “field effect” of altered metabolism and microenvironment 
rather than species specific changes. Of the models proposed for any potential 
role of the microbiome in CRC generation, these results would appear to support 
the “intestinal microbiota adaptions” model (238-240). This model postulates that 
CRC and dysbiosis may have a symbiotic relationship. The CRC environment is 
characterised by host-derived immune and inflammatory processes that would 
affect microbial regulation. The model proposes that altered immune and 
inflammatory processes brought about by dysplasia or mutations, could, 
potentially, alter the microbiome composition and favour the proliferation of pro-
carcinogenic bacteria, thus amplifying the effect of dysbiosis, and further 
promoting CRC. It is unclear what effect diet could have on these changes, as little 
is known about whether the dietary factors themselves are linked to CRC 
development or rather the effects of the dietary factors on the microbiome.  
 Given that for the most part the studies to date have identified recurrent bacterial 
differences in CRC to order or family level, rather than specific species this would 
be more in keeping with a generalised alteration of microbial metabolism. These 
changes could be related to a more anaerobic environment, as clostridales are 
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obligate anaerobes. This may be less likely given the finding here that clostridiales 
can also be found at higher levels in healthy controls.  
The relative abundance and PCA plots of the CRC samples with the healthy 
controls show tha the overall composition of the microbiome is very similar, 
indeed the ANOSIM analysis returned an R value of 0.067 (p=0.001). There are still 
subtle differences within the microbiome composition, but mostly not to 
significant levels. This could support the findings of previous studies of subtle 
alterations in the CRC microbiome (214, 221, 229, 245) and be in-keeping with the 
theory of dysbiosis in the context of CRC, or it could represent normal population 
variation of the microbiome with underpowering preventing any microbiome 
differences from being apparent. Fewer stool samples were returned by recruited 
subjects than urine samples, again reflecting the lower uptake of tests involving 
faecal matter. This led to smaller sample sizes for each of the three main groups 
than for the urine experiments, given the observed loss of statistical significance 
in Chapter 5 when the CRC urine sample cohort was reduced, this could well have 
resulted in underpowering.  
Comparison of the two control groups, relatives and spouses, revealed that >95% 
of the microbiome was not statistically different. Of the identified 567 OTUs, 25 
(4.4%), were shown to be statistically significantly different in relative abundance 
between the two control groups. There were 14 OTUs with increased abundance 
in relatives and 11 OTUs in spouses. Of these different OTUs, 18 (72%) were 
clostridiales, with 10/14 increased OTUs in the relatives and 8/11 in the spouses 
   
 
253 
 
identified as such. This could represent normal variation of the microbiome profile 
within the general population. 
Further studies are required to determine the extent  of the alteration of the 
microbiome in CRC, in particularly with regards to whether the microbiome 
appears to be affected by genetics or environment. Larger studies would also be 
needed to avoid any potential underpowering of experiments. This study does 
seem to confirm some of the previous work into the microbiome in CRC, in regards 
to altered clostridiales population and subtly different, although not to 
stastictically significant levels, of bacterial diversity.   
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CHAPTER 8 
Stool 16s RNA profiling of colorectal cancer patients prior to 
treatment and after treatment 
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8.1. Introduction 
As an extension of the microbiome profiling of pre-treatment CRC patients 
described in Chapter 7, the microbiome of the CRC patients were also studied in 
post-treatment samples, which were collected at 3 and 6 month intervals, after 
the subjects had undergone their initial treatment. This was to attempt to 
determine whether the microbiome alters after the primary cancer has been 
removed.  
The aim of this study was to assess the microbiome in CRC patients and determine 
if successful treatment leads to any significant changes in the microbiome profile.  
Further analysis was also carried out to determine whether site of CRC (right sided, 
left sided, or rectal) affected the microbiome composition. 
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8.2. Methods 
CRC patients were recruited as described in section 3.2.1.  Sample collection and 
storage was performed as described in section 3.2.4.  The samples were frozen at 
-80ºC as soon as possible after their receipt. They were transferred to the 
University of Warwick in dry ice and, again, stored frozen at -80ºC. Samples were 
thawed and analysed using 16s RNA sequencing on an Illumina MiSeq platform, as 
described in section 3.3.3. The analysis of the .fastq sequence files from the Miseq 
were processed and analysed as described in chapter 3.3.3.7, using UPARSE and 
QIIME software and pipeline commands. 
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8.3. Results 
As for the experiment outlined in Chapter 7, 44 CRC patients returned pre-
operative samples. Of these, 15 returned samples after 3 months and 14 returned 
samples after 6 months.  
The mean age of the pre-treatment group was 65.3 years (SD 11.2). For the 3 
month post-treatment samples it was 63.2 (SD 12.1), and 66.9 (SD11.4) for the 6 
month post-treatment samples. There was no statistically significant difference 
between the ages of the groups using ANOVA analysis, p = 0.69.  
There were 25 males and 19 females with CRC in the pre-treatment cohort; with 
8 males and 7 females in the 3 month post-treatment cohort, 7 males and 7 
females in the 6 month post-treatment cohort. The male: female distribution was 
analysed using the Chi squared test, and found to not be significantly different; chi 
squared statistic 0.21, p = 0.90.   
The average cigarette consumption per day was 0.73 (SD 2.6) for pre-treatment 
CRC patients, 0.67 (SD 2.5) for the 3 month post-treatment cohort and 0.7 (SD 2.6) 
for the 6 month post-treatment cohort. There was no statistically significant 
difference using ANOVA analysis, p = 1.  
Average alcohol consumption (units per week) was 7.8 (SD 11.6) for pre-treatment 
CRC patients, 6.1 (SD 11.2) for the 3 month post-treatment cohort and 7.2 (SD 
12.5) for the 6 month post-treatment cohort. There was no statistically significant 
difference using ANOVA testing, p = 0.91.   
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No CRC subject had received recent courses of antibiotics prior to providing either 
pre-treatment or post-treatment samples. They had not undergone recent 
endoscopic investigation, so had not consumed bowel preparation medications.  
Mean BMI for the pre-treatment CRC cohort was 27.4 (SD 4.3), 28.5 (SD 7.7) for 
the 3 month post-treatment cohort and 26.8 (SD 4.6) for the 6 month post-
treatment cohort. There was no statistically significant difference using ANOVA 
testing, p = 0.61.   
The Duke’s stages of the various groups are shown in table 8.1. There was no 
statistically significant difference seen between the groups using Chi squared 
analysis; chi squared statistic 0.67, p = 0.99.  
The anatomical distribution of the various groups is shown in table 8.2. There was 
no statistically significant difference seen between the groups using Chi squared 
analysis; chi squared statistic 3.7, p = 0.45.  
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Duke’s Stage Pre-treatment 
CRC 
3/12 CRC 6/12 CRC 
A (%) 9 (21.4%) 3 (20.0%) 3 (21.4%) 
B (%) 15 (35.7%) 5 (33.3%) 5 (35.7%) 
C1 (%) 13 (30.1%) 5 (33.3%) 6 (42.9%) 
C2 (%) 5 (11.9%) 2 (13.3%) 0 (0%) 
 
Table 8.1. Duke’s stages of the pre-treatment CRC group, the 3/12 and 6/12 
samples of the same group. 
 
Anatomical 
distribution 
Pre-
treatment 
CRC 
3/12 CRC 6/12 CRC 
Right sided (%) 18 (42.9%) 9 (60%) 9 (64.3%) 
Left sided (%) 13 (31.0%) 4 (26.7%) 4 (28.6%) 
Rectal (%) 11 (26.2%) 2 (13.3%) 1 (7.1%) 
 
Table 8.2. Anatomical distribution of the pre-treatment CRC group, the 3/12 and 
6/12 samples of the same group. 
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The 16s microbiome OTU data was analysed as described in section 3.3.3.7. Once 
the raw sequence data had been merged, quality controlled and filtered to exclude 
low quality reads, 10 samples had been excluded. This left remaining sample sizes 
of 42 for pre-treatment CRC, 15 3 month samples and 14 6 month samples.  
Relative abundance plots of the pre-treatment samples compared with pooled 
post treatment samples can be found in Figure 8.1 
The QIIME script identify_paired_differences.py was used to compare the pre and 
post operative samples. This script runs a Bonferroni corrected T-Test on each 
BIOM table observation to determine if the mean of each distribution of pre/post 
differences differs from zero.  
There were 567 OTUs identified across pre-treatment and 3 and 6 month post-
treatment samples.  
Of these 17 (3.0%) were found to be statistically significantly different between 
the pre-treatment and 3 month post-treatment group. Of these 11 were more 
abundant in the pre-treatment samples and 6 were more abundant in the post-
treatment samples. These are outlined in table 8.1. Figure 8.2 contains plots of 
OTUs 213 and 542, which had increased in abundance post-treatment and OTUs 
44 and 627 which decreased in abundance post-treatment.  Figure 8.3 shows a 
rarefaction curve with an average of the number of OTUs and sequences per 
sample. This shows an increase in the number of observed OTUs post-treatment 
compared to pre-treatment, but not to statistical significance.  
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Figure 8.1. Relative abundance plots of pre-treatment CRC subjects (left) and all 
post op samples (right).  
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OTU Test-
Statistic 
Pre-
treat
ment
mean 
3 month 
post-
treatme
nt mean 
Taxonomy 
order/family 
species P 
OTU_50 2.39 15.40 2.07 Ruminococcaceae  - 0.005 
OTU_87 2.73 0.93 0.00 Rikenellaceae - 0.006 
OTU_171 -2.29 0.07 2.50 Lactobacillaceae Lactobacillus 
zeae 
0.007 
OTU_65 2.64 5.67 0.64 Ruminococcaceae Oscillospira 
sp 
0.012 
OTU_235 -2.26 0.53 22.29 Clostridiales - 0.017 
OTU_44 2.21 23.80 5.00 Clostridiales Roseburia sp 0.020 
OTU_542 -2.55 0.00 0.50 Clostridiales - 0.024 
OTU_278 2.14 0.93 0.14 Coriobacteriaceae - 0.025 
OTU_92 1.68 4.00 0.00 Bacteroidales Bacteroides 
fragilis 
0.026 
OTU_213 -1.85 0.47 4.50 Clostridiales - 0.028 
OTU_627 2.37 4.93 1.14 Clostridiales - 0.030 
OTU_29 -1.44 17.87 187.36 Streptococcaceae Streptococcu
s sp 
0.034 
OTU_73 1.98 5.73 1.00 Bacteroidales Bacteroides 
sp 
0.036 
OTU_939 2.21 1.87 0.36 Clostridiales Ruminococcu
s sp 
0.036 
OTU_220 1.44 16.07 0.00 Clostridiales Parvimonas 
sp 
0.040 
OTU_116 -1.62 0.13 16.57 Clostridiales Veillonella 
dispar 
0.043 
OTU_118 1.90 4.27 1.14 Clostridiales Ruminococcu
s sp 
0.049 
 
Table 8.3. Table of OTU which were statistically significant in distribution between 
the pre-treatment and 3 month post-treatment samples. OTUs with higher 
abundance in pre-treatment CRC subjects are highlighted grey. Relative 
abundances and p values included.  
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Figure 8.2. Plots of mean abundances pre and post-treatment at 3 months for 
OTUs 213 and 542, which had increased in abundance post-treatment and OTUs 
44 and 627 which decreased in abundance post-treatment.   
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Figure 8.3. Rarefaction curve of observed number of OTUs against sequences per 
sample for pre-treatment samples (blue) and 3 month post-treatment samples 
(red).   
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The same analysis was then performed between the pre-treatment samples and 
the 6 mont post-treatment samples. Of the 567 OTUs, 22 (4.0%) were found to be 
statistically significantly different between the pre-treatment and 6 month post-
treatment group. Of these 21 were more abundant in the pre-treatment samples 
and only 1 (OTU 213) was more abundant in the post-treatment samples. These 
are outlined in table 8.2. Figure 8.4 contains plots of OTUs 213, which had 
increased in abundance post-treatment and OTUs 240, 278 and 1145, which all 
decreased in abundance post-treatment.  Figure 8.5 shows a rarefaction curve 
with an average of the number of OTUs and sequences per sample. This shows an 
increase in the number of observed OTUs post-treatment at 6 months compared 
to pre-treatment, but not to statistically significance. 
A comparison of OTUs according to site of CRC; right, left or rectal, was performed. 
This showed that there were 20 OTUs (3.5%) which had statistically significant 
levels of abundance depending on the site of CRC. See table 8.3. Of these, 4 were 
predominant in right sided lesions, 5 in left sided and 8 in rectal cancers. The 
remaining 3 were equally abundant in 2 areas, but significantly more so than the 
remaining region.  
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OTU Test-
Statistic 
Pre-
treatme
nt mean 
6 month 
post 
treatment 
mean) 
Taxonomy order/ 
family 
Species P 
OTU_95 1.08 70.62 0.07 Clostridiales Peptostreptoco
ccaceae sp 
0.008 
OTU_511 3.37 0.77 0.07 Clostridiales Ruminococcus 
sp 
0.008 
OTU_110 2.38 5.31 0.43 Clostridiales - 0.010 
OTU_308 1.59 3.92 0.50 Clostridiales;  Ruminococcus 
gnavus 
0.012 
OTU_37 1.93 13.62 2.93 Bacteroidales - 0.014 
OTU_455 2.85 0.38 0.00 Clostridiales  0.017 
OTU_220 1.24 14.85 0.57 Clostridiales Parvimonas sp 0.021 
OTU_79 1.77 6.77 0.79 Coriobacteriales  Eggerthella 
lenta 
0.023 
OTU_33 1.95 31.92 7.57 Clostridiales  Dorea sp 0.025 
OTU_278 2.36 0.69 0.07 Coriobacteriaceae - 0.026 
OTU_240 2.15 2.00 0.64 Clostridiales Coprococcus sp 0.028 
OTU_42 1.81 33.62 10.86 Clostridiales Dorea 
formicigeneran
s 
0.031 
OTU_213 -1.86 0.31 5.71 Clostridiales - 0.031 
OTU_1145 1.94 1.85 0.36 Clostridiales - 0.031 
OTU_247 2.35 1.62 0.36 Clostridiales - 0.035 
OTU_1039 1.97 0.23 0.00 Clostridiales - 0.035 
OTU_412 1.45 0.85 0.00 Bacteroidales - 0.037 
OTU_488 2.30 0.54 0.00 Clostridiales - 0.038 
OTU_1237 1.90 1.46 0.14 Clostridiales - 0.041 
OTU_620 1.88 2.77 0.43 Bacteroidales Bacteroides sp 0.043 
OTU_1 1.46 238.85 25.57 Verrucomicrobiale
s 
Akkermansia 
muciniphila 
0.044 
OTU_772 1.36 2.08 0.07 Lactobacillales Enterococcus 
sp 
0.048 
 
 Table 8.4. Table of OTU which were statistically significant in distribution between 
the pre-treatment and 6 month post-treatment samples. OTUs with higher 
abundance in pre-treatment CRC subjects are highlighted grey. Relative 
abundances and p values included.   
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Figure 8.4. Plots of mean abundances pre and post-treatment at 6 months for 
OTUs 213, which had increased in abundance post-treatment, and OTUs 240, 278 
and 1145, which all decreased in abundance post-treatment. 
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Figure 8.5. Rarefaction curve of observed number of OTUs against sequences per 
sample for pre-treatment samples (blue) and 6 month post-treatment samples 
(red). 
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OTU Test-
Statistic 
Right_mean Left_mean Rectal_mean taxonomic order/family species P 
OTU_643 14.02 0.00 0.08 0.08 Clostridiales - 0.003 
OTU_365 14.01 0.00 0.50 0.08 Clostridiales - 0.003 
OTU_1066 11.46 0.06 0.17 0.00 Burkholderiales Oxalobacter formigenes 0.009 
OTU_160 11.20 1.12 6.33 4.67 Desulfovibrionales Bilophila sp 0.011 
OTU_921 10.60 1.06 0.00 0.75 Lactobacillales Streptococcus sp 0.014 
OTU_45 9.63 1.47 11.08 16.25 Clostridiales - 0.022 
OTU_225 9.13 0.24 0.08 0.00 Bacteroidales Bacteroides plebeius 0.028 
OTU_1 9.10 142.47 355.00 442.67 Verrucomicrobiales Akkermansia muciniphila 0.028 
OTU_530 8.85 0.12 0.00 0.83 Clostridiales - 0.031 
OTU_804 8.79 0.12 1.08 0.08 Clostridiales Ruminococcus sp 0.032 
OTU_463 8.74 0.06 0.17 0.58 Clostridiales - 0.033 
OTU_363 8.60 0.12 0.08 2.25 Clostridiales Ruminococcus sp 0.035 
OTU_36 8.39 44.24 14.92 70.75 Clostridiales - 0.039 
OTU_572 8.38 0.35 0.00 0.42 Clostridiales - 0.039 
OTU_35 8.38 75.29 174.83 16.08 Clostridiales Ruminococcus gnavus 0.039 
OTU_408 8.34 0.82 0.33 1.67 Clostridiales - 0.040 
OTU_82 8.19 6.76 4.42 15.58 Clostridiales - 0.042 
OTU_737 7.98 0.71 0.42 0.00 Clostridiales - 0.047 
OTU_22 7.86 128.29 58.58 49.08 Clostridiales - 0.049 
OTU_1122 7.85 1.59 1.58 0.08 Unassigned 
 
0.049 
Table 8.5. Table of OTUs which were statistically significant in distribution between different sites of pre-treatment CRC. OTUs with higher abundance 
in Right sided CRC subjects are highlighted dark grey and left sided CRC in light grey. Relative abundances and p values included.
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8.4. Discussion 
The microbial 16s profiling of pre and post-treatment CRC samples using Illumina 
16s sequencing and bioinformatics analysis revealed that there was no significant 
difference for >95% of the bacterial OTUs identified.  
Only 3% and 4% of the 567 identified OTUs in the 3 and 6 month post-treatment 
samples were significantly different from the pre-treatment samples, although 
there was an increase from 3 to 6 months. This supports previous work which has 
shown that there is a change in post-operative CRC microbiome (245, 246), 
although here, with the exception of 2 OTUs, there were no consistent differences 
with increasing time from surgery in the same patient cohort. There was a mild 
increase in relative abundances from 3 to 6 months post-treatment which could 
suggest a progressive change in the microbiome post CRC treatment, however is 
more likely to represent normal variation with the population. Although much 
longer term sample collection would be needed to confirm whether this occurs.  
The rarefaction curve plots of observed OTUs, plotted gainst average number of 
sample reads shows an increase in the number of observed OTUs in post-
treatment samples, though not to statistically significant levels. This suggests that 
the restriction of the microbiome, found previously by other studies (214, 218) 
and described in Chapter 7, could be partially reversed once the CRC has been 
treated, although not to significant levels. 
There were 2 OTUs, 213 and 278 which were significantly different between pre-
treatment samples and both 3 month and 6 month post-treatment samples. OTU 
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213 showed increased levels of abundance, relative to pre-treatment samples, in 
both 3 and 6 month post-treatment samples, whilst OTU 278 showed decreased 
levels of abundance in post-treatment samples compared to pre-treatment 
samples. OTU 213 corresponded to bacteria from the Clostridales order and OTU 
278 to a bacteria from the Coriobacteriales order. Unfortunately, identification 
beyond the phylogenetic order was not achieved in either case. Of the 17 OTUs to 
show significant differences at 3 months and the 22 OTUs at 6 months, 11 and 16 
respectively were Firmicutes and more specifically clostridales. Firmicutes 
represent approximately 10% of the colonic bacteria and are obligate anaerobes. 
Most of the changes observed showed a reduction in the numbers of these 
bacterial OTUs, although some Clostridales, such as OTU 213, did increase. This 
could reflect an overall less hypoxic environment within the colonic lumen in 
response to CRC resection. This in turn could also lead to fewer ROS and hence 
less potential for cellular and DNA damage as a result of anaerobic metabolism.  
These findings correspond with previously reported work which has implicated a 
role for Clostridales species in CRC (214, 221, 245). 
As discussed in Chapter 7 of the models proposed for the role of the microbiome 
in CRC generation, the current favoured one is the “intestinal microbiota 
adaptions” model (238-240). This model suggests that CRC and dysbiosis may have 
a symbiotic relationship. The CRC environment is characterised by host-derived 
immune and inflammatory processes that would affect microbial regulation. This 
could, potentially, alter microbiome composition and favour the proliferation of 
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pro-carcinogenic bacteria, thus amplifying the effect of dysbiosis, and further 
promoting CRC progression. This would seem more likely than the “alpha bug” and 
“driver/passenger” theories, as to date, there have been no bacterial species 
which have been consistently found to be increased in CRC. These models could 
still be correct, but if different bacteria were functioning as the “alpha bug” then 
this would suggest it is the overall effects of altered bacterial composition rather 
than the effects of individual bacteria.   
The changes in microbiome composition, particularly with regards to those seen 
for OTUs 213 and 278 would need to be further investigated. It may be unlikely 
that these bacteria are acting as lone carcinogenic or carcinoprotective agents, but 
may represent more of a “field effect” found in the dysbiotic microbiome of 
patients with CRC. It should be noted that the sample sizes here (44, 16 and 13) 
were relatively small and so may be underpowered to detect any changes in the 
microbiome composition.  
Analysis of the microbiome profiles of pre-treatment CRC by site of cancer, 
identified 20 OTUs, which had significantly different expression levels between the 
different sites. There was a roughly equal mix of those more common in right 
sided, left sided and rectal cancers. Again the OTUs corresponded to mainly 
clostridiales, although 1 could not be assigned. The sample sizes here were small, 
18 right sided, 13 left and 13 rectal. This would suggest that the data is 
underpowered to detect any differences in microbiome profile between the 
different disease sites. The microbiome studied is also obtained from stool 
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samples obtained by defaecation, rather than from the site of the tumour. Any 
right sided tumour stool will have passed through the left colon and the rectum to 
be obtained. This means it could be contaminated by colonic micro-organisms 
which are not from the site of the tumour. This is an area which will require much 
larger sample numbers and more stringently acquired samples.  
Given the relatively small sample sizes here, the lack of significant differences 
between the cohorts is potentially due to underpowering. Although subtle 
differences were observed, these were not to statistically significant levels and 
further larger studies would be required to determine if the microbiome does 
indeed alter post CRC removal.  Larger samples sizes would also allow the effects 
of other potential confounding factors, such as chemotherapy, to be assessed. 
Longer follow up samples would also need to be collected to allow for better 
mapping of termporal changes in microbiome composition in the post operative 
CRC patients.   
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CHAPTER 9 
Final Discussions 
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9.0 Final Discussions 
The aim of this thesis was to characterise the urinary VOC profile of CRC patients 
and determine whether it could be distinguished from the VOC profiles of genetic 
and environmental controls (relatives and spouses) using an LC-FAIMS-MS 
apparatus, which is a variant on the FAIMS technology which has previously 
successfully been able to show this distinction. This was with the intention to 
support the growing body of evidence that urinary VOCs could distinguish CRC 
patients from healthy controls and potentially serve as a new, alternative, non-
invasive biomarker for the disease (158-161).  
The microbiome analysis via 16s RNA analysis of stool samples from the 3 groups 
was aimed at determining whether there was a significant difference in 
microbiome composition in CRC subjects compared to genetic and environmental 
controls. Urinary VOC and stool microbiome profiling were also performed on pre- 
and post-treatment CRC patient samples to determine if the urinary VOC and 
microbiome profiles altered in response to treatment of the CRC.  
The LC-FAIMS-MS apparatus was able to show that pre-treatment CRC subjects 
could be distinguished from both control groups, relatives and spouses, using a 5-
fold cross validation for sparse logistics regression and Random Forrest models 
The obtained sensitivities of 63-69%, specificities of 64-69% and AUC 0.71-0.72 are 
in keeping with previous work published on urinary VOC detection of CRC by a 
variety of different technologies (158-161). This discrimination was not found 
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when a smaller subset of CRC samples were compared to the control groups. This 
suggests that the study became underpowered by loss of these samples. The PPVs 
of the two models were 54 and 60%, which compare favourably to FOBT/FIT, but 
the NPVs of 46% and 76% compare less favourably. One of the major obstacles 
that would need to be overcome in the future if VOC analysis is to enter clinical 
practice as a screening tool for CRC would be the relatively poor performance with 
regards to definitively excluding disease. The relatively poor NPVs may be due to 
the artificial nature of the population being analysed, in that the prevalence of CRC 
will be far greater in a study such as this compared to a screened population. 
Future studies should perhaps look at recruiting far higher numbers of controls to 
correct for this.  
As discussed in Chapter 5, the LC-FAIMS-MS technology is a variant on the FAIMS 
technology, which has previously been able to distinguish CRC patient urinary 
samples from healthy controls. The configuration used in this thesis is novel, and 
has not been used to investigate urinary VOCs in CRC before, although broadly 
based on the same technology. Not only is the technology relatively novel, but 
recognised statistical pathways for analysing the data do not exist. The 
bioinformatician who performed the analysis here reported that work on 
optimising the statistical method would represent a Doctor of Philosophy (PhD) 
thesis in its own right. Given these limitations, it is very encouraging that 
significant differences betwee the cohorts could be found. It should also be noted 
that is the first study to use healty control subjects that are connected to the CRC 
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subjects, by either sharing an environment, or being first degree relatives. All 
previous studies had used completely separate healthy controls. It is therefore 
also encouraging that despite the closer association of the controls used here to 
the cancer subjects, that they could still be distinguished with similar sensitivities, 
specificities and AUCs to those previously demonstrated using these techniques.  
The lack of a demonstratable significant difference in VOC profile post-treatment 
is likely to represent underpowering of the analysis due to small sample sizes. The 
alternative explanations could be that the  samples were collected too soon post-
treatment for an effect to be observed, or that there is no change. If it is the former 
case, then given that the samples were collected 6 months after treatment, then 
this would indicate that VOC profiling would not be an ideal medium for 
monitoring for disease recurrence as the interval for change appears too great for 
accepting in clinical practice. If it is the latter then it is obviously not an appropriate 
method.  
Profiling of the microbiome via 16s RNA analysis of stool samples from the CRC 
subjects and control groups identified 1346 unique OTUs across all samples. Of 
these >93% were similar between the CRC patients and control groups. This was 
backed up by an analysis of similarity result of returned an R value of 0.067 
(p=<0.001). This indicates that whilst there is a subtle difference in the microbiome 
profile of patients with CRC that it is not statistically different from the variation 
that is seen in the general population, as the control groups had a variation of 4%.  
Of the identified OTUs, 82 (6.2%) were significantly different in the CRC cohort, 
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with 46 showing increased abundance in CRC subjects. Subset analysis of a smaller 
CRC patient cohort, similar to that conducted on the urinary samples, identified 
45 OTUs, with 22 identified in both analyses. However, as for the urinary VOC 
results, given the reduction in sample size, this leads to the possibility of 
underpowering for the experiment and so that data must be interpreted with 
caution. The OTUs with significantly different abundance were identified as 
predominantly Clostridiales, Coriobacteriales, Bacteroidales and Fusobacteriales, 
as previously reported (214, 221, 229, 245).  
There were differences in the microbiome of 3% and 4% respectively at 3 and 6 
month post-treatment, in addition to a subtle increase, though not statistically 
significant, in microbial diversity. 2 specific bacterial OTUs showed significantly 
altered levels at both 3 and 6 months. OTU 213, a Clostridales, increased post 
operatively and OTU 278, a Coriobacteriales, decreased post-treatment. The 
alteration in these bacterial orders have been reported previously (243, 244, (247). 
The data on both the comparison of CRC microbiome with controls and post-
treatment samples is too limited to draw conclusions about any potential 
microbiome role in CRC carcinogenesis, or whether the observed changes are 
merely an effect of CRC generation.  
The original intention of this study was to recruit 200 CRC subjects, 100 relatives 
and 100 spouses to try and prevent underpowering of the study. This was based 
on previous VOC studies by our group on CRC and other diseases which had shown 
that sample sizes as low as 20 were able to distinguish disease groups from 
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controls (162, 163). Recruitment reached only approximately 50% of the intended 
target. This was multi-factorial, but highlights the difficulties in recruiting sizable 
patient numbers within the limited time window of a 2 year MD project. There 
was also a marked number of first degree relatives, 24, out of 61 recruited, who 
did not return samples. This is perhaps reflective of the fact that the study possibly, 
carries less importance to them, than the CRC subjects and their spouses. The final 
numbers for each group, 56 (CRC), 37 (relatives) and 41 (spouses) were appear to 
be large enough to answer the main study question with regards to urinary VOCs. 
However, when smaller groups were analysed, such as the CRC subset, CRC by site 
of tumour, or 3/6 month post-treatment samples, then the sample sizes became 
much smaller and the risk of underpowering increased. This can be seen in the loss 
of signal after a more stringently matched subset of CRC subjects was compared 
to relative and spouse control groups.   
The data obtained does not allow us to determine whether the microbiome affects 
the VOC profile found in urine for either CRC subjects nor the healthy control 
groups. Nor does it allow us to infer whether genetic or environmental factors 
have a greater effect on VOC profiles, microbiome profiles or CRC generation. 
However, given that the healthy control groups were distinguishable from the CRC 
cohort using urinary VOCs, but indistinguishable from each other, it would suggest 
that the genetic and environmental factors although important in CRC not 
represented in the VOC profiles of individuals. These factors may well be beyond 
the scope of urinary VOCs and microbiome profiling to adequately characterise.   
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This thesis, as far as I am aware, provide the first work on the degradation of 
urinary VOCs for samples stored at room temperature prior to freezing. Previously 
only the effects of storage conditions on blood and faecal VOCs had been studied 
(241, 242).  The experiments showed that urine samples show a consistent 
degradation pattern when stored at room temperature for increasing time 
intervals prior to freezing. This pattern included a plateau of degradation between 
12 and 48 hours, before further degradation occurred. Interestingly it also 
highlighted that the samples appear to degrade within the sampling time frame of 
the FAIMS machine, in that the first run of a sample gave a different FAIMS matrix 
than the fourteenth and final run, even when stored in a chilling tray to allow 
automated sampling. The degradation pattern was consistent across all samples, 
indicating that it is a intrinsic feature of the VOCs, rather than as the result of 
individual sample contamination. The role of bacterial degradation is questionable 
here, as the degradation pattern was consistent across all subjects and samples 
were obtained from healthy individuals.  
This work into the degradation of urinary VOCs at room temperature will hopefully 
add to our ever increasing understanding of VOCs and their potential role as non-
invasive biomarkers of disease. It highlights how little is known about the effects 
of storage on VOC profile and how there is a pressing need for an agreed on 
standardised sample collection and storage protocols to allow comparison 
between different studies. This experiment has affected the ways in which further 
sample collection is conducted at our centre and follows up on previous work that 
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suggests urine samples can only be stored frozen at -80°C for up to 9 - 12 months 
before they degrade (248).  
Potential limitations of the work presented in this thesis include, the potential for 
underpowering, particularly with regard to the pre and post-treatment sample 
analysis, as already discussed in Chapters 6 and 8. Furthermore, as with all VOC 
studies, the lack of an agreed upon optimum collection and storage methodology 
means that any results must be interpreted with caution. The degradation study 
conducted in Chapter 4 indicate sthat storage does affect VOC profile, and while 
it appears unlikely to have greatly affected the results as described here, it remains 
a possibility.  
The results reported in this thesis will hopefully add to the growing body of work 
which demonstrates the detection of CRC in patients via analysis of the urinary 
VOC profiles. The long term goal being to find a screening test which is more 
acceptable to the general public than the current stool based BCSP tests of 
FOBT/FIT and would thusly result in a higher uptake than is currently seen. The 
sensitivities and specificities demonstrated are comparable to previous urinary 
VOC studies in CRC and to that achieved by FOBT/FIT, suggesting that if an agreed 
upon metholodgy could be developed for sample collection, storage and analysis 
that urinary VOCs could potentially be used in CRC screening programmes, 
although the NPV is currently too low for clinical use. Further larger studies, 
including larger control cohorts, are required into the use of urinary VOCs in CRC 
detection, particularly in direct comparison to the other screening tools used such 
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as FOBT/FIT to determine whether indeed urinary VOC analysis is superior in terms 
of accuracy and uptake. These studies would also need to have a more stringent 
sample collection protocol, either fresh samples, or samples within a 12-48 hour 
period post voiding. Ideally these would be fresh samples, given that the long term 
goal would be to have urinary VOC screening for CRC available as a point of care 
test in clinically settings.  
This is the first study to utilise this precise FAIMS variant, the LC-FAIM-MS, to 
detect urinary VOCs in CRC patients and therefore as further work is conducted in 
this area then more refining of the both the LC-FAIMS-MS apparatus and statistical 
pathways used may yield further progress in the quest for a reliable, non-invasive, 
urinary biomarker for colorectal cancer.  
 
  
   
 
283 
 
Bibliography 
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 
2010;127(12):2893-917. 
2. J F, I S, M E, R D, S E, C M, et al. Cancer Incidence and Mortality Worldwide: 
IARC CancerBase No. 11 [Internet]. GLOBOCAN 2012 v10 [Internet]. 2013. 
3. UK CRC. 2013 diagnoses  [Available from: 
http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/bowel-cancer#heading-Zero. 
4. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and 
Mortality Rates and Trends-An Update. Cancer Epidemiol Biomarkers Prev. 
2016;25(1):16-27. 
5. Jones AM, Morris E, Thomas J, Forman D, Melia J, Moss SM. Evaluation of 
bowel cancer registration data in England, 1996-2004. Br J Cancer. 
2009;101(8):1269-73. 
6. UK CR.  [Available from: http://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/bowel-
cancer/incidence#ref-0. 
7. Scholefield JH, Eng C. Colorectal Cancer: Diagnosis and Clinical 
Management. 1st ed: John Wiley and Sons Ltd; 2014. 
8. UK CR. 5 year survival statistics  [Available from: 
http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/bowel-cancer/survival#heading-Three. 
9. Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB. Sex 
disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J 
Cancer. 2011;128(7):1668-75. 
10. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J 
Gastroenterol. 2006;101(2):385-98. 
   
 
284 
 
11. Gala M, Chung DC. Hereditary colon cancer syndromes. Semin Oncol. 
2011;38(4):490-9. 
12. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of 
colorectal cancer for individuals with a family history: a meta-analysis. Eur J 
Cancer. 2006;42(2):216-27. 
13. Zöller B, Li X, Sundquist J, Sundquist K. Familial transmission of prostate, 
breast and colorectal cancer in adoptees is related to cancer in biological but not 
in adoptive parents: a nationwide family study. Eur J Cancer. 2014;50(13):2319-
27. 
14. von Holst S, Picelli S, Edler D, Lenander C, Dalén J, Hjern F, et al. Association 
studies on 11 published colorectal cancer risk loci. Br J Cancer. 2010;103(4):575-
80. 
15. Niittymäki I, Kaasinen E, Tuupanen S, Karhu A, Järvinen H, Mecklin JP, et al. 
Low-penetrance susceptibility variants in familial colorectal cancer. Cancer 
Epidemiol Biomarkers Prev. 2010;19(6):1478-83. 
16. Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, et 
al. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal 
cancer risk. Nat Genet. 2012;44(7):770-6. 
17. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial 
colon cancer. Gastroenterology. 2010;138(6):2044-58. 
18. Martínez ME, Baron JA, Lieberman DA, Schatzkin A, Lanza E, Winawer SJ, 
et al. A pooled analysis of advanced colorectal neoplasia diagnoses after 
colonoscopic polypectomy. Gastroenterology. 2009;136(3):832-41. 
19. Hassan C, Gimeno-García A, Kalager M, Spada C, Zullo A, Costamagna G, et 
al. Systematic review with meta-analysis: the incidence of advanced neoplasia 
after polypectomy in patients with and without low-risk adenomas. Aliment 
Pharmacol Ther. 2014;39(9):905-12. 
20. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, 
Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an 
   
 
285 
 
updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 
2013;19(4):789-99. 
21. Chiong C, Cox MR, Eslick GD. Gallstone disease is associated with rectal 
cancer: a meta-analysis. Scand J Gastroenterol. 2012;47(5):553-64. 
22. Chiong C, Cox MR, Eslick GD. Gallstones are associated with colonic 
adenoma: a meta-analysis. World J Surg. 2012;36(9):2202-9. 
23. Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and 
incidence and mortality of colorectal cancer: a systematic review and meta-
analysis of cohort studies. Eur J Epidemiol. 2011;26(11):863-76. 
24. Krämer HU, Schöttker B, Raum E, Brenner H. Type 2 diabetes mellitus and 
colorectal cancer: meta-analysis on sex-specific differences. Eur J Cancer. 
2012;48(9):1269-82. 
25. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal 
cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679-87. 
26. Luo W, Cao Y, Liao C, Gao F. Diabetes mellitus and the incidence and 
mortality of colorectal cancer: A meta-analysis of twenty four cohort studies. 
Colorectal Dis. 2011. 
27. Wu L, Yu C, Jiang H, Tang J, Huang HL, Gao J, et al. Diabetes mellitus and 
the occurrence of colorectal cancer: an updated meta-analysis of cohort studies. 
Diabetes Technol Ther. 2013;15(5):419-27. 
28. Jinjuvadia R, Lohia P, Jinjuvadia C, Montoya S, Liangpunsakul S. The 
association between metabolic syndrome and colorectal neoplasm: systemic 
review and meta-analysis. J Clin Gastroenterol. 2013;47(1):33-44. 
29. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Obesity and risk of 
colorectal cancer: a systematic review of prospective studies. PLoS One. 
2013;8(1):e53916. 
30. Cong YJ, Gan Y, Sun HL, Deng J, Cao SY, Xu X, et al. Association of sedentary 
behaviour with colon and rectal cancer: a meta-analysis of observational studies. 
Br J Cancer. 2014;110(3):817-26. 
   
 
286 
 
31. Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical activity and risks of 
proximal and distal colon cancers: a systematic review and meta-analysis. J Natl 
Cancer Inst. 2012;104(20):1548-61. 
32. Aune D, Lau R, Chan DS, Vieira R, Greenwood DC, Kampman E, et al. 
Nonlinear reduction in risk for colorectal cancer by fruit and vegetable intake 
based on meta-analysis of prospective studies. Gastroenterology. 
2011;141(1):106-18. 
33. Tse G, Eslick GD. Cruciferous vegetables and risk of colorectal neoplasms: 
a systematic review and meta-analysis. Nutr Cancer. 2014;66(1):128-39. 
34. Wu QJ, Yang Y, Vogtmann E, Wang J, Han LH, Li HL, et al. Cruciferous 
vegetables intake and the risk of colorectal cancer: a meta-analysis of 
observational studies. Ann Oncol. 2013;24(4):1079-87. 
35. Koushik A, Hunter DJ, Spiegelman D, Beeson WL, van den Brandt PA, Buring 
JE, et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort 
studies. J Natl Cancer Inst. 2007;99(19):1471-83. 
36. Lee JE, Chan AT. Fruit, vegetables, and folate: cultivating the evidence for 
cancer prevention. Gastroenterology. 2011;141(1):16-20. 
37. Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, et al. Red 
and processed meat and colorectal cancer incidence: meta-analysis of prospective 
studies. PLoS One. 2011;6(6):e20456. 
38. Sandhu MS, White IR, McPherson K. Systematic review of the prospective 
cohort studies on meat consumption and colorectal cancer risk: a meta-analytical 
approach. Cancer Epidemiol Biomarkers Prev. 2001;10(5):439-46. 
39. Norat T, Lukanova A, Ferrari P, Riboli E. Meat consumption and colorectal 
cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer. 
2002;98(2):241-56. 
40. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a 
meta-analysis of prospective studies. Int J Cancer. 2006;119(11):2657-64. 
   
 
287 
 
41. Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk--a systematic 
review and meta-analysis of the epidemiological evidence. Cancer Epidemiol 
Biomarkers Prev. 2014;23(1):12-31. 
42. Key TJ, Appleby PN, Masset G, Brunner EJ, Cade JE, Greenwood DC, et al. 
Vitamins, minerals, essential fatty acids and colorectal cancer risk in the United 
Kingdom Dietary Cohort Consortium. Int J Cancer. 2012;131(3):E320-5. 
43. Parkin DM, Boyd L. 6. Cancers attributable to dietary factors in the UK in 
2010. III. Low consumption of fibre. Br J Cancer. 2011;105 Suppl 2:S27-30. 
44. Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, et al. Dietary 
fibre, whole grains, and risk of colorectal cancer: systematic review and dose-
response meta-analysis of prospective studies. BMJ. 2011;343:d6617. 
45. Aune D, Lau R, Chan DS, Vieira R, Greenwood DC, Kampman E, et al. Dairy 
products and colorectal cancer risk: a systematic review and meta-analysis of 
cohort studies. Ann Oncol. 2012;23(1):37-45. 
46. Keum N, Aune D, Greenwood DC, Ju W, Giovannucci EL. Calcium intake and 
colorectal cancer risk: dose-response meta-analysis of prospective observational 
studies. Int J Cancer. 2014;135(8):1940-8. 
47. Carroll C, Cooper K, Papaioannou D, Hind D, Pilgrim H, Tappenden P. 
Supplemental calcium in the chemoprevention of colorectal cancer: a systematic 
review and meta-analysis. Clin Ther. 2010;32(5):789-803. 
48. Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation 
for preventing colorectal cancer and adenomatous polyps. Cochrane Database 
Syst Rev. 2008(1):CD003548. 
49. Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin 
D and risk of colorectal cancer: a systematic review of prospective studies. J Clin 
Oncol. 2011;29(28):3775-82. 
50. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a 
systematic review. Lancet Diabetes Endocrinol. 2014;2(1):76-89. 
51. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Serum 
vitamin D and colorectal adenoma risk. Prev Med. 2011;53(1-2):10-6. 
   
 
288 
 
52. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-
analysis of observational studies of serum 25-hydroxyvitamin D levels and 
colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 
2011;128(6):1414-24. 
53. Leenders M, Leufkens AM, Siersema PD, van Duijnhoven FJ, Vrieling A, 
Hulshof PJ, et al. Plasma and dietary carotenoids and vitamins A, C and E and risk 
of colon and rectal cancer in the European Prospective Investigation into Cancer 
and Nutrition. Int J Cancer. 2014;135(12):2930-9. 
54. Li P, Xu J, Shi Y, Ye Y, Chen K, Yang J, et al. Association between zinc intake 
and risk of digestive tract cancers: a systematic review and meta-analysis. Clin 
Nutr. 2014;33(3):415-20. 
55. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, 
Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal 
cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 
2009;125(1):171-80. 
56. Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer 
incidence and mortality: systematic review and meta-analysis. Int J Cancer. 
2009;124(10):2406-15. 
57. Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, et al. Alcohol 
drinking and colorectal cancer risk: an overall and dose-response meta-analysis of 
published studies. Ann Oncol. 2011;22(9):1958-72. 
58. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, et al. A 
randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. 
Gastroenterology. 2006;131(6):1674-82. 
59. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer 
incidence and metastasis: a systematic comparison of evidence from 
observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518-27. 
60. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. 
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the 
randomized trials. J Natl Cancer Inst. 2009;101(4):256-66. 
   
 
289 
 
61. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. 
Gastroenterology. 2010;138(6):2029-43.e10. 
62. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone 
therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 
1999;106(5):574-82. 
63. Hébert-Croteau N. A meta-analysis of hormone replacement therapy and 
colon cancer in women. Cancer Epidemiol Biomarkers Prev. 1998;7(8):653-9. 
64. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement 
therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol. 
1999;93(5 Pt 2):880-8. 
65. Green J, Czanner G, Reeves G, Watson J, Wise L, Roddam A, et al. 
Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-
control study within a prospective cohort, and meta-analysis. Int J Cancer. 
2012;130(10):2387-96. 
66. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal 
cancer risk: a systematic review and meta-analysis. Hum Reprod Update. 
2009;15(5):489-98. 
67. Lee JE, Willett WC, Fuchs CS, Smith-Warner SA, Wu K, Ma J, et al. Folate 
intake and risk of colorectal cancer and adenoma: modification by time. Am J Clin 
Nutr. 2011;93(4):817-25. 
68. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, et al. Folic 
acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 
2007;297(21):2351-9. 
69. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR, Group uT. 
Aspirin and folic acid for the prevention of recurrent colorectal adenomas. 
Gastroenterology. 2008;134(1):29-38. 
70. Stevens A, Lowe J. Pathology. Mosby; 2000. p. 259-64. 
71. UK CR. Anatomical site  [Available from: 
http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/bowel-cancer/incidence#heading-Five. 
   
 
290 
 
72. Colledge N, Walker B, Ralston S. Davidson's Principles and Practice of 
Medicine. 21st edition ed: Chruchill Livingstone Elsevier; 2010. 
73. Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: 
Pathologic aspects. J Gastrointest Oncol. 2012;3(3):153-73. 
74. DENOIX P. [Not Available]. Bull Inst Natl Hyg. 1946;1:12-7. 
75. Dukes C. The Classification of Cancer of the Rectum. J Path Bad; 1932. p. 
325-32. 
76. Rao AR, Kagan AR, Chan PM, Gilbert HA, Nussbaum H, Hintz BL. Patterns of 
recurrence following curative resection alone for adenocarcinoma of the rectum 
and sigmoid colon. Cancer. 1981;48(6):1492-5. 
77. Böhm B, Schwenk W, Hucke HP, Stock W. Does methodic long-term follow-
up affect survival after curative resection of colorectal carcinoma? Dis Colon 
Rectum. 1993;36(3):280-6. 
78. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. 
Disease-free survival versus overall survival as a primary end point for adjuvant 
colon cancer studies: individual patient data from 20,898 patients on 18 
randomized trials. J Clin Oncol. 2005;23(34):8664-70. 
79. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence 
and patterns of recurrence after resection for cure of colonic cancer in a well 
defined population. Br J Surg. 2006;93(9):1115-22. 
80. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et 
al. Guidelines for colorectal cancer screening and surveillance in moderate and 
high risk groups (update from 2002). Gut. 2010;59(5):666-89. 
81. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, et al. 
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc 
Netw. 2009;7(8):778-831. 
82. Plumb AA, Halligan S. Colorectal cancer screening. Semin Roentgenol. 
2015;50(2):101-10. 
   
 
291 
 
83. Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C, et 
al. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after 
the first 1 million tests. Gut. 2012;61(10):1439-46. 
84. Bevan R, Rubin G, Sofianopoulou E, Patnick J, Rees CJ. Implementing a 
national flexible sigmoidoscopy screening program: results of the English early 
pilot. Endoscopy. 2015;47(3):225-31. 
85. Rabeneck L, Rumble RB, Thompson F, Mills M, Oleschuk C, Whibley A, et 
al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for 
population-based colorectal cancer screening. Can J Gastroenterol. 
2012;26(3):131-47. 
86. Steele RJ, McDonald PJ, Digby J, Brownlee L, Strachan JA, Libby G, et al. 
Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-
line test in a national programme constrained by colonoscopy capacity. United 
European Gastroenterol J. 2013;1(3):198-205. 
87. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken 
HH, et al. Random comparison of guaiac and immunochemical fecal occult blood 
tests for colorectal cancer in a screening population. Gastroenterology. 
2008;135(1):82-90. 
88. Huddy JR, Ni MZ, Markar SR, Hanna GB. Point-of-care testing in the 
diagnosis of gastrointestinal cancers: current technology and future directions. 
World J Gastroenterol. 2015;21(14):4111-20. 
89. Fraser CG, Digby J, McDonald PJ, Strachan JA, Carey FA, Steele RJ. 
Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening 
programme. J Med Screen. 2012;19(1):8-13. 
90. Kuipers EJ, Rösch T, Bretthauer M. Colorectal cancer screening--optimizing 
current strategies and new directions. Nat Rev Clin Oncol. 2013;10(3):130-42. 
91. Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of 
the impact of new faecal haemoglobin test technologies on population 
participation in screening for colorectal cancer. J Med Screen. 2003;10(3):117-22. 
   
 
292 
 
92. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et 
al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 
2014;370(14):1287-97. 
93. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution 
from occult blood to molecular markers. Clin Chim Acta. 2002;315(1-2):157-68. 
94. Tonus C, Sellinger M, Koss K, Neupert G. Faecal pyruvate kinase isoenzyme 
type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol. 
2012;18(30):4004-11. 
95. Schmidt K, Podmore I. Current Challenges in Volatile Organic Compounds 
Analysis as Potential Biomarkers of Cancer. J Biomark. 2015;2015:981458. 
96. Arasaradnam RP, Covington JA, Harmston C, Nwokolo CU. Review article: 
next generation diagnostic modalities in gastroenterology--gas phase volatile 
compound biomarker detection. Aliment Pharmacol Ther. 2014;39(8):780-9. 
97. Williams H, Pembroke A. Sniffer dogs in the melanoma clinic? Lancet. 
1989;1(8640):734. 
98. Pickel D, Manucy G, Walker D, Hall S, Walker J. Evidence for canine 
olfactory detection of melanoma. Applied Animal Behaviour Science. 
2004;89:107-16. 
99. Willis CM, Church SM, Guest CM, Cook WA, McCarthy N, Bransbury AJ, et 
al. Olfactory detection of human bladder cancer by dogs: proof of principle study. 
BMJ. 2004;329(7468):712. 
100. McCulloch M, Jezierski T, Broffman M, Hubbard A, Turner K, Janecki T. 
Diagnostic accuracy of canine scent detection in early- and late-stage lung and 
breast cancers. Integr Cancer Ther. 2006;5(1):30-9. 
101. Gordon RT, Schatz CB, Myers LJ, Kosty M, Gonczy C, Kroener J, et al. The 
use of canines in the detection of human cancers. J Altern Complement Med. 
2008;14(1):61-7. 
102. Horvath G, Järverud GA, Järverud S, Horváth I. Human ovarian carcinomas 
detected by specific odor. Integr Cancer Ther. 2008;7(2):76-80. 
   
 
293 
 
103. Moser E, McCulloch M. Canine scent detection of human cancers: A review 
of methods and accuracy. Journal of Veterinary Behaviour. 2010;5:145/52. 
104. Sonoda H, Kohnoe S, Yamazato T, Satoh Y, Morizono G, Shikata K, et al. 
Colorectal cancer screening with odour material by canine scent detection. Gut. 
2011;60(6):814-9. 
105. Willis CM, Britton LE, Harris R, Wallace J, Guest CM. Volatile organic 
compounds as biomarkers of bladder cancer: Sensitivity and specificity using 
trained sniffer dogs. Cancer Biomark. 2010;8(3):145-53. 
106. Cornu JN, Cancel-Tassin G, Ondet V, Girardet C, Cussenot O. Olfactory 
detection of prostate cancer by dogs sniffing urine: a step forward in early 
diagnosis. Eur Urol. 2011;59(2):197-201. 
107. Taverna G, Tidu L, Grizzi F, Torri V, Mandressi A, Sardella P, et al. Olfactory 
system of highly trained dogs detects prostate cancer in urine samples. J Urol. 
2015;193(4):1382-7. 
108. Ehmann R, Boedeker E, Friedrich U, Sagert J, Dippon J, Friedel G, et al. 
Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling 
phenomenon. Eur Respir J. 2012;39(3):669-76. 
109. Buszewski B, Ligor T, Jezierski T, Wenda-Piesik A, Walczak M, Rudnicka J. 
Identification of volatile lung cancer markers by gas chromatography-mass 
spectrometry: comparison with discrimination by canines. Anal Bioanal Chem. 
2012;404(1):141-6. 
110. Amundsen T, Sundstrøm S, Buvik T, Gederaas OA, Haaverstad R. Can dogs 
smell lung cancer? First study using exhaled breath and urine screening in 
unselected patients with suspected lung cancer. Acta Oncol. 2014;53(3):307-15. 
111. Arasaradnam RP, Nwokolo CU, Bardhan KD, Covington JA. Electronic nose 
versus canine nose: clash of the titans. Gut. 2011;60(12):1768. 
112. Bjartell AS. Dogs sniffing urine: a future diagnostic tool or a way to identify 
new prostate cancer markers? Eur Urol. 2011;59(2):202-3. 
   
 
294 
 
113. Boedeker E, Friedel G, Walles T. Sniffer dogs as part of a bimodal bionic 
research approach to develop a lung cancer screening. Interact Cardiovasc Thorac 
Surg. 2012;14(5):511-5. 
114. Jezierski T, Walczak M, Ligor T, Rudnicka J, Buszewski B. Study of the art: 
canine olfaction used for cancer detection on the basis of breath odour. 
Perspectives and limitations. J Breath Res. 2015;9(2):027001. 
115. Silva CL, Passos M, Câmara JS. Investigation of urinary volatile organic 
metabolites as potential cancer biomarkers by solid-phase microextraction in 
combination with gas chromatography-mass spectrometry. Br J Cancer. 
2011;105(12):1894-904. 
116. Horvath I. Smells like cancer. Lung Cancer. 2010;68(2):127-8. 
117. Smith D, Spanel P. Pitfalls in the analysis of volatile breath biomarkers: 
suggested solutions and SIFT-MS quantification of single metabolites. J Breath Res. 
2015;9(2):022001. 
118. Gordon SM, Szidon JP, Krotoszynski BK, Gibbons RD, O'Neill HJ. Volatile 
organic compounds in exhaled air from patients with lung cancer. Clin Chem. 
1985;31(8):1278-82. 
119. Preti G, Labows JN, Kostelc JG, Aldinger S, Daniele R. Analysis of lung air 
from patients with bronchogenic carcinoma and controls using gas 
chromatography-mass spectrometry. J Chromatogr. 1988;432:1-11. 
120. O'Neill H, Gordon S, O'Neill M, Gibbons R, Szidon J. A computerized 
classification technique for screening for the presence of breath biomarkers in 
lung cancer. Clinical Chemistry. 1988;34(8):1613-8. 
121. Phillips M, Gleeson K, Hughes JM, Greenberg J, Cataneo RN, Baker L, et al. 
Volatile organic compounds in breath as markers of lung cancer: a cross-sectional 
study. Lancet. 1999;353(9168):1930-3. 
122. Krilaviciute A, Heiss JA, Leja M, Kupcinskas J, Haick H, Brenner H. Detection 
of cancer through exhaled breath: a systematic review. Oncotarget. 
2015;6(36):38643-57. 
   
 
295 
 
123. Phillips M, Cataneo RN, Cummin AR, Gagliardi AJ, Gleeson K, Greenberg J, 
et al. Detection of lung cancer with volatile markers in the breath. Chest. 
2003;123(6):2115-23. 
124. Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Greenberg J, et 
al. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark. 
2007;3(2):95-109. 
125. Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Kloss R, et al. 
Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin 
Chim Acta. 2008;393(2):76-84. 
126. Fu XA, Li M, Knipp RJ, Nantz MH, Bousamra M. Noninvasive detection of 
lung cancer using exhaled breath. Cancer Med. 2014;3(1):174-81. 
127. Li M, Yang D, Brock G, Knipp RJ, Bousamra M, Nantz MH, et al. Breath 
carbonyl compounds as biomarkers of lung cancer. Lung Cancer. 2015;90(1):92-7. 
128. Sponring A, Filipiak W, Ager C, Schubert J, Miekisch W, Amann A, et al. 
Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung 
cancer cells. Cancer Biomark. 2010;7(3):153-61. 
129. Hu YJ, Qiu YH, Chen EG, Ying KJ, Yu J, Wang P. [Determination of volatile 
organic compounds in lung cancer cell lines and lung cancer tissue]. Zhejiang Da 
Xue Xue Bao Yi Xue Ban. 2010;39(3):278-84. 
130. Filipiak W, Sponring A, Filipiak A, Ager C, Schubert J, Miekisch W, et al. TD-
GC-MS analysis of volatile metabolites of human lung cancer and normal cells in 
vitro. Cancer Epidemiol Biomarkers Prev. 2010;19(1):182-95. 
131. Buszewski B, Ulanowska A, Kowalkowski T, Cieśliński K. Investigation of 
lung cancer biomarkers by hyphenated separation techniques and chemometrics. 
Clin Chem Lab Med. 2012;50(3):573-81. 
132. Filipiak W, Filipiak A, Sponring A, Schmid T, Zelger B, Ager C, et al. 
Comparative analyses of volatile organic compounds (VOCs) from patients, tumors 
and transformed cell lines for the validation of lung cancer-derived breath 
markers. J Breath Res. 2014;8(2):027111. 
   
 
296 
 
133. Taivans I, Bukovskis M, Strazda G, Jurka N. Breath testing as a method for 
detecting lung cancer. Expert Rev Anticancer Ther. 2013. 
134. Kalluri U, Naiker M, Myers MA. Cell culture metabolomics in the diagnosis 
of lung cancer-the influence of cell culture conditions. J Breath Res. 
2014;8(2):027109. 
135. Machado RF, Laskowski D, Deffenderfer O, Burch T, Zheng S, Mazzone PJ, 
et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am J 
Respir Crit Care Med. 2005;171(11):1286-91. 
136. Dragonieri S, Annema JT, Schot R, van der Schee MP, Spanevello A, Carratú 
P, et al. An electronic nose in the discrimination of patients with non-small cell 
lung cancer and COPD. Lung Cancer. 2009;64(2):166-70. 
137. McWilliams A, Beigi P, Srinidhi A, Lam S, MacAulay CE. Sex and Smoking 
Status Effects on the Early Detection of Early Lung Cancer in High-Risk Smokers 
Using an Electronic Nose. IEEE Trans Biomed Eng. 2015;62(8):2044-54. 
138. Mazzone PJ, Hammel J, Dweik R, Na J, Czich C, Laskowski D, et al. Diagnosis 
of lung cancer by the analysis of exhaled breath with a colorimetric sensor array. 
Thorax. 2007;62(7):565-8. 
139. Mazzone PJ, Wang XF, Xu Y, Mekhail T, Beukemann MC, Na J, et al. Exhaled 
breath analysis with a colorimetric sensor array for the identification and 
characterization of lung cancer. J Thorac Oncol. 2012;7(1):137-42. 
140. Mazzone PJ, Wang XF, Lim S, Choi H, Jett J, Vachani A, et al. Accuracy of 
volatile urine biomarkers for the detection and characterization of lung cancer. 
BMC Cancer. 2015;15:1001. 
141. Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, et al. Diagnosing 
lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol. 
2009;4(10):669-73. 
142. Barash O, Peled N, Hirsch FR, Haick H. Sniffing the unique "odor print" of 
non-small-cell lung cancer with gold nanoparticles. Small. 2009;5(22):2618-24. 
   
 
297 
 
143. Di Natale C, Macagnano A, Martinelli E, Paolesse R, D'Arcangelo G, Roscioni 
C, et al. Lung cancer identification by the analysis of breath by means of an array 
of non-selective gas sensors. Biosens Bioelectron. 2003;18(10):1209-18. 
144. D'Amico A, Pennazza G, Santonico M, Martinelli E, Roscioni C, Galluccio G, 
et al. An investigation on electronic nose diagnosis of lung cancer. Lung Cancer. 
2010;68(2):170-6. 
145. Santonico M, Lucantoni G, Pennazza G, Capuano R, Galluccio G, Roscioni C, 
et al. In situ detection of lung cancer volatile fingerprints using bronchoscopic air-
sampling. Lung Cancer. 2012;77(1):46-50. 
146. Gasparri R, Santonico M, Valentini C, Sedda G, Borri A, Petrella F, et al. 
Volatile signature for the early diagnosis of lung cancer. J Breath Res. 
2016;10(1):016007. 
147. Westhoff M, Litterst P, Freitag L, Urfer W, Bader S, Baumbach JI. Ion 
mobility spectrometry for the detection of volatile organic compounds in exhaled 
breath of patients with lung cancer: results of a pilot study. Thorax. 
2009;64(9):744-8. 
148. Darwiche K, Baumbach JI, Sommerwerck U, Teschler H, Freitag L. 
Bronchoscopically obtained volatile biomarkers in lung cancer. Lung. 
2011;189(6):445-52. 
149. Peled N, Hakim M, Bunn PA, Miller YE, Kennedy TC, Mattei J, et al. Non-
invasive breath analysis of pulmonary nodules. J Thorac Oncol. 2012;7(10):1528-
33. 
150. Poli D, Goldoni M, Caglieri A, Ceresa G, Acampa O, Carbognani P, et al. 
Breath analysis in non small cell lung cancer patients after surgical tumour 
resection. Acta Biomed. 2008;79 Suppl 1:64-72. 
151. Capuano R, Santonico M, Pennazza G, Ghezzi S, Martinelli E, Roscioni C, et 
al. The lung cancer breath signature: a comparative analysis of exhaled breath and 
air sampled from inside the lungs. Sci Rep. 2015;5:16491. 
   
 
298 
 
152. Rocco R, Incalzi RA, Pennazza G, Santonico M, Pedone C, Bartoli IR, et al. 
BIONOTE e-nose technology may reduce false positives in lung cancer screening 
programmes†. Eur J Cardiothorac Surg. 2015. 
153. Dragonieri S, van der Schee MP, Massaro T, Schiavulli N, Brinkman P, Pinca 
A, et al. An electronic nose distinguishes exhaled breath of patients with Malignant 
Pleural Mesothelioma from controls. Lung Cancer. 2012;75(3):326-31. 
154. Chapman EA, Thomas PS, Stone E, Lewis C, Yates DH. A breath test for 
malignant mesothelioma using an electronic nose. Eur Respir J. 2012;40(2):448-
54. 
155. Liu H, Wang H, Li C, Wang L, Pan Z. Investigation of volatile organic 
metabolites in lung cancer pleural effusions by solid-phase microextraction and 
gas chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed 
Life Sci. 2014;945-946:53-9. 
156. Hanai Y, Shimono K, Matsumura K, Vachani A, Albelda S, Yamazaki K, et al. 
Urinary volatile compounds as biomarkers for lung cancer. Biosci Biotechnol 
Biochem. 2012;76(4):679-84. 
157. Di Lena M, Porcelli F, Altomare DF. Volatile Organic Compounds (VOC) as 
new biomarkers for colorectal cancer: a review. Colorectal Dis. 2016. 
158. Altomare DF, Di Lena M, Porcelli F, Trizio L, Travaglio E, Tutino M, et al. 
Exhaled volatile organic compounds identify patients with colorectal cancer. Br J 
Surg. 2013;100(1):144-50. 
159. Wang C, Ke C, Wang X, Chi C, Guo L, Luo S, et al. Noninvasive detection of 
colorectal cancer by analysis of exhaled breath. Anal Bioanal Chem. 
2014;406(19):4757-63. 
160. Amal H, Leja M, Funka K, Lasina I, Skapars R, Sivins A, et al. Breath testing 
as potential colorectal cancer screening tool. Int J Cancer. 2016;138(1):229-36. 
161. Ma YL, Qin HL, Liu WJ, Peng JY, Huang L, Zhao XP, et al. Ultra-high 
performance liquid chromatography-mass spectrometry for the metabolomic 
analysis of urine in colorectal cancer. Dig Dis Sci. 2009;54(12):2655-62. 
   
 
299 
 
162. Arasaradnam RP, McFarlane MJ, Ryan-Fisher C, Westenbrink E, Hodges P, 
Thomas MG, et al. Detection of colorectal cancer (CRC) by urinary volatile organic 
compound analysis. PLoS One. 2014;9(9):e108750. 
163. Westenbrink E, Arasaradnam RP, O'Connell N, Bailey C, Nwokolo C, 
Bardhan KD, et al. Development and application of a new electronic nose 
instrument for the detection of colorectal cancer. Biosens Bioelectron. 
2015;67:733-8. 
164. de Boer NK, de Meij TG, Oort FA, Ben Larbi I, Mulder CJ, van Bodegraven 
AA, et al. The scent of colorectal cancer: detection by volatile organic compound 
analysis. Clin Gastroenterol Hepatol. 2014;12(7):1085-9. 
165. Batty CA, Cauchi M, Lourenço C, Hunter JO, Turner C. Use of the Analysis 
of the Volatile Faecal Metabolome in Screening for Colorectal Cancer. PLoS One. 
2015;10(6):e0130301. 
166. Wang C, Li P, Lian A, Sun B, Wang X, Guo L, et al. Blood volatile compounds 
as biomarkers for colorectal cancer. Cancer Biol Ther. 2014;15(2):200-6. 
167. Xu ZQ, Broza YY, Ionsecu R, Tisch U, Ding L, Liu H, et al. A nanomaterial-
based breath test for distinguishing gastric cancer from benign gastric conditions. 
Br J Cancer. 2013;108(4):941-50. 
168. Kumar S, Huang J, Abbassi-Ghadi N, Mackenzie HA, Veselkov KA, Hoare JM, 
et al. Mass Spectrometric Analysis of Exhaled Breath for the Identification of 
Volatile Organic Compound Biomarkers in Esophageal and Gastric 
Adenocarcinoma. Ann Surg. 2015;262(6):981-90. 
169. Huang J, Kumar S, Abbassi-Ghadi N, Spaněl P, Smith D, Hanna GB. Selected 
ion flow tube mass spectrometry analysis of volatile metabolites in urine 
headspace for the profiling of gastro-esophageal cancer. Anal Chem. 
2013;85(6):3409-16. 
170. Kumar S, Huang J, Cushnir JR, Španěl P, Smith D, Hanna GB. Selected ion 
flow tube-MS analysis of headspace vapor from gastric content for the diagnosis 
of gastro-esophageal cancer. Anal Chem. 2012;84(21):9550-7. 
   
 
300 
 
171. Markar SR, Wiggins T, Kumar S, Hanna GB. Exhaled breath analysis for the 
diagnosis and assessment of endoluminal gastrointestinal diseases. J Clin 
Gastroenterol. 2015;49(1):1-8. 
172. Amal H, Leja M, Funka K, Skapars R, Sivins A, Ancans G, et al. Detection of 
precancerous gastric lesions and gastric cancer through exhaled breath. Gut. 2015. 
173. Buszewski B, Ulanowska A, Ligor T, Jackowski M, Kłodzińska E, Szeliga J. 
Identification of volatile organic compounds secreted from cancer tissues and 
bacterial cultures. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;868(1-
2):88-94. 
174. Zhang Y, Gao G, Liu H, Fu H, Fan J, Wang K, et al. Identification of volatile 
biomarkers of gastric cancer cells and ultrasensitive electrochemical detection 
based on sensing interface of Au-Ag alloy coated MWCNTs. Theranostics. 
2014;4(2):154-62. 
175. Leja M, Amal H, Lasina I, Skapars R, Sivins A, Ancans G, et al. Analysis of the 
effects of microbiome-related confounding factors on the reproducibility of the 
volatolomic test. J Breath Res. 2016;10(3):037101. 
176. Navaneethan U, Parsi MA, Lourdusamy D, Grove D, Sanaka MR, Hammel 
JP, et al. Volatile Organic Compounds in Urine for Noninvasive Diagnosis of 
Malignant Biliary Strictures: A Pilot Study. Dig Dis Sci. 2015;60(7):2150-7. 
177. Navaneethan U, Parsi MA, Lourdusamy V, Bhatt A, Gutierrez NG, Grove D, 
et al. Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma 
in patients with primary sclerosing cholangitis: a pilot study. Gastrointest Endosc. 
2015;81(4):943-9.e1. 
178. Qin T, Liu H, Song Q, Song G, Wang HZ, Pan YY, et al. The screening of 
volatile markers for hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 
2010;19(9):2247-53. 
179. Amal H, Ding L, Liu BB, Tisch U, Xu ZQ, Shi DY, et al. The scent fingerprint of 
hepatocarcinoma: in-vitro metastasis prediction with volatile organic compounds 
(VOCs). Int J Nanomedicine. 2012;7:4135-46. 
   
 
301 
 
180. Phillips M, Cataneo RN, Ditkoff BA, Fisher P, Greenberg J, Gunawardena R, 
et al. Volatile markers of breast cancer in the breath. Breast J. 2003;9(3):184-91. 
181. Phillips M, Cataneo RN, Ditkoff BA, Fisher P, Greenberg J, Gunawardena R, 
et al. Prediction of breast cancer using volatile biomarkers in the breath. Breast 
Cancer Res Treat. 2006;99(1):19-21. 
182. Phillips M, Cataneo RN, Saunders C, Hope P, Schmitt P, Wai J. Volatile 
biomarkers in the breath of women with breast cancer. J Breath Res. 
2010;4(2):026003. 
183. Phillips M, Beatty JD, Cataneo RN, Huston J, Kaplan PD, Lalisang RI, et al. 
Rapid point-of-care breath test for biomarkers of breast cancer and abnormal 
mammograms. PLoS One. 2014;9(3):e90226. 
184. Shuster G, Gallimidi Z, Reiss AH, Dovgolevsky E, Billan S, Abdah-Bortnyak R, 
et al. Classification of breast cancer precursors through exhaled breath. Breast 
Cancer Res Treat. 2011;126(3):791-6. 
185. Patterson SG, Bayer CW, Hendry RJ, Sellers N, Lee KS, Vidakovic B, et al. 
Breath analysis by mass spectrometry: a new tool for breast cancer detection? Am 
Surg. 2011;77(6):747-51. 
186. Mangler M, Freitag C, Lanowska M, Staeck O, Schneider A, Speiser D. 
Volatile organic compounds (VOCs) in exhaled breath of patients with breast 
cancer in a clinical setting. Ginekol Pol. 2012;83(10):730-6. 
187. Barash O, Zhang W, Halpern JM, Hua QL, Pan YY, Kayal H, et al. 
Differentiation between genetic mutations of breast cancer by breath 
volatolomics. Oncotarget. 2015. 
188. Silva CL, Passos M, Câmara JS. Solid phase microextraction, mass 
spectrometry and metabolomic approaches for detection of potential urinary 
cancer biomarkers--a powerful strategy for breast cancer diagnosis. Talanta. 
2012;89:360-8. 
189. Asimakopoulos AD, Del Fabbro D, Miano R, Santonico M, Capuano R, 
Pennazza G, et al. Prostate cancer diagnosis through electronic nose in the urine 
headspace setting: a pilot study. Prostate Cancer Prostatic Dis. 2014;17(2):206-11. 
   
 
302 
 
190. Roine A, Veskimäe E, Tuokko A, Kumpulainen P, Koskimäki J, Keinänen TA, 
et al. Detection of prostate cancer by an electronic nose: a proof of principle study. 
J Urol. 2014;192(1):230-4. 
191. Khalid T, Aggio R, White P, De Lacy Costello B, Persad R, Al-Kateb H, et al. 
Urinary Volatile Organic Compounds for the Detection of Prostate Cancer. PLoS 
One. 2015;10(11):e0143283. 
192. Amal H, Shi DY, Ionescu R, Zhang W, Hua QL, Pan YY, et al. Assessment of 
ovarian cancer conditions from exhaled breath. Int J Cancer. 2015;136(6):E614-22. 
193. Schmutzhard J, Rieder J, Deibl M, Schwentner IM, Schmid S, Lirk P, et al. 
Pilot study: volatile organic compounds as a diagnostic marker for head and neck 
tumors. Head Neck. 2008;30(6):743-9. 
194. Leunis N, Boumans ML, Kremer B, Din S, Stobberingh E, Kessels AG, et al. 
Application of an electronic nose in the diagnosis of head and neck cancer. 
Laryngoscope. 2014;124(6):1377-81. 
195. Gruber M, Tisch U, Jeries R, Amal H, Hakim M, Ronen O, et al. Analysis of 
exhaled breath for diagnosing head and neck squamous cell carcinoma: a 
feasibility study. Br J Cancer. 2014;111(4):790-8. 
196. van Hooren MR, Leunis N, Brandsma DS, Dingemans AC, Kremer B, Kross 
KW. Differentiating head and neck carcinoma from lung carcinoma with an 
electronic nose: a proof of concept study. Eur Arch Otorhinolaryngol. 
2016;273(11):3897-903. 
197. Kwak J, Gallagher M, Ozdener MH, Wysocki CJ, Goldsmith BR, Isamah A, et 
al. Volatile biomarkers from human melanoma cells. J Chromatogr B Analyt 
Technol Biomed Life Sci. 2013;931:90-6. 
198. Abaffy T, Möller MG, Riemer DD, Milikowski C, DeFazio RA. Comparative 
analysis of volatile metabolomics signals from melanoma and benign skin: a pilot 
study. Metabolomics. 2013;9(5):998-1008. 
199. Balseiro SC, Correia HR. Is olfactory detection of human cancer by dogs 
based on major histocompatibility complex-dependent odour components?--A 
   
 
303 
 
possible cure and a precocious diagnosis of cancer. Med Hypotheses. 
2006;66(2):270-2. 
200. Hakim M, Broza YY, Barash O, Peled N, Phillips M, Amann A, et al. Volatile 
organic compounds of lung cancer and possible biochemical pathways. Chem Rev. 
2012;112(11):5949-66. 
201. Wang C, Dong R, Wang X, Lian A, Chi C, Ke C, et al. Exhaled volatile organic 
compounds as lung cancer biomarkers during one-lung ventilation. Sci Rep. 
2014;4:7312. 
202. Chen X, Xu F, Wang Y, Pan Y, Lu D, Wang P, et al. A study of the volatile 
organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. 
Cancer. 2007;110(4):835-44. 
203. Filipiak W, Sponring A, Mikoviny T, Ager C, Schubert J, Miekisch W, et al. 
Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-
1 in vitro. Cancer Cell Int. 2008;8:17. 
204. Sponring A, Filipiak W, Mikoviny T, Ager C, Schubert J, Miekisch W, et al. 
Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in 
vitro. Anticancer Res. 2009;29(1):419-26. 
205. Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump 
inhibitors affect the gut microbiome. Gut. 2016;65(5):740-8. 
206. Shirasu M, Touhara K. The scent of disease: volatile organic compounds of 
the human body related to disease and disorder. J Biochem. 2011;150(3):257-66. 
207. Bikov A, Hernadi M, Korosi BZ, Kunos L, Zsamboki G, Sutto Z, et al. 
Expiratory flow rate, breath hold and anatomic dead space influence electronic 
nose ability to detect lung cancer. BMC Pulm Med. 2014;14:202. 
208. Queralto N, Berliner AN, Goldsmith B, Martino R, Rhodes P, Lim SH. 
Detecting cancer by breath volatile organic compound analysis: a review of array-
based sensors. J Breath Res. 2014;8(2):027112. 
209. Dent AG, Sutedja TG, Zimmerman PV. Exhaled breath analysis for lung 
cancer. J Thorac Dis. 2013;5 Suppl 5:S540-50. 
   
 
304 
 
210. Haick H, Broza YY, Mochalski P, Ruzsanyi V, Amann A. Assessment, origin, 
and implementation of breath volatile cancer markers. Chem Soc Rev. 
2014;43(5):1423-49. 
211. Altomare DF, Di Lena M, Porcelli F, Travaglio E, Longobardi F, Tutino M, et 
al. Effects of Curative Colorectal Cancer Surgery on Exhaled Volatile Organic 
Compounds and Potential Implications in Clinical Follow-up. Ann Surg. 
2015;262(5):862-6; discussion 6-7. 
212. Schumer EM, Black MC, Bousamra M, Trivedi JR, Li M, Fu XA, et al. 
Normalization of Exhaled Carbonyl Compounds After Lung Cancer Resection. Ann 
Thorac Surg. 2016;102(4):1095-100. 
213. Weisburger JH, Reddy BS, Narisawa T, Wynder EL. Germ-free status and 
colon tumor induction by N-methyl-N'-nitro-N-nitrosoguanidine. Proc Soc Exp Biol 
Med. 1975;148(4):1119-21. 
214. Gagnière J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, et al. Gut 
microbiota imbalance and colorectal cancer. World J Gastroenterol. 
2016;22(2):501-18. 
215. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev 
Microbiol. 1977;31:107-33. 
216. Suau A, Bonnet R, Sutren M, Godon JJ, Gibson GR, Collins MD, et al. Direct 
analysis of genes encoding 16S rRNA from complex communities reveals many 
novel molecular species within the human gut. Appl Environ Microbiol. 
1999;65(11):4799-807. 
217. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and 
disease. Physiol Rev. 2010;90(3):859-904. 
218. Bultman SJ. Interplay between diet, gut microbiota, epigenetic events, and 
colorectal cancer. Mol Nutr Food Res. 2016. 
219. Xu Z, Knight R. Dietary effects on human gut microbiome diversity. Br J 
Nutr. 2015;113 Suppl:S1-5. 
   
 
305 
 
220. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, 
et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 
2014;505(7484):559-63. 
221. Bultman SJ. Emerging roles of the microbiome in cancer. Carcinogenesis. 
2014;35(2):249-55. 
222. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and 
colorectal cancer. Nat Rev Microbiol. 2014;12(10):661-72. 
223. Franzosa EA, Morgan XC, Segata N, Waldron L, Reyes J, Earl AM, et al. 
Relating the metatranscriptome and metagenome of the human gut. Proc Natl 
Acad Sci U S A. 2014;111(22):E2329-38. 
224. Neish AS. Microbes in gastrointestinal health and disease. 
Gastroenterology. 2009;136(1):65-80. 
225. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 
2006;7(7):688-93. 
226. Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci U S A. 
2003;100(18):10452-9. 
227. Stecher B, Hardt WD. The role of microbiota in infectious disease. Trends 
Microbiol. 2008;16(3):107-14. 
228. Boleij A, Tjalsma H. Gut bacteria in health and disease: a survey on the 
interface between intestinal microbiology and colorectal cancer. Biol Rev Camb 
Philos Soc. 2012;87(3):701-30. 
229. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host 
Microbe. 2014;15(3):317-28. 
230. Burns MB, Lynch J, Starr TK, Knights D, Blekhman R. Virulence genes are a 
signature of the microbiome in the colorectal tumor microenvironment. Genome 
Med. 2015;7(1):55. 
231. Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, et al. 
Tumour-associated and non-tumour-associated microbiota in colorectal cancer. 
Gut. 2016. 
   
 
306 
 
232. Zackular JP, Rogers MA, Ruffin MT, Schloss PD. The human gut microbiome 
as a screening tool for colorectal cancer. Cancer Prev Res (Phila). 2014;7(11):1112-
21. 
233. Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, et al. Potential 
of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 
2014;10:766. 
234. Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, et al. Metagenomic 
analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers 
for colorectal cancer. Gut. 2015. 
235. Hullar MA, Burnett-Hartman AN, Lampe JW. Gut microbes, diet, and 
cancer. Cancer Treat Res. 2014;159:377-99. 
236. Sears CL, Pardoll DM. Perspective: alpha-bugs, their microbial partners, 
and the link to colon cancer. J Infect Dis. 2011;203(3):306-11. 
237. Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger 
model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 
2012;10(8):575-82. 
238. Consortium HMP. Structure, function and diversity of the healthy human 
microbiome. Nature. 2012;486(7402):207-14. 
239. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 
2013;13(11):800-12. 
240. Yu YN, Fang JY. Gut Microbiota and Colorectal Cancer. Gastrointest 
Tumors. 2015;2(1):26-32. 
241. Forbes SL, Rust L, Trebilcock K, Perrault KA, McGrath LT. Effect of age and 
storage conditions on the volatile organic compound profile of blood. Forensic Sci 
Med Pathol. 2014;10(4):570-82. 
242. Berkhout DJ, Benninga MA, van Stein RM, Brinkman P, Niemarkt HJ, de 
Boer NK, et al. Effects of Sampling Conditions and Environmental Factors on Fecal 
Volatile Organic Compound Analysis by an Electronic Nose Device. Sensors (Basel). 
2016;16(11). 
   
 
307 
 
243. Kogan MI, Naboka YL, Ibishev KS, Gudima IA, Naber KG. Human urine is not 
sterile - shift of paradigm. Urol Int. 2015;94(4):445-52. 
244. Kearns B, Whyte S, Chilcott J, Patnick J. Guaiac faecal occult blood test 
performance at initial and repeat screens in the English Bowel Cancer Screening 
Programme. Br J Cancer. 2014;111(9):1734-41. 
245. Ohigashi S, Sudo K, Kobayashi D, Takahashi O, Takahashi T, Asahara T, et 
al. Changes of the intestinal microbiota, short chain fatty acids, and fecal pH in 
patients with colorectal cancer. Dig Dis Sci. 2013;58(6):1717-26. 
246. Ohigashi S, Sudo K, Kobayashi D, Takahashi T, Nomoto K, Onodera H. 
Significant changes in the intestinal environment after surgery in patients with 
colorectal cancer. J Gastrointest Surg. 2013;17(9):1657-64. 
247. Borges-Canha M, Portela-Cidade JP, Dinis-Ribeiro M, Leite-Moreira AF, 
Pimentel-Nunes P. Role of colonic microbiota in colorectal carcinogenesis: a 
systematic review. Rev Esp Enferm Dig. 2015;107(11):659-71. 
248. Esfahani S, Sagar NM, Kyrou I, Mozdiak E, O'Connell N, Nwokolo C, et al. 
Variation in Gas and Volatile Compound Emissions from Human Urine as It Ages, 
Measured by an Electronic Nose. Biosensors (Basel). 2016;6(1). 
  
  
   
 
308 
 
Appendices 
1. Patient information sheet – cancer subjects 
2. Patient information sheet – relatives and spouses 
3. Consent form – cancer subjects 
4. Consent form – relatives and spouses 
  
   
 
309 
 
 
 
PARTICIPANT INFORMATION SHEET FOR PARTICIPATION IN RESEARCH 
PROJECT 
Title of the Project: The Use of Electronic Noses (eNOSE) in Assessing Volatile 
Organic Substances (VOCs) in the Urine and Stools of Colorectal Cancer (CRC) 
Patients, their Blood Relatives and Individuals with Whom they Share Dwellings 
Names of the Investigators: Professor Chuka Nwokolo, Dr R P 
Arasaradnam, Mr Chris Harmston, Dr James Covington 
 
Invitation  
You are being invited to take part in a research study. Before you decide to go 
ahead, it is important for you to understand why the research is being done and 
what it will involve. Please take time to read this information carefully and ask us if 
there is anything that is not clear or if you would like more information.   
This study involves  
The use of an electronic eNose for non invasive testing and recording of the profile 
of substances found in your urine and stools.  The eNose is pictured below: 
 
Figure above is an example of an e-nose machine which samples the vapour 
released by urine and other bodily substances and recognises a unique pattern 
associated with some diseases. 
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What happens  
You will be recruited on to the study at diagnosis or post CRC resection.  You will 
be asked to provide urine and stool samples to provide us with a record of your 
profile of substances, using the eNose. 
With your permission, we will then contact your first degree relatives (father, 
mother, brother, sister or child) and/or non blood relatives with whom you share 
your home, to ask if they would be willing to provide urine and stool samples to 
provide us with a record of their profile of substances so that we can draw a 
comparison with yours.  They will be contacted by letter and followed up by 
telephone contact.  They will also be offered a face-to-face meeting.  A participant 
information sheet will be sent to them with a consent form to sign and telephone 
contact will be made for them to ask any questions.  Once they return a completed 
consent form, they will be sent containers for urine (10 ml) and stools (5 ml) along 
with a secure self addressed envelope for the samples to be returned to us. 
What does the study involve? 
The aim of the study is to compare the profile of substances found in your urine 
and stools, to those of your first degree relatives, who share your genes, and/or to 
those who share your home/environment. 
What is the reason for this study? 
Preliminary results suggest that patients with cancer produce a unique profile of 
substances in urine and stools.  Presently, approximately 10 to 15% of colorectal 
cancer is believed to be genetic and over 80% has no clear-cut genetic pattern.  
There is evidence to suggest that the environment may influence the risk of 
colorectal cancer i.e. dietary factors.  Comparing the patterns in your profile of 
substances, to those found in your blood relatives and/or non blood relatives you 
live with, will help to determine the present hypothesis of whether the cause is by 
“nurture or nature” as well as allowing us to further evaluate the use of the eNose 
in cancer.  These findings could ultimately lead to the first non invasive screening 
tests for CRC in the UK becoming readily available to the public as a preventative 
measure. 
Do I have to take part? 
No, the choice is entirely yours.   
What will happen to me if I do take part? 
If you do decide to take part, once you have read this information sheet and have 
had the opportunity to have any questions answered satisfactorily, you will be 
asked to sign a consent form and we will ask you to provide urine and faecal 
samples. 
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You may withdraw at any time without providing an explanation.  If you choose not 
to take part, it will not change any care you may need in the future. 
What happens to the samples taken? 
We request your permission to store your samples indefinitely as in the future, 
further techniques may become available to allow us to perform an even more 
detailed analysis. 
Your samples will be kept anonymised so that no-one outside the research 
team would be able to identify you.   
 
What are the possible benefits of taking part? 
There are no immediate benefits for yourself, although future generations of 
your family could benefit as well as other members of the public.  Research 
of this kind helps to increase the understanding of many diseases, including 
cancer. 
Who has reviewed the study? 
West Midlands – Solihull Research Ethics Committee. 
Confidentiality 
All information we have about you from this study is strictly confidential and will be 
kept securely for the duration of the study with only the research team having 
access to it.  Any information about you that leaves the hospital as part of a 
research report will have your name, address and any other personal information 
removed so that you cannot be identified. 
Who is your immediate contact for further information: 
Professor Chuka Nwokolo 
Honorary Professor of Gastroenterology 
Department of Gastroenterology 
University Hospitals Coventry & Warwickshire NHS Trust 
Clifford Bridge Road 
Coventry 
CV2 2DX 
Direct Tel: 02476966087 
Email: chuka.nwokolo@uhcw.nhs.uk or michael.mcfarlane@uhcw.nhs.uk  
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What happens if something goes wrong? 
Nothing is expected to go wrong as all that is required from you is that you post 
samples by post to us for analysis, therefore nothing can foreseeably go wrong.  
However, if you do experience any problems you feel are specific to the study that 
you think we have overlooked, we would appreciate your feedback.  In the unlikely 
event that you wish to make a formal complaint, you can do so by writing to: 
Ceri Jones 
Head of Research, Development & Innovation 
Research, Development & Innovation Department 
University Hospitals Coventry & Warwickshire 
Clifford Bridge Road 
Coventry CV2 2DX 
Direct Tel: 02476966069 
Email: ceri.jones@uhcw.nhs.uk 
 
For independent advice on research, you can contact PALS (Patient Advice and 
Liaison Service) on freephone 0800 028 4203, Email: PALS@uhcw.nhs.uk 
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PARTICIPANT INFORMATION SHEET FOR RELATIVES/NON RELATIVES 
(CONTROL GROUP) WHO LIVE WITH THE PARTICIPANT WHO IS IN THIS 
RESEARCH PROJECT 
Title of the Project: The Use of Electronic Noses (eNOSE) in Assessing Volatile 
Organic Substances (VOCs) in the Urine and Stools of Colorectal Cancer (CRC) 
Patients, their Blood Relatives and Individuals with Whom they Share Dwellings 
(Control Group) 
Names of the Investigators: Professor Chuka Nwokolo, Dr R P 
Arasaradnam, Mr Chris Harmston, Dr James Covington 
 
Invitation  
Your relative (our patient) is taking part in a research study and has given us 
permission to contact you to ask if you would also be willing to take part in the 
same study.  Before you decide to go ahead, it is important for you to understand 
why the research is being done and what it will involve. Please take time to read 
this information carefully and ask us if there is anything that is not clear or if you 
would like more information.   
 
This study involves  
The use of an electronic eNose for non invasive testing and recording of the profile 
of substances found in your urine and stools.  The eNose is pictured below: 
 
 
Figure above is an example of an e-nose machine which samples the vapour 
released by urine and other bodily substances and recognises a unique pattern 
associated with some diseases. 
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What happens  
You will be asked to provide urine and stool samples to provide us with a record of 
your profile of substances, using the eNose, so that we can draw a comparison 
with those of your relative (our patient). 
Once you have read this information sheet, we will telephone you so that you can 
ask any questions, following which, if you wish to take part, we will ask you to sign 
the consent form sent at the same time as this information sheet.  You will also be 
offered a face-to-face meeting if you prefer.  Once you return a completed consent 
form, you will be sent containers for urine (10 ml) and stools (5 ml) along with a 
secure self addressed envelope for the samples to be returned to us. 
What does the study involve? 
The aim of the study is to compare the profile of substances found in your urine 
and stools, to those of your relative (our patient) as his/her first degree relative, 
who share his/her genes, and/or as someone who shares his/her 
home/environment. 
What is the reason for this study? 
Preliminary results suggest that patients with cancer produce a unique profile of 
substances in urine and stools.  Presently, approximately 10 to 15% of colorectal 
cancer is believed to be genetic and over 80% has no clear-cut genetic pattern.  
There is evidence to suggest that the environment may influence the risk of 
colorectal cancer i.e. dietary factors.  Comparing the patterns in your profile of 
substances, to those found in your relative’s (our patient’s), will help to determine 
the present hypothesis of whether the cause is by “nurture or nature” as well as 
allowing us to further evaluate the use of the eNose in cancer.  These findings 
could ultimately lead to the first non invasive screening tests for CRC in the UK 
becoming readily available to the public as a preventative measure. 
Do I have to take part? 
No, the choice is entirely yours.   
What will happen to me if I do take part? 
If you do decide to take part, once you have read this information sheet and have 
had the opportunity to have any questions answered satisfactorily, you will be 
asked to sign a consent form and we will ask you to provide urine and faecal 
samples. 
You may withdraw at any time without providing an explanation.  If you choose not 
to take part, it will not change any care you relative (our patient) may need in the 
future. 
What happens to the samples taken? 
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We request your permission to store your samples indefinitely as in the future, 
further techniques may become available to allow us to perform an even more 
detailed analysis. 
Your samples will be kept anonymised so that no-one outside the research 
team would be able to identify you.   
 
What are the possible benefits of taking part? 
There may be no immediate benefits for yourself, although future 
generations of your family could benefit as well as other members of the 
public.  Research of this kind helps to increase the understanding of many 
diseases, including cancer. 
Who has reviewed the study? 
West Midlands – Solihull Research Ethics Committee. 
Confidentiality 
All information we have about you from this study is strictly confidential and will be 
kept securely for the duration of the study with only the research team having 
access to it.  Any information about you that leaves the hospital as part of a 
research report will have your name, address and any other personal information 
removed so that you cannot be identified. 
Who is your immediate contact for further information: 
Professor Chuka Nwokolo 
Honorary Professor of Gastroenterology 
Department of Gastroenterology 
University Hospitals Coventry & Warwickshire NHS Trust 
Clifford Bridge Road 
Coventry 
CV2 2DX 
Direct Tel: 02476966087 
Email: chuka.nwokolo@uhcw.nhs.uk or michael.mcfarlane@uhcw.nhs.uk 
 
 
 
 
What happens if something goes wrong? 
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Nothing is expected to go wrong as all that is required from you is that you post 
samples by post to us for analysis, therefore nothing can foreseeably go wrong.  
However, if you do experience any problems you feel are specific to the study that 
you think we have overlooked, we would appreciate your feedback.  In the unlikely 
event that you wish to make a formal complaint, you can do so by writing to: 
 
Ceri Jones 
Head of Research, Development & Innovation 
Research, Development & Innovation Department 
University Hospitals Coventry & Warwickshire 
Clifford Bridge Road 
Coventry CV2 2DX 
Direct Tel: 02476966069 
Email: ceri.jones@uhcw.nhs.uk 
 
For independent advice on research, you can contact PALS (Patient Advice and 
Liaison Service) on freephone 0800 028 4203, Email: PALS@uhcw.nhs.uk 
 
  
   
 
317 
 
Patient Identification:                                          
 
 
CONSENT FORM FOR PARTICIPATION IN RESEARCH PROJECT 
 
Title of the project: The Use of Electronic Noses (eNOSE) in Assessing Volatile 
Organic Substances (VOCs) in the Urine and Stools of Colorectal Cancer (CRC) 
Patients, their Blood Relatives and Individuals with Whom they Share Dwellings 
 
Names of the Investigators: Professor Chuka Nwokolo, Dr R P 
Arasaradnam, Mr Chris Harmston, Dr James Covington 
 
 Please Initial 
(don’t tick) 
 Yes No 
1. I confirm that I have read and understand the information sheet 
dated 12 March 2013 for the above study. I have had the 
opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
 
  
2. I understand that my participation is voluntary and that I am 
free to withdraw at any time without giving any reason, without my 
medical care or legal rights being affected.   
 
  
3. I understand that giving samples for this research is voluntary 
and that I am free to withdraw my approval for the use of the 
samples at any time without giving any reason and without my 
medical treatment or legal rights being affected.   
 
  
4. I agree to give samples of urine and faeces for this research 
project.  I am aware that the samples will be analysed for 
gaseous products and I understand that the samples given for 
research purposes will be anonymised and therefore cannot be 
traced back to myself.  Clinical findings will be fed back to my 
Consultant. 
 
  
5. I understand that relevant sections of my medical notes and 
data collected during the study may be looked at by individuals 
from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for 
these individuals to have access to my records.  
 
  
6. I understand that any personal information obtained as a result 
of my participation in this study will be treated as confidential and 
will not be made publicly available. 
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7. I understand that I will not benefit financially if this research 
leads to the development of a new treatment or medical test. 
 
  
8. I agree to take part in the above study.  
 
  
 
 
 
 
Name of the patient 
 
 
Date Signature 
Name of person 
taking consent 
 
 
Date Signature 
 
When completed: 1 for participant; 1 for researcher (original) site file; 1 to be kept 
in medical notes.     
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Patient Identification:                                           
 
CONSENT FORM FOR RELATIVES/NON RELATIVES (CONTROL 
GROUP) WHO LIVE WITH THE PARTICIPANT WHO IS IN THIS 
RESEARCH PROJECT 
 
Title of the project: The Use of Electronic Noses (eNOSE) in Assessing Volatile 
Organic Substances (VOCs) in the Urine and Stools of Colorectal Cancer (CRC) 
Patients, their Blood Relatives and Individuals with Whom they Share Dwellings 
 
Names of the Investigators: Professor Chuka Nwokolo, Dr R P 
Arasaradnam, Mr Chris Harmston, Dr James Covington 
 Please Initial 
(don’t tick) 
 Yes No 
1. I confirm that I have read and understand the information 
sheet dated 12 March 2013 for the above study. I have had 
the opportunity to consider the information, ask questions 
and have had these answered satisfactorily.  
 
  
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time without giving any reason, 
without my legal rights being affected.   
 
  
3. I understand that giving samples for this research is 
voluntary and that I am free to withdraw my approval for the 
use of the samples at any time without giving any reason and 
without my legal rights being affected.   
 
  
4. I agree to give samples of urine and faeces for this 
research project.  I am aware that the samples will be 
analysed for gaseous products and I understand that the 
samples given for research purposes will be anonymised and 
therefore cannot be traced back to myself.  Clinical findings 
will be fed back to your GP 
 
  
5. I understand that any personal information obtained as a 
result of my participation in this study will be treated as 
confidential and will not be made publicly available. 
 
  
6. I understand that I will not benefit financially if this 
research leads to the development of a new treatment or 
medical test. 
 
  
7. I agree to take part in the above study.    
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Name of the patient 
 
 
Date Signature 
Name of person 
taking consent 
 
 
Date Signature 
When completed: 1 for participant; 1 for researcher (original) site file; 1 to be kept 
in medical notes.    
 
